var title_f39_29_40400="Diffuse choroidal hemangioma in SWS";
var content_f39_29_40400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse choroidal hemangioma (capillary-venous malformation) in a patient with Sturge-Weber syndrome and glaucoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEpAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5bdm3t8x6+tJub+8fzof77fWkpki7m9T+dBZv7x/OkoNAC7m9T+dJub+8fzpKSgY7c3qfzrpvDmiNKVub0ERjlIyfvfWm+GtF8zbd3a/uxyiHv7muqMbK26PH+72rz8Vire5Bn12S5LosTiF6L9X+iJx0A5AHTHSpYxyMkg/rVaOZXO0/JJ6HvVqLryDXkyuj7GLT2HAFehNTox4yx/OkQBuvGOKVRtYg4wORWEpXNEiQlg5yx/E07aHXDd/WmrkkYOD61NsJCtnPHNZt2LSIMvC3zyMVbgMeqn0NSAvn7xyO2aVsEFTzngg81EoMTYJLRdM919vpRe4tiYMR1J/GnlyG5Yg9zTD1A9KeDjJPQd8Umyh25umTnGetH8JGfxpF4zkjNSdOeue9IdiNSd33mwPQ1FfQvLGGQkTIdyfX0qyvTHB5yeKTGTwf8TTTadxNJ6EdnP50CSL36jPQ96n3H1yBVK2/c300R4V8SD+tXOCv3SR644py0egltqKxPODn0zUbqZFGGIkXlWp4PJVu4pT905z9c0h2FtpmaPdnGPvL6GpW3EBiTzz1qpKPLbzkUlcfvB/X8KsqQ4G05BGQfWiwhYX2MCeex5/nTixyW3knPSoz8rgEEjvSgZxngY60wsJYhmFw247mcj3NWkZTG8bsfzqtpsohMmfvLKe1PlfM5cADJzgjgUCsQucocnnOKhLY6kip2OXYgdR6VHtBbLD6e1BSIWfn5dx9hTtz7Rwx57mnBMnj8+1Jjb16mmMjw687yMnpigK5DbnYgc4BpWBIGB60rH+526ke9AEZyvAB9TjtTGLk5OB+Oc1N0G3GAe1MIPHT3oCxDLHvidSTlhjJrHv9Kh1jTUSZtl1HlElHUEdj6itzcCTxz1qrKDbzGXrHJgOD2PrWtOcov3XZnPXoQqxcaivF7nlOpWdzp929vdArIvvwR6j2qrub1P516rrmjw6ramKUgToMxy+h9PpXmN/Zz2F1Jb3KFJEOCPX3HtXv4TFqvHXdH53nGTzwE+aOsHs/0f8AWpBub+8fzo3N/eP502lrsPDHbm/vH86Te394/nSZooEO3N6n86mhZth+Y9fWq9TwfcPHegCJ/vH60lK332+tNoAMUUtJQMK3fDelC5kFzc8QKflB/iP+FUtF09tRvAnIiX5nb0Fd5HsjVI4wFRRgKOwrixeI5FyR3PpMiytVn9YrL3Vsu7/yRKpBA249OKenzYBOSPaq5XByDtbGfangS4/gAx2z0ryWj7ZSuTvEkihX69j6VFFO8H3wZE6B+lWEUucSEY6gKOD9anYBlwQCMdKz5raPU05b6oIWldQyrGV7ZbPFK3nFgV8on0BIquInt23WxypOTGen4VPBcLM2zJSQfwHrWbVtVsWn0ZIjTAf6tcZ7tT2eVTygK/7LVIFA5pcfNnGKybXY1sNimRyVBIb+63BqUAOeeg6iomRXGJACB+n40DzI8KuHX0bqPxpWXQeohzGccmL2PKf/AFqnXBAxhskYI9KijlBchxsfptbp+dSeUVYNHhX64PQ/hSfmC8iQAbscU8nJP4c4pkcgd9rDy3x90/0pcDB4PJOSfSkMeoPQUrYIxg4NMbg/XjilOQ4Hb0pgVLvK3Fm5xkMRn29KvAgjjnntVPUwPsgYH7jKwPvVhXQkHeqt1FU9kSt2SHqe+OtIMYPOO4oUlm5Az146Um5c9iT0ANIY9sBQSM+3rUEQMUnlEkI3Keg9VqZeOT8zDjPp/hSSRiRCDwOoOehpgLgknnn17U/bjj9DUUMjMdsgAlHUdiPUVKSEDFuijJ5osBBCuZrnDH74AAPfFPdAFzyD696SyysQLfekJY596kJxkDge3eiwITLEclfTpjNNJ9cj3xmn55/pSE5AIySaLAR4AJ55pZOGwB+nWpAMKMjAFNbkA5+agCEKegHHvxTNvJwOD2qfAB/nSMMgnPHQ07DuQjORzyMilYEBQQPWnEYYY6Nwf8aGAznHTvSAhIGeM+nFDIJFKNyp4P1qRj7Yz6UzjqR9Ce1AFW1LNCUbloztPv6Vn67pFrq20XLNG6KNkigZAz0561o423zIvHmJu59RUm0B1woyUP8AOtIzcJc0XZmFSjCtB06iujjrvwXA0Z+xXknmgcCVRg/iOlcZd28tpcSQToUlQ4YGvY2QdP19K4X4iRIt5ZygAPJGQ2O+Dwa9TA4uc5+zm73PlM+ybD0cO8RRXK1a/Z30ORooor2D4kKng+4frUFTwfcP1oERP95vrSUr/fb602gAJp0cbSOscYLOxwAKbXSeF7EKpvZRyfljHp6ms6tRU43O3AYSWLrKmtuvkja020TT7JYFwXPMjerVbXqD+dRA4IJ5xT85rxpXk7s/RacY04qEFZLYm+8QMds5qZCCOeoqKL8R61OgDHJyaxkdMSSJsOvoeMVYByKrBeQQOQamU56VjJG0R4wp7jPSiWJJl/eLnHfuKE6c84qUHgDPFZttPQtK+5EPtFuOP38eMYJwwqWK5idsFij/AN1xin4HT160rxpIuJVDA88ipbT3KSa2JDjuD+NKB34yf5VVjjliP+jvuT/nnIcj8DUiXUbECQNE54w/T86nl7DUu5PtDgq2GHcEZFN8tlwIpCB6MMin4wOAMex605cEjtUlWIBJg7bhBs4ww6f4iphmADcd0R/Er/iKfwOSB071Gv7iQLk+WxwM87T6fSnuInyBgryPUUh9BnrUXETbcfu3PH+y1TgHjPGKYFPUOkUYHyvIBirbYwMZxVXUMrJbNjpJj86tk+mecdaq2iEtxnlIP4Aee1Ku0FkYDnoRxmnI2D3ye1Nl/wBUWycjkZPNKwxzEgHBz+HNORsnnPHXjFC9MZ5FB+9nqf50wGzIJAuMhx91hVecuyrDIu15GxuHQirYGSMgZ9MVXvsiAyL1jYEcdKdhFn7vt6e1NMhBy2PxGKUuGxnHPNKRkHJ/4DRa4DWGc46Glxg8f400ZWTaQzYHyj29Kdhm2liVX0B5H40AI46AcleT7Uo5AOeOc0bQO2Oe1IuQwIPHp607AJtye+cc1Hkcjsal9x601sM3IBJ9qBkcw/dMQOVwfpim4LAHovoadKgKOoY5wcZoUbo0YggkUgI2Hzegz+VNLDd17/WpWUFcnk5796jOCMDgA/nSsNFUkC/iz3Q47VK3Eyj0Q9ajul2y2x7q+PwNSsv75QOMA02T3Gv3AJJxXCfEKzmF3BeZLW7IIxgfcI7fj1rvcc9agvraK+s5rS5H7uRcZ/unsR9K2w1b2NRTOLM8F9dw0qN7Pp6o8Zpas6jZy2F7NbXAxJG2D7+9Va+ni1JXR+U1ISpycJKzQtTQfcP1qGp4PuH60yCJ/vt9abTn++31ptAFiwtmu7tIV6E/MfQd67aNVRUVQAigBR6CsXw/beTbGZuJJenstbQORyMY4rzsTPmlboj7TJcL7Cjzv4pa/Lp/mSJ0OakQjgEVErc8jqOtTr2PT8K5JHvRJYSMZP1qwpGcg9OlV1OSOlWFYdT16kVhI6IEvTk9aevOBjHvUSnnnlalXIXj1zWTNkS9/apFzmoSxBGaejcdhWTRomTKTxzz1zThjPPaos4FPB/wrMskU8+pHp3oK7lClQw6YIzTeoJ6Gng4z6+lIZCIjESbbOB1jJyD9PSp4p1lT5OCPvA9QaQkduR09aimCr++BKMO4/i9iKfxbi22LW8YB984psgLoyk7Qeh6n2qur3RwwijX/eP9KkZ71jndAvbGKfKFx6OJFaOYYfHXsfcVLAJGU7hkodpP9aqNDLO22aYAKAQEFM8gxsRLLIB/z0H9RTshXZY1TKRRsykDeMZq2N23eQQh79qzLjzR5ai4WVScgMeM1a/tCVT/AKVEy47gZFVZCuWcB+uM02ZT5TYbPH8Qp0TJMP3Dh+OQDyPwpQVAIx1H0zRYdwJ79cjg0AduQcf1pEYeWgJyV+U984pRkgnP4dcUJBcXvxjNJInmqyHuMcDpRgZ46DqM0vIbJosAlqwks0zyyjY4PYilBOM9vSoY8R3uC22OYYPswqdhhircEHBB9adhDIjukkYY7L/9apGAIxxnNQR4KsxIGXJ/Wp1+7g9BycihDY1uFPPAphyVy2P8Kl3+YcgfID+Zprd+fxp2QrjQeMZ5P6U3gM3PApeqjBOfU9/wph3KcqSw6kd8+1SMVvTjjt2pifIzRZPXcufQ1KpyAVIwPWo5vk2SDqD29D1ptABGSQSAueppuB1/OpGIBwTwaYRkknqfT+dKwyrqGPLRguCHU1JIMzJjg4JzTdRx5CqByZF6U6Qg3Cg9NpoaDqKTgEY5zj0qM8qe/epGJPYn6Uwjg9x1pDOR8e6aJ7OPUIV/eQ4SXHdex/A1wJr2eVUkieOVd0Ui7XHqCK8j1WzawvpYG52n5T6g9K9rLa3NF030/I+F4owHJUWKgtJaP1/4K/IqVPAfkP1qCpoPuH616h8iRP8Aeb61NZQG6u4oR0Y8/TvUL/eb61s+HodqyXBHX5FP86zqT5YtnXgaHt68YPbr6G2u3YAvCqMAY7U8Er0qKMnHzKAfapVJwK81n3cNiaMn+8cnnFThyuNwwPUCoFzweOKkUjnPIrOR1RZYQjjnrUyse/6iqqqM5BKt1wKlQuuDgMPbrWMkbxZcQ8ZFPVtuOTtPr2qujqeATn0PFTKc8cVi0bxZY9MdfengZAz+YquoK5xkqO3cVKmD0wR1HFZNGiZID8uM9BxUqHOeR9aiGCP6+lKjDbgnJ6YFZtFpkucHOTmnZ7c/So93/wCql7c8E9KmxSJCVCszcKoySajiQuwll69VQjhRQR5soUAeXGQW5+83p+FPByPensG4/oeTzSrxgHPpzTCeeOKdngD/ADmkUPbJ5U/MPfj6UqkOAwzzxj0poY56ZoHD5AwCMn2NMRHPbJJGQqhX6ggdKWxnMqGOTiVOGBHX3qbGT1PXtVe6jZZBNHkMv3uOoqvJkvTVErWsZbcgaN/VOKfGlzHhYrkH/fXqfSprPbdxsUYB+4p3ltGQSMZFUk9xXRAty0G77VbB425LRtjB+v8AjV1IGvAfsIaaMLlsfeQf1qPBI3Z9iO9Q20TRTiS2ne1lyWDJ06+lWuzJd90WAhRCNpUD1FI3IJPH8qfPqGpSMGv0W9hBJJjADD3BHP8AOoPtlo7ALI6HoA45/Gm7CTfUbcxebblcYYDKgjoRVqSWO8tUuohtfAR1PQHHWm7kEZYTRbQcYLYqvpK4nu413fdLLtGQeaS3suoPv2JYkAtoTjqvf1z1oIw2HAGOcdqnhU/2bG7DjcQCB6E1DIAM7yDnj602rIadyODiME5JPzfnzT8jbjIzTEUhSMbmU7M+3al9sehGaixQsg2ng575pi4CAnPJ5A5qTv8AMOnY96aFGM56U7BchKsCWVgueoI4oYu6shiU7h2fpUpGDg456YpFUmTt6D0pWHcgBkeIfIApHOW7jimmTYcSrj1xyPzqWL5TKnHDZHPrRjO7H/66QFOdlmuoEQgjluKew/eruA5Q81HcDbPaseDvKmp5iA8ZOe4yT7UMFuM6jk4HcU05Iwc59KkB+QZHPGKaec8Hp6dKViivOf8AR2OOcY4rmPHWm+bp8d4gJkt/kfA6oeh/A11Lne6J2HzMB7U2eFLmCWCQZSVShz6H/CtaNV0pqS6HHjcKsXRnRfVfj0PGqmgxsP1ovbd7S6mt5Rh42KnPtRD90/Wvp07q6PyapBwk4y3RFJ99vrXVWsPk2sSDHyqCfqa56xhM+oRoAD82TnpgV0/LEkAYJ4HTFcuJltE97JKOkqj9P8/0JEx254p4HGAeahjyBnt7Cpl+Y9a5WfSwJEOFyv481Ip5z1qNAQfcnrUqn0yKzZ0xJU9xipoz0wOKgUgHkgZqSNgSMEHHbNZSRtFloqGXDgHNCx4bIZ19OaaGyCRz9fSpD93IPPasdTdWHqr5x5zYxn7oqRY3XO2ZsnrkAg0wZI+vepl4P0rOTNEh26VQNyB/9w4P5UiTL8xdXXLdStOJGcURsQXA45z+lZljxNGcYdD7ZprzEt5UBBlHDHHCUkzIkTNJggDjIyc+lFujRwqG++3zN7mpsrXHdvQkjVYlCqSU7k+vrUueeT9KZ1JB5FKvB2n6/hUvUtaDyCOcgHtz1pRz349TTSRz+VITg89GP4ZoQyX+mTSjhuPTFM554pVyzADPuBQBICOcDB/OnthFDuQqdmbiqbzgMUiHmSe3QU9Is4eUmVh69B9BVeor9iuryRTPLaRO8YPBHStS31aK5jEV1EVcf8tF6j6io1Y47/570yeOOZ8OBkDO7oR+NWpWIcbmhHAxTfFJHIvcxnP44qCDJClSCfz4qibSSMhreb5h2Y8j6Ef1qxHqUsA239ssg4+crtP4MOPzqrpsWqLjPhCSCPcDGKUbHiAmVWGOd65FNzbXMe60kdeOUkPT6HoaVUcRJmLhuMrVK7egrqxG9jaMuRFtY9AjHk0sVpJZzpcaa7GVP+Wb/wAXqM/0qcrhkKsMg9O9WIWXOJVPu3SrUURJ6EllfafcabLAd8E7T5aGTgRsR2PoSOnbNQzWjwSMjLulAyzZyPwpupafFdo0qkRvwqP97dz0bH8+1JpesyxSRWupHdGjbULjO09hn+tNrW0jON0m4a90QjMUofbkEhXXPr0/KiSMr97GTxjpirGsKZZ7gKApxldo4PcVBGwlKspyCM5PvUONnY2jK6uRsABycD2phViCARk/l+NTFclAM5JxgUYw2Qw9APWlYq5EuCDkFe2D2oVcA9cjt70+XcHDnvgE/wBaacDORSHchl4nRj0f5Tnp7UjAdug/Ki4HmQyADkDcMDuKHKHaQVGcdO1KwypqA22+7urA5zzT51VVVlHIKtzTb8g2kqrkjqDinlPMtu3zJx7nrUjCRSpyAcehNM7Y6E1LncqN0yM5FQzMAGPYc+1JoaYyEZ8x+cscD6ClI3KO4FNiBSBAeuMnj1oY+vU+lIFscF8QbMQ6nFdKPluE5/3hwf6VzcP3T9a9D8a232nQJHAy8DiQH/Z6H+leeQ52nHrX0GAqc9FX6aH5txFhvYY2UltLX/P8TQ0KIm6efkImV47k9q3OOAOD3wKoaMhSz3D+NycZ/lV3d0yD+NRWfNNnp5bSVPDxXfX7yQHAGDx707IJyRTFYEjBBA/Sn45/rWR6sSQLxzk1IEUjnP51H6dKkX+dQzeNiQBQ33RUwVWz8oH4YqAZyfXvUyg456jsazkbRJEVlPyPwOzc09PMfnKoPUDJpgJ69CeMGpo+FwPpWTZrEVIFJ4eUEd91SLE4A2zOM+uDSpx9KkB+UVk5M2SQzFxuK+cuMZJ2U7ZKpyswb2deDUbXMcbMScseAq8k0v724/1n7mLuoPzNSs+uwXWy3GvLJPKFEQdYzlgrDk9uateZccnyFH/A+aYVWPy/LUIFOPYipS3qMc96iTT2RcU+rEFwq/6xJIye5XI/SpFdJB+7dTj0NIG/M0jRpIPmUdeCOKjQvUmG49QeO+aeFIHIODVMQLnO+UKenzmnhHH3ZZB9TkUnFdxqT7FkFlYAEN2wRmo5nZmMMZBkYfMR0Ue9Ru8+UjXZlgTv9BUkSiMbRk+rHqTRsO99EPiRIVKpwO57k1Nng9MimfwjP4U8gLnOAO+aChVJOBk+20URvtBc4wSMNioySRjseKnABXAxwOP8KaVxMUnPBzzTQ25h2HX61GcoMclO3qP8alXBcEcjGQae4tiOa0hYMyqysT1RsVLa3d/p+PIfzYzg4xyPw6Gn8Er1z1xSORlQScAZHNUmS4p6MsLq8FzcKsxwzj5gy7QP8KtOitKphb5W5BZgV/A9Kz2iin+WVFcDjkcj6VXw9hMMSSNadCDhiv19fr1rRTfUz5Ox0Cz+WrCRCHPBAHysPeo7y1gaxdgqSbiPNiB7diD1BFUI9TETFFZ2kBxj72KY01zdKVjXZHnPP3q09qmrbmapNO+xE17cxt5UbC6iXGxwCWAHTkf1qa01OBYwlxaJJhi26NsNz2/yKu2VnBCp8uSZLtgdm0Es5/3ByR79KtaZYDxFcSR3fl2flAhlUBndu3J4X9frUqD76inWgr3WiItPitrp5JXvEj2j9yhHzsx9upI9ADRPbSx74xC8Gzq9wMN/3wOn4moNT0G50Ly7yz8xR/eBJfHqCece1acN8+u6Qqu8K3cLAlnbG9fUH+lUo/Ze5m5vScXeP5GE0CA5JaQ9Az8/XHYVGE2ko/zMBnPqPWta8spbRQJlIZhu6dqzpgeDj51zzjqO4qHGx0wmpK6I3QYzgDtwahtceTtI5XKnj0qyQGQbDkEZBz2qCMfvJlOCQ24e+f8A9VZtW2NENlUSIyY6rgCotObNrFkfd+U/hVmX73TntVK0AW4miYdTvXPvQ9GBMnyoy8/I+BnrjrUF38sL9TxU0gVZgwz5b/K3+961Dd/6ph0OQD6daTK6CnsPYCmMOmOuKkbrnAA9KjYdumfeoGRT24uYJoG5WVChHYZFeSqhjZ0YfMrFT+Feu5Awc++fSvNPEUIt9cvVC4VpN4HsRmvUyyfvSgfJcV0U6VOr2dvv1/Q0rdPKt4kAyVXPPvzUmSFHA6U91AY5AOPl3VGcenOK0vd3LhHkSSHAjI6H8KVR6cfQ0wkDqD9aevYgcn1qjZMkQkHIb6ZqVSRyVyPao+e4/WpB36YNQzoiTq6EZyMe9AmRSQMkewqFR5j5YDH86sqAANv6Vk0kbRbYCUEqSH4yOlSJcAHOyT8qD1X0zUpJEbNz0zgVm7djZX7gJJZQBFDtU/xMacIJGOJpjj+6vFPTiNR6Cn5zkjr1rJytsaJdxkKJE7KgAyOvep89Oo9MiolAbJJHt9KcvGc5PH41L1LWgsjcA5wAwNT5qA4fIzx3oic+WpYFu+RzUtFJk4IzwcUuc+vIqNSDzkE9KkGQahopMeOgHSgHANNB96eg3MAD17mpehQxTuuW5HyqB9M1YXB4yMZwRVW1GVZyCS7E/wBKsKfypS3sOOquSqRg9wfbil3c8j5h0PrUeQCM9+AaUnIwAST68YoLJDjhsd+hqRjkZI471C2TjczE/wCzQiguMFhjkktmmhD8hBucgfWmgneDEhKk8gnAI9qdhUzsUZz1pNx43ZoAf5yr/rFKf73I/OhZ4t27chpFJMgzjGetTB1A4UU1cTIWuFBATMjdMDpSiJpSGuCWH90cD8TUp+faMBcHt608ccEjGewpoRUuLBHfdATFL7H5akjvZ7GQLfQlwOjZ4PvmrBwGGCSPUDrTZrpIgUyJAf4euatNIhq5Zi1u2gtttqhjYnLs2S7/AO83U0un6uiX8kiW7TiWPY4C9geCPfrWXDaefITLH5anoqDGK1LLQ7eQp53yqx+9knB7dO2a0hzz2Mpxp007nXWesaNq9uthPJLaXgXbFJK3t3yMVyOr6fdaFqDv5WFJ+ZQMr/vD2NNudNEFwIrdy3GG3HzU9uvSpjqepWUQtdR/e2zN8vy5BH+y3X8K0d/tLYwp0vZu9J3T6P8AQ0ra6TV7GGFpcSbvlLc/Keq4/vD9ah1K0jguBHEcDqdx+Yen/wBerF14dkulS/8ADFyt0rrmeLGHDDvt/wAmsyXUfMmY3kDW8zYDDGVLevqKctveCm03+7enbsVQNkrK3IPK49e4qEgi4XGfmQ/oavS2rOI/nRo3PySIcrxVZiDPb/IQd5XaOoOKxlGx1xlci2nGScY/Cqd2nlNHON3B2tnuDWlL8p43MSckelV7iIywSoerDI7nik49Ck7ivHG0bA5w2MYqlKfMRUb7+8Bvf3qxZuZbZWyeBg5qO6UCSJ8AZbbkd6h7XKQ1j15HNRsCCc1MRwTzk+lMYE424+tS0UV3GBtPU8Vyni3TzcaossYyGiXP1GR/SusZgpZuiqMk1D9mN0BIWVB0UN1xW2HqulPmPPzDCRxlL2Uu9zln/wBY+D94mm8Zzj396JCMkZxg4ApGPOFGa70eOmJnr69acue3P86YGJ609eDz+QqjSLJQccjpTup2qeT3PYUxmA4wM+lSRLgZPJNS9NTeOuhNGoCgDt2qZfu9cgcdaiHHJx70+NctggbR2rGRvEki5IOCR0HFTN/qnC4PBqJTtPPAzipwC6dDg/gRWUmbRJV5UD2pQDj2FRRNhCG4KcdKlB5555wKyZqncEzxxxS5wCcjBFKOnWm9COOhpFbDgm8AHO30PU/WnkYP+FGd2MUqk44xxUu5SDGR8wB/WhikQycDPQdSfwpJHCEBRuc8hB/WnRx7cMcNIRlmP8qXqHoKrkniJ8EewpVLygAny07Bep/GlkzsIzkngAU/oPapuWMgI8tARg4wAanUZOMGoIcGIE8j0qwqsPuk9OeaT3KjsPVQp5+tP4I+U5GPXvTY1DDjkmjkpjHIOOlFigBwM96UH8vegD5u49yKcUyeeFx6UgGgYJ65pSOBwTTHCqcNwPrzU0USmEPKWLlsBc8AY700rg3YRPvDpnHfiljKNIitIgDHBJbpRFAhJxGrHg4qaZGuJ1jSJRJIRGFVcCqSJbIWmi8wqGDn0UZqUi4cYWLA7Fj/AErTuituojjAVdpC4GBx0qo0xkwzELjHFW4W0uRGfMrkDWm1DJcszkfw7sCpreyESH5AGwAQev4GpLWJ7m9ghZgEBMrbuRtHNX7lWWUtgFB8xZRgH39a0jBWvYzlUafKU9hSMInLHhc96nhmMAUHc53dB61HG+ZXZuFjGPUZJ9KmEJlKuw/dtkjj9farj5ETt9ouaWpkcll+V2Oc9D/nFasKRXKPDOqPGQV2ZAfgc/U1kJK0CFeVJORz396b9r2RlCODyVB5B9R/WuhNI4505Td0MsJD4a1OSe1nM1pMpVsjIAzyGHr7102rWmh67paX9qGaYqEMiNh4iO3/AOuszSLJbiI7mEhl3ck9SR0I7VVnM/hm8S+0/E1ix/fQtyR7H1+tCXKtdiZ/vJ3i7TX4mPLaXmjSSOU8yBzln25yPcdPxGDUFzslY3EMm94iHIB6L/Xiup0rUY9Zu5GdjGsnBjByIvQkenvWDr+lvpV49xahQUz5qJ0wf4gP7p5yKzqU1y3jsdVKt7/JU0kNliHlRzLkowyGxUGf3ikHk45XsasW1wkukJAqKpRydynOc84J9AOlRrHkkYBHvU2uk0aptXUjNtVMdzcxjgqdw59aW+z5aE4H7wHjvUjL/wATeUdAYwelR6ht8k8DG8HisWrJmyd2hHx0HHse1RPgjtjrmkluYoycks5PCgVVnE0o/eExqTgKvWs7dymyO5mjaXqXA6KvRj70RWbzAyXMxSRjnaB0HpUsUKQDCjnoc8mrEZ+Xnj6mmpW+EzlG/wARxL4LEHOM4xTDhfbHTdSyiTcd0mOecLSeWAck7j33HpXpI+cVxu/P3ctinqC2MnAP50g9gMfSnL16jI9Kq5rFEiAKBnmpo+MjnI4wahU/Lg9CfyqXoAT2PI9qhm8WTKuakQZ9fyqJcYGRk+hqZDz1wDzWMjeI9eTjpVhD6gnioU6ZAyemf8amVB2wT9axkbxFX/XMQc5UGpAP8BTGyJIyoPORjpT1+YjB6fpUM0QAgD0+tPwevUUADOOKPLXpk4x2NTcsVQFGev07UxwVAKHDMcD/ABp5Tjhjj3pIl3Dc+STwM9hQn1H5DokEanGTnqx6mphUS55yc4p4zxxnHSolqUgHLjPYZqTnHP8AKoww34z1H8qk3A5wRj3NSykN4Vj2Ruw7VYXHGMA1F9fTFS24+Vl3YwcA0iloA27jvHB7jpU21gctznjNQn7xyOPpipoXOVD5aMdj1X6UXKFAwcEZxT1HynBx9R0oAzkgjnvUUpUAgt8xHQcmi4hMFzvIGD93B6CpY2wo+RiSeoIqJ5QflSN8+mMVZtLSSaFJJnEUb8AKMsfr6U4pvYTkluTxS25VRKZEfBBHHSn6Zc29vq0bXEqGIKwypzjPepY9LhVi6EMBnAY1FBHElxGghQbmCkpwQDxWqTumzFuMk0TXlxZzCV1nQMB8qH+dZolZzsgieQ+vStvULWKC4tIxEDumUFzznH9Kuw2wxbpFF88vI+X9a0cOZmSrRhFWMOzu/s1ysk1nKHCsgEfOQRg1alv7QwgRvciTGSsqd/QVvR6btSNTtkdFCBwPvseTj/Paq9zGRcLbQxjcoJlP4dKtRaVrmXtoTlexzdve27eYhkYKxDc8c+ldBaXEbhNxCx7Djjgnpj+tMk0JWg5VSR94MoNZyaUVuFNtKFkQ5VQcqT9OlEFKLLnKnVWjJ5nMkm2EEjOAc9ala2UQCOOIqxGTkdT/AIVTnnvbd3Uojv6KuMfSprLVoS8aXQEag4xN069atTSeopRla8S/ukh2tEBHKR90k4cf0+tXoLi2nZop/kkPXzeefb2qvOYAWMUsDRuPkbOQuPfuaopPDOqiXCyL0LL94elb3XQ5eTnV7FXV9KezuDeaS6+YhJeJe3uPY+lOjvo9V08kbhOhwyg5AHp9Klmu0UD7Owxj5k6j6g/0rnbx/Iuzc23yxyfeA4GawnNQd0ddOEppc266ksI+yah5cf8AqpOQD0H+ea0ZcMpbp7A1j3cwkkgmVQMHsau+cA2AWKgdTxWEaiVzolBuzK+SdTlJbkRhfxqrOxnZ1DHYvc9DTUmZhKUP72Vzls52ilkIhjWOPq3TP86iUi0h6tEkKyHapK8nvUQc+Ysnl5HReeaciKoQk+Yy/p7U9jnO7I+lRcohLgHiOXPYYoic7TmOUc9mFKxIB5496dCcqc7Tz3oJkcXJ95scfN0pD1PH0qSUHewAwN2RxnnrTG5HXg16aZ84lYYASBxxTh3JyD6ikGSffpTgvy5A/EelXctDh16VMBnPOeKiGQ2B2HSpkzwo5PXNRI1iOTOAD1/pU+M5weBzxUS/fGemcVNyCAO9YyZ0RJhjgjn0qQDI69sZqGLg84yOBirCY6Z5z+VYyN46i4O9enINSLhuo6UwDlc52jPenDrkf4VDNUPAGep/LrSlgPdvQUhDEZBx+FORSCe+e5qSxPLyp38k9BnpTxjHtTlwCACOnFG3HFS2UkJg7gRwMU7/ADjNKBj0xSgYAz0qbjSGNkFD6GpOOhANGMg85z60pBHHNK5SEUYyOdvr6U/aRgjt0INAJ+bGAaMAZYjoO3FIZIzArnsOaRA78xqNv95uM0kUQcb5GJx90VLknr09OlK9hjYEDJmZ2b0VeBUjlUQiONU9+ppsYIiDcEEnpUscDSKdg5HTvRdt2AaAWbOc57+9aECiK0bziQGf5cDO3jJzTQttBjewdu4UdPWkkvlkKIBiNQePWqi1EiV2TfaWlkwF2oc8Z6VY0WEfbzM+7bHkoq8lmHb6VSVoz9wHP1P8/wAa1rQeU2STwuQRx1HetIS6syqq0WkM1NwwiMak3COH2nsBV/RL6IkBhIJBGwjOOozyR9Ky45h5LF4iWdioz12DtW2jR+Vbxsqp5IMgXvgjFawldnNWilDlsaUUot4o1Zf3hdm+UY+g9v8A69JbW6xTuX275JNz5Gdw6Ac1XguY1kiWULnPyMT0Pp+lXotx3szB4l5VR1c/XtWzR57vG/mV9XtQ1wILdDGZXKlx1x1PFJLaJaQwJZxRBgfmEhwxB54PrVlg5mRZIyHcb5DuBGB061m3upyuz29tARcKAskw5UZ67c/gKuKu9AjzSSihL2yVEeZykaMAC78AfnXO3BjYBEPnEe3y/maluleR99wZJCehkJPPtTFUbQSuMnuMjNOV3ozvpR5Fe9yk9hlSUdYSeDsHBPpTmunhVUnTjoH7H2qWVxnONuO3enWUL3s6W4UMZCMCuabUNjqV2ry2Ilje6UFCd3qDwae2nKDsuSRuJVl7qf6g+tdnp/gyfzA2lXEkUxOGikiDqM+hHf6V1+lfDBpow+s3RkdvVQDj2A/rWUYyqM4a2aYeh8Uv8zwCWIwLNA/LRnKn1FOuXKQZHAYDBFer/FnwbpfhjSbW7t5p5LiSYRBJSDuB+grymWMG6WEEfIx+U+vpSnTcHqdmExUMVT9rT2IUAgQFvr160sYIbzH5Y9PYVbewfYJXO8jPygcD3qs528Dk/wBKzuzoHH5eD2zUZK556etOO4jGOf5UxiqHLFSevXpTTGNk5HQnPNWLVSyMcgfN6ZqqzruzuBHoO1PF9FbKqsSM/NzxVWb2IlJR1bOPjl8+2t2z/wAswBx+f1oPPQfKBVXRnEmmLuJOxmTIPTnIq2QMY9PWvUkuWTR8zQn7SlGfdIYFO4EH3FOUjAbJx9aDlf5cCmnOeOAexp7m60JExzg8E5AqVc9P09ajUccfoalXpjuOalmsUSIDwc8VJ0+uetMU5459qkBIHvj9KxZ0RJI/mBPQZ7VMpCZPp7VDb4Cg98ZqVM5yQR9ayluaxLEakg9yaUDOcZ9KReBz9KkVTjP6ismzdCqCD7U8Eeh69hSBec/hTgcHnpWbZohASACVY847UeYoOMkt6Ac05iFG49BTlU43N1PJ/wAKWgxn7wrwqj6nmnqwJwQVY9BnrR/nNPIDJtYAjvkZpNlIRQffFLxngUnkR8Y3Ajrg08WyHacs31OaV0NXGbgSFX5j6Cn+WzH95hEIyQOtP+WI4RQDnNAYsSSen5Ur9hjjgYA9KTkngZPpSr656dcVatVxLvOMqmQPQ1K1HckZI4ljSXB2jLAep/hFQy3BcbYwY4x/Dnr7mi73Kyljktknn3qqSQORQ30JH5xmm7h+FRs+MZ7U0Sc8fzo5WFy4jFOVJ9etW7WY7SvmbT2xz+FZ6MOuasWhHmgkED60k2mG5oSXIWT5v3oB5Ge1aenTG/uSuwHMLKT6c5AH5VgO6bgVUg9DzxWn4ZmKamoA3M4xn0HrWkJvmMq0PcbW5oedteGRkyFkJXPXPY/hjNdFbYFs6IOFOMg5z0PP51zWpQNDNIgPDA4/mcVt6VJJLp0TqW+UADnqeoPvXoNnmVopxUkaUkpihleVvM8nO8cnOfT14rMiu/PkaT7G43vlcEfKB7UyeS5W7uIGkzhC0bFeAxHOT7dKpGSZdJt1ilZJnflwvQjnPt3/ADraOmpjGmN1yTE0KBSZACxXHbNYlxKGk2pGcdccf41fv7YJOz3MpZnXIaT5ic+/bpWTJEqgBVXHpis6rkejh4xSRFMxwfl2D1Jrt/h3pRuPOvZrOWaNMKoDBUOe57nHpXDbQAxA/MkkV7j8KoAPDNu7ADNwxIA6jjrXA9XqZ5pX9hh2110PQ/Dmn2trbqY1RJCM9MYraaJDlieF9KfbgeUvFTV9BhqKjBH5pWrOc3Jny/8AEfUtV8XeM1s7NBILaQxwQAcDHVmz9K5nVfDXiM+IzYXNqv8AaV0ocBWUBgehB7dDX03rOj2iaibqCCNbludyr8xNecatcLqPxkskidHNqqRuytnBCMxH6gV5uIp+9K59pgM1vBQowSjGLfzX+Z5fd219plwLPUbV7W6C/dchsr0yCOvNYl/AIZCBn0OOOa9M+K1tHeaqjLK8c0QO11xkgnpXl+oR3cczK00cjDjcVriqR5XY9/CV3WpKbWrK+Bgkgn6mk4GMKM+1QtHcn71wM+irTDFcZz9oH4rSSXc3u+xYZuck54rj/GV80OrLEvGyFQfqcn+tdNvnRh5qo69Mp1/KvPdeuRd61eyjO3zCq59Bx/SvQy+nepd7JHgcRYl0sKlHRtr9Sbw1KN11Cx4yJF5/A1snBBOAe+a5bSJhBqsTN9xmKN9DxXWFDyG5xxx3rqxMeWpfueVk9X2mGUf5dP1Iu2fxHagA+bg8gCnEH3OeKaoCysB0Izmskz1USg9uKcnbPOfWgKPXrTkz6dKhm0UPQjv+lSNxExGfwNNQDk8jvTlHmuy4+RT83v7Vm9zeJKGC5UE57AcmpFLk9Nue7UiqoPAwAO1TL2GaybN4ocic8knvU68d8+xNRoOMA1KmATg89KxkzaKHDGeT+ZpQcngE/hSKBzT+T/8AXqGaIYueM/dB5HUn0qU5Az1pP4jgY4BpT9z8Klu41oKAdo+n509BwOPypo+YetL14H3R1NSUPBycjJzT8hjz2HamqMHBwfelPp68ipKGHn04pcEc80FcEEcn0oXDdBxnrQIUnj264q1buSpB7/L0qovvjrUifICc8A55o2AmuCsg3+vNVSBj/wCvU7Z2cnoOB6VGF9hgdsVNwZWlUkCohkYwO9Wyme2fpTPLwTxitFPSxLQsee3H4VYidlxyCB61GEwM4H0qQDjoD6Gs27jQo+Y/P83GKs2TvBcxzQZWVGyMHHfpUGB68VLArkqB948Agf55pxvcb1Wp0uoSSafdmSRsxE4JUdj6VdtLgrqXlxBRBhSOOAD3puqx/a9JbdH+8aI859xz/Ks6wnWG9eCQDbwpJPoP5V6Sfc8vlU4PTVG/d27TySyKXyq4XsTk8Gq8tu0lvbxSAROpLODwA3Axj6VftYiFllPz7gNqEkj8RTra7W5Fz5cgGwZ2464POPatVK1jjUmtuhk6lDGsDJhi6Ec9cAdMHpiubmKBSGkQYJA5wa9BnvLVbPz7hlZtgwjJnNc1qF5HesFSCGNQODtG4/jRL3zow1SS6aHMOuSQjA+mOa9K+H2sS2migyOrQw3KKy9Cobjd+dcFcWibchFbryowas6UzCaKza7ljt52Alj4+ZRyOfTIrjnHlep14mnHEUuVn1Zpd6k1sjjGCM1DqetW+nWstzezpBAo4PUn6Dua810TxQ1sZI5TlSAdpGCO3FX7u+XUmAjuF2LjaHTdtPcj3r0aWJfIo3PhpZW41Pe2OR8TeLvEnii8ksfDVpNa2uTvuGOxmX1Zz90fSvOIpJtE1uGbTL8S3asyySxn5c9G5PX616J421+zt4bixa6+1uRt+z2o2gf75FeVxxlY5JeFc/cX0571y156n2GWUUqVlFRj27+re502v6hLcSb5HBbGXfuT7Vyc5Ds3JY+hNST3csp8i4wsg7Do30qHbwa45vmZ6NOmqceVELIo6ICPpTCi7QMD3qduOvOajZcg89ecUI0KtzMLa2muCFAiRpOnoK8njJfczHJJya9A8cXJttDaMEb7mQJx6Dk/0rz6D7h+te1lsLQc+/6Hw3FOI5q0KK+yr/N/8BIic4ckZBBrtrScXFjBMP4wN2PUcGuJflz9a6HwrOGSW2bkqfMX1x0NdOLheHN2POySvyVnTf2vzX9M2sZOOfWk2jzFB9Mc+1SlMnrg/XGKYyA4yMHPB715qZ9bYcBTghPTjB4NRBmjI38r2Yf1qePBGRkg96Hoax1HRqGPP3qltvuOOSNxFMxt5/AgVJBhXkXJHOQPas5ao2juTx5H5cipF64Xr600NsUnGSOn1qSMEAA4/KsWdERwXHA6VIByCaYTtA659KeisTlj+A4xWbNEPAz05GKkHuRSKDggHjryadg4OPSs2zRCFc9DyOlPXk9MEdhQF6+1OAJYbcZAxyetS2MYp4CjOe571IuMAAYxUcOSgPHPA5qRcnn+QoY0OBo7Hnim8jG37xqRY+Pnl2nPZaVihuOcjHFNT7vPapXjdZGChZAuMlTio0YbCSrDDHIx0osAo4YDNLGAzMWztXge9Km1mxlSCexqa3AMbKCRjJFIBUUFPn7cUwpjqDxznHBqeFDI3PRhn6Ug3CJyASF4OfpRy3ArEYHOD75pG7/StGC383DEL5agE5oaGEnapHOTgnFPke5N1sUAoxjoPenIuV4HNTwxIZQirywyPXNXJNPMJXLkZ4Y+3vQoNhzJaFKOMs4GMgdR3ra0qxP2q3mK52hm2jv6CoILSXzVdGHA3E4yBVuym8q8WOXZkkJvQH6gVvSp2ephWm3FqJu3KGRYy4QFQ2Mg/MfpWLdaPLE3m20jIsaDO8dW6/hxiuijVVUyZZg+QdxyfSqmomWMzhHMYdQFUnIGPaulpM82jUlF2RDoeqZW4jvQBPsABJ4IxxjFUZ3KLDLalkuI+WwSVJ9KzpUdZjJAMjup4PXtTVvDhQIJHJ/upnn+VO/RnUqKT5o9TWWQ3YVpGJTqVA6fSlmgiSRfKXG9RtHUms+xu4sbJtyYP3ZRgEVom7hRQ8TxoO+OCOPbtWsbNGU4yi7IV4ZJtoRTGuPvyL/ICsfUYjZ3JZfmK4YuRgD2+tdFBqP2hlis4pbu4Ay237i+5J6VnX9l/on2vUJUKBjtWI/KCOuB3PuadSmpR0FRqOErS+4zZtXkeNi0rQw4B44d/YelZ8OrTJl3Zih+5Hkk49SaqXSNJKXZeOQinqcd6ntbRgm9gSxxk46e1cHLJOyPS5YJbD5JbqRo2lIjidvuKcfifWmRS7PNgc5zypPXBqTZ5txtZsBBkk981HPbs4LJgPGcgeoPal7OciuaK0KcxMqDcCWzimpIY3VJ8tH0zjkVLDh2KDKMecH1qWWASKVII4yPepURsYQg+6GPPJxULbc+je9LbysjGKbcrr90g4p91eC1tZri54WFDISeQ2O31zxVpEuVld7HnXxAvPO1hbRGzHapsOD1Y8mudh+4frSXU73NzLPKcySMXY+5OadB9w/WvpKFP2cFDsflOPxLxWInWfV/h0/Ahf77fWrGnXRs72KcDIU/MPUdxVd/vn60laNJqzOWnOVOSnHdHof3hlWBjIDA+oPIphJXGCPxrO8LXguLIwOcywfdHqh/wNa2wnjtmvEnF05OL6H6Fh60cRSjVj1I8HqM++KFTad6cHqVJ4NPCcnuB2NPU7SDj2qeY6EhYSGwemOoNLCNlxtJ6oMf4UMithgQrL6U6JGM7xyAFmAII7fSpvubLoWF+aTjICnn61NxjGfrUdvgwr689+9PkyyOF4OKwe50R2Fi3Od54B4Un0qyCeoHFRIcgbemKkC5OR1rORoiQ9On/wBan5/T2qIknJxk1Kp7gd81m0aIM4YD17UrNwSeQKAPmPXGQKUDB6f/AFqkpIbFxEhGOlOxnsabFkAr0KHb/hT/AG6c03uNbCpgEbQMAc4qU4MiehPPHUVEAMnp1qQEDBPQUFCy8IVQ8E/mamllCQFIhtbbhiO9VpGxyAMAg/rViQbiF7nHA+tUkIkuVhSKGIIpKAZIGCTUdtbMbiQb2CY3Bw3SludqySlSDzwBV7SYAkDzTgMmfpz1q4x5pakSfLG5DJbSwImNsiYwW+6eaYJCYZQInXzDyT0HpW2sP2i2jJCoS28AdcdB9fWknRXnkiiVQwHIxnj1PrWnsluZKt0ZQsZovs4JYNhcYA5B6VTdVZ8AkJ298dqtnSyplTjnDbs4IP0pzaRNHsweTyvUZP8ASj2U2th+1gnuPsbdTcGaQ/KijafUnr+grWWBrjBk3LvGcMOcVhTW10kitI+3fjaOOfpVtrO9WMs8srtnIOclvpVwg9rGVSz15jemgS2EjLlWl+UJnGQOv0qvpMctyqymFPLy0iHdg46AdOpxVGOy1O4dZWnnkbaVVXwRVzSr8rNFFMnlFECKh+UAjrn8a1Ss9TllFqDUXdl66jvHkSBYMll2gK4+Xvk1m6i1xGVQ3SSPg9FyPpU1xqU0d385bbgggH5jketZbB2XduBY84I/rRa46UGrXsMMRf5pGJOdvIwPwq7AuzovfGCc4qvaK0rrtY47Ac4PvV6KBmKq5XgZKgkfrWsY9S6kraMfFBDcyIsiiVhlsnB4q/baHbNKC0ceRkFsVLa2u51aJQqL7ckH0q3rGqR6LAiXDq67CFiVcs34/wBa1UUtzglUnJ8sCxKE0uzARIogch8cKfrXn+u6idQvhFbKJthIQIvy8/z/AApl/d6hrWpQrdqdrlfLt0HRfXH9TXeWfheLT0jdJVhlOCWPzH6Z9faou56LRGqUMJaVR3kzD0PwpKbZrq9G+5df3MbEYU+p/Xir1xoCW9o07SxxwRjJ3dfXP4119vFHp1nJI5A+X7x67fYVwfifW21K5S2jIFsW+6B1C9Pzq0ox0SOeFatiKjs9DCjs5G3ydd/znB59h+VV1BDzbz/ETwa1Lm6YDEabvU+nFZ7oohDAg7ssayskenGUnuZl7FG23fk4PLKOhIqGKRlk8mcjevIb+8Kt3ADZB4BGMVQePzouTtlU5DE965amrOyGxLdxmVA8Z/eoMg561xvj7VQNPisYvledvMlX0A6D8Tz+FdXFdRrExumCCNSzk+g615LrmoPqmqXF2/Akb5R/dXsPyrowVL2lTmfQ8LiHG/V8N7OL96eny6/5fMoVPB9w/WoKng5Q/WvcPzsif75+tNpz/fb602gRa0y8awvY515A4Yf3lPUV3avujWSOJmSQBkbI5FedV1Pg+/DobCY8rl4ff1X+tcONpXj7RdD6LIcZyT+ryektvX/g/mbnmSn/AJY4x1BakPnhgdsS8dC2asOoB+velVcE8fmeleZzJdD65RfciCTkH5owc5PFO8mU/N5q7l5X5e/pU6kEkZDd80/IbgE4FTzs0UUVre525Eykc8sOxPqKvLyBz/hVeSIOpIOHx1xn8PpUMMphZo5FIGMgf3T/AIUNKWqNItx0ZoQkKgGRxxUy5zwccdT/AIVBDGqRqMc45NTr16ZzXPLc3iOQEHFPOVIUDJbke1NBwQe5pYjudmzwPlB/nUM0Q9QVGCQSO+OtO4IPHWmjjHXJ6CncZA9OtSWho+WYjBO5c8+opRTfvT4B6L1/GpQATy2ePWmNADyMH8akB7AgUzudv/6qceCDyM8UDBk4ypOQc7R0q1AYmXzGzgcY6YqBSpAHbNBV3fzEYLkDr0b8P61UXYTC4XdtHHJHJrWQgQorMNvfHf8ACsieQbCJVIZeh6hvoatxSNKI1QnDAc5zgVdN2ZMldGzaThpDK3CBSq4p9syNbyXBYh5GwB1IUdBWc8oSMRx7QpGPQ4pXl8q1VsKw27Rnsfaug5XC/wAzbsDDIA7OEAyMt8xYDv8AXNXoiJnZxkOw+VC3btXPaJLLDuDgn5cAj8zVuWQKwlJb92Tgg4y2O1bRb5bnLUpe+0WL1Fn1CASHa6oQuejHOcVOlxuv0hh/hB3sTxjHJ+o6Vzj3bO5LMzE4wO+fUU03kkVwsrNujYAFx95frWXtDb6s7WfY6q/1NLbEVuBsDdTyT71zjypMZGukLu33Sx5T3Bp1wuxwY3SRcHle9V1ywK7QR3NN7lUqUYLQTyp3kxDcgrjIWUUJJexMwWGJscFlarCZ3Anq3OB2qXbkElgSeP8A6woVN7ouU11RUiubuFy6RYU/ewchfpWtY6kkkKoWUP1CuOvrSQQyEJG8aKc/KrE559cVU1fS0t4i+f8AebsPwrZKUVcwk6dR8r0Z2/2iCz0mS4lkUlEyzKOvtiuCur+WcS6lcruXOyIOeMjp+AqrbNPd2wN5O6adGS2D39h6n3q/odqniDWYzcqUsoB8kK8gDsD7nvRzudrEwoRw/NKWvf8Ay9ToPBGiyiybWLuQJdTH5RKMYT1P17Vcv9TlkuCYgTbQEgPnduYDt7CotT1kxpJZKn+jr9+Veo9sVWlxDYp5A/dYJVMg/jWiilocTUqkuea329Czc6uk1sIWlwMHIbkr7VySShb+5AOFAC/hU10fMXeGJZz90dKzIpMXUxcfI7BQ2e4rOpK1rHfh6CinYvM22MbAN2Du9xWe7lSASCBkYz+VWGK/NjgdBmqcjAy/OT0wKynJnTTgiMsfmJYelMj275Q3qKcQpwAOB171RvbuDTra6urk5ijUEDOCx7L+NYat2NZSjCLlJ2SOf+I2ppFbQ6fFxPJh5T3VOy/j1rzurGo3kt/ezXVwcyytuPt7VXr38PR9lBR6n5fmuOeNxDqdNl6f1qFTwfcPTrUHep4MbD9a3PNIn++31pKV/vt9abQIKdDI8MqSxMVdCGUjsRTaKGr6FJtO6PRdMv11KyW4Thx8sqj+Fv8AA9qtYG3J4A4Oe9cBompPpl4JQC0TfLIn94f413qXNs6LJHMjRsMqcV4mJoOlLTZn3+VZhHGUvefvrf8Az+f9dBwGCcD9acvIyD1xzSNLHn5ZF6etRyXUY4H6mudRb6Hq6LqXAM5PUD+VRXMYlickDeF+U5xVVbmWQEQwknPXtT1F44AY7B3xxQoOLvexXMmrJFqyl3IqyH5gAQc8MKtqeoH4VkxWiB9k29ST8rA8GrC21xEcwzZx2aonCLejNISlbVGg7BFZj2GaI8rGgIII68VQ+1SK6pcxFQvJ2859KuwzxOflkUn0J5/KspQaRtGSbJ1wSeead344+lM9Mj9KcD2HGKzNRsX35geTu/pUnQY4/EUxM+bKOByDx9Klx1+vNMEKM9iMe/Sl3bn6Hgc9+aUdAMfU0w8OvU54oGPUHNSjrjHAHFMUg8D9euacuA4GPl607ATwsyAgNjPGOoqEBkk3QcZB3Rk8fUf4UpJ4AAwe9SLhYzk85AqrEjreZZGJbnaMkd/xpJXeeaMZxj5jgdhUTxK53AEOP414NIjPFcRiYghh8rLwGP8AjVKT2YrLc10kMUZUNxjOfSojdq4UOwwT9PxqB5d3rnPH1pB8oUMNwHJ+tbc7exkoLdhklyV69qeB354pjrhgyLh89j96nIwkwyZwT0x0PcUDIebdgMYic4Iz901oIAiEgkc9fWq5QOpVxkEYIp2moJNwkc/I23JpwjZ2Jm7q5ctY8/OVJJPXsB9Kvx2cux54CC4ywYDIx/s06AII2lnZYbROrHqT6D1NJsudT0+R7cG1sXOxSDgtj1x3rrUUtDhnNyd9kSLqVnpih5ZGkuGXPygEqf1GayJ3uNduGlmH2bT05YscA4+vU1Fd2llpg2uZJJjnZGD97Ht6VRLXl1Kkc7bYiwKxg5H4+tRKT2aNqdKK9+L17v8ARF24db6VbSzgYwxc4b7uOoPtXVaIhsdKnlgt2d1TO0HDE9zVbw9YRpcCOPn5tzs38X1/wrV1m6RJo2jnEFzGTGjoeSuOQe2O9bqHKr9WcdapztUorQz/ACBZ2wa5DSM3zMGIHJ55rEvCJCWjwi4+4Pu//Wq3qd0buRHWZpEVQN5GATjmsx5SRsUAZ5xjr7VlM2owa1e5HJKQCMMcdgcgcVUsCDZFTk78kg9TUlw6iJiSAcE8/T+VR2ylbWHpgJk+9czfvHco+6NyQfLfkqMg+o/xqtM3Qfex1qadmVw44CHnPJwfWo2UcHGQfUVnJ30NY6ajI1Zm2g9fWvNfG2tLqN99ntWzaW/ygjo7d2/oK6DxzrgsYH060f8A0mZf3zd0X+79T/KvOa9DA4f/AJey+X+Z8hxJmu+DpP8Axf5f5/d3CgUUV6p8WFTwH5D9ahqaH7n40xET/eP1ptOf75+tIaQCUtJRQAVt+G9UjtJhBeANaufvEZMZ9fp61iUVFSmqkeVnRhcTPDVFVp7r+rHpv2WFlZjGm0jIA6Y9fenwW0SoD5alvfmuU8M66IEFjesPJPEUh/5Zn0Pt/Kuzxzg9exHevDrwnSfLI/RMBiqOMpqpT+a7P+thFztz+FP2nPH69aaOuD27U8YHr061zM9JICI5F2uu5f1FIrPEpEvzJ2cdvrS9T+FSqSh3D7wpXLS6iREMXcEEE4B9abLbRSAkx4b1HXNDFY5AVwEkJ4PZqmHUHNJ3WqKST0ZFFDcI22JxKp6I3X86nWUK5SYeXJnkHv8AjSr7fWllAmXEw3L9Oalu+5SjbYPuz9OGX9RU4ORjHWoUsJiqy2kivs/gY8j8KUXCoQk6mJ++7ofxp8rGpLqSj/Z6UrqSAflDA5A9aRHDHgq3uDTiPmAPAAzjFKxQoIYAr93P4j605jyGI4HXNI6AsDyGJ6jjNAVjgLKTkdGXP607CHkfKMinKOMEDp27VEBKij7rqOMYwfwp4kG7DbkboQ4/kapLqImHTB7dec49KieNJAynjfwTnrjpUpXA3BTj+dORu4APHpV8t9CblVJWhkC3HK9FkH9auNgoWJ49QaDENhVhkehqq9rJEN1s7AA5CNyv501FxFdMtrnIKkYzTihVi8eDn7yg/qKht7hXLKwMcq8Fc/yqzFcWsQbz50Unt1NaxSl1M5Nx6EttiXp1PHPr70+GHyL9xJ/q2I3exH8qzmvBDOZLRC6lcneMAH1AqHUG1GZQbrIVsMo3Y/QVXMktrsnkbe9kzSvbpZr3yncR2Ub5PbnH60+68SBY1tNKjBQdXKls/QVnP4fmhhE1zv8AM2hvJCnIJ6A57mum8O6TbidGCE7SOv8AGfr7VpCNWT7GNSVGMbvWxHpOiIZzdavcEysA2xuWPsf8BSarHBJq1vHZBZHDDcB6c4H4VYv5zLeytbtlC20c9APWqfhkKdRvLtwJDFuPp0GK2WlomCcmnUk+mxvvfQ2MLwWvEuP3jgdW9K5u9k82Xc7HcfmYkdafPcM85kJwzEnDDof8mq0k/wC7MYGWzu3dTnFTOSZVGlyakDuUJaM/IOqH+npTEmD4JbDDqD2pZgckDGPT+VQsFdFLID26dK5JNndFKwy95tiBgliF9+TU6FVTIyp+7+H+RVCUk3Mcf3lB38nmpt7rjcAqjrz0qOb3i+XSxfhVfLY4yvQ571zXivXodCs2VNj3kmRBGecD++fYdvWrPiPxBbaHpwkfD3Dj91CDguf7x9hXj2pX1xqN7LdXchkmkOST/Ie1dOGwzrPml8P5ngZzm6wUXSpP94/w8/Xt9/rDPNJPM8szl5HJZmPUk96joor2krH57KTk7sO1LRRTJCpoB8h+tQ1PB9w/WgCF/vN9abVyT77fWk7UwKlFWxQe1AFSira0o60gKZrp/DfiHyAlnqDEwDiOU8mP2PqP5VhUGs6tKNWPLI7MHjKuDqKpSf8AwfU9Q64x82cEFeQfcGgd/WoPDn/IAsf+uZ/nV5en5189OHK2ux+nUqvtKcZ23Sf3ohXsfSnE88fpU5+/+NIvQ1FjZMidVMZD4xj8qS2kLYVwVkHrxmpZ/up9as3n/HpH/wBdBSa2XcalrchB6jnHtTxz35qSHo3+8aev3DU2NUyNWK5ZSR3zml4ucG5BkGMe4H1qWX/Ut/umlt/9Yf8APemkDZH/AGfaSD5JHQAcZHSnx6eij5LyQNnC46e2c1ZH3F+tCf8AHxF+H860ST3M/Qhns7+BisgSVc/eU4z6cimwzLL8qkq4PzI3BFdAn/LP/f8A8a5mf/kIn/rqaurBQehNOo5LU0hGcAY56cUNGHXhcr6EZBq1bdPwFNl/49T9f61o0rC5nexUWAqMwP5a9dp+Zf16UkM0UCFJmRHU5zu4YZ7VBqHT86yh0f6Vkn1RUn0ZttqUDMBGJJW9FWmStfzkLDbyQ56D+I/X0rR+HX/IY/4Af5V0Okf8hJ/of5GumnSdRas5amI9m2ktkZ0Pg1Hs4JXuMyscyYAwMdQCep6VCmm2UBkCIWOcFnAP6dq6aL/UQf8AXw38hVGf/j/k+p/lXTCjBbI5ViKkm+ZmNPLa2KM8kcZHKhMYLH2H9ar6HZtPqMdzMfmZh5cX/s+PSodX/wCQv/2zNdH4a/5CUH/XH+lZQtKpbsdFSTp0uZbtHTeVvvYJpmD2yLk7wOWx1+uK528vYo7mdrY7gxbZ2CD0963L7/kBQfVv/QjXLXP+q/H+ldUtFc8/DxUtX6FESsIFI53D8Oc1Bol28dtfANgnjnnqxrRf/V/gP6Vnad/x5Xv+9/7NXI21NP1PSjZwat2GvMQDhiWbjJPIqJM7iTwf0pf4h/ntVyP7q/j/ACrN+89Ta/KtCkeHIHAHv0pjYzgNjn61dPQfSnD7j/WspIpSMWJhLNLKehO0e2KoeI9dt9EtxJMFku2/1UIPX3PoK2rP/j3P/XQ/zrzH4hf8jTc/7q/yq8NSVWfK/NnBnGNng8O6lNa3SXlfqc1qV/cajeSXN3IXlc8nsB6AdhVWrdA6V7sUoqyPzOpUlUk5zd2ypS1aFFUZlWirY6Ug6UAVamhxsOfWpB1qe3+4frQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fundus photograph of a diffuse capillary-venous malformation in a patient with Sturge-Weber syndrome. Note \"tomato catsup\" appearance to fundus and increased cupping of the optic nerve head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold DH, MD, and Weingeist TA, MD, PhD. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40400=[""].join("\n");
var outline_f39_29_40400=null;
var title_f39_29_40401="Patient information: Balanitis (The Basics)";
var content_f39_29_40401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87105\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/59/13246\">",
"         Anatomy of penis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/40/21135\">",
"          Paraphimosis",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/48/41729\">",
"         Patient information: Caring for an uncircumcised penis (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Balanitis (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H4789287\">",
"      <span class=\"h1\">",
"       What is balanitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Balanitis is the medical term for when the head of the penis (in a man) or the clitoris (in a woman) is swollen, sore, or inflamed. This condition most often affects men and boys, so this article will focus only on them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4789302\">",
"      <span class=\"h1\">",
"       What are the symptoms of balanitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms often get worse over 3 to 7 days and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain, tenderness, or itching on the head of the penis (also called the &ldquo;glans&rdquo;) (",
"        <a class=\"graphic graphic_figure graphicRef87005 \" href=\"mobipreview.htm?12/59/13246\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Red sores on the head of the penis or the skin around the head of the penis (also called the foreskin or &ldquo;prepuce&rdquo;)",
"       </li>",
"       <li>",
"        Thick, bad-smelling pus on the head of the penis",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these symptoms are not treated in a man or boy who is not circumcised, the penis can swell and the foreskin can get stuck to the head of the penis or just below the head of the penis. The foreskin can also form scars.",
"     </p>",
"     <p>",
"      In some cases, balanitis can make it hard to urinate.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4789340\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have the symptoms described above, see your doctor or nurse right away. Go to the emergency room if you are not circumcised and your foreskin is stuck just below the head of your penis and won&rsquo;t move. This could cause permanent damage (",
"      <a class=\"graphic graphic_figure graphicRef87006 \" href=\"mobipreview.htm?20/40/21135\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4789372\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Your doctor or nurse will need to find out what might be causing your balanitis. To do that, he or she will probably:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take samples of the fluid from your penis to check for infection",
"       </li>",
"       <li>",
"        Order blood tests to check for diabetes or infection",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4789387\">",
"      <span class=\"h1\">",
"       How is balanitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment varies depending on the cause of the balanitis.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If your balanitis is caused by a yeast infection, you will be treated with medicines called &ldquo;antifungals.&rdquo; These medicines come as a cream or gel that you put on your penis, or as pills you take by mouth. Yeast infections most often affect men with diabetes.",
"       </li>",
"       <li>",
"        If your balanitis happened because you did not clean your penis well, you will have to rinse your penis twice a day. After your symptoms get better, you will need to begin cleaning yourself better with mild soap and water every day. (But don&rsquo;t use soap while you still have symptoms. Soap can make symptoms worse.)",
"       </li>",
"       <li>",
"        If your balanitis is caused by infection with bacteria you will be treated with antibiotic pills. Infections that can cause balanitis include infections you can catch during sex.",
"       </li>",
"       <li>",
"        If your balanitis is caused by an allergy or skin reaction to soaps, medicines, or chemicals, you will be treated with steroid creams or ointments. These steroids reduce inflammation and help the skin heal.",
"       </li>",
"       <li>",
"        In rare cases, balanitis is a symptom of cancer or a sign that cancer might soon develop. If your balanitis is related to cancer, you will get treated with surgery or cancer medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment of balanitis in boys is very similar to treatment in men. But boys sometimes need special treatments to help them urinate. Boys also sometimes get antibiotic creams or ointments to put on the penis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4789419\">",
"      <span class=\"h1\">",
"       Can balanitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can reduce your chances of getting balanitis by keeping your penis clean. This is especially important if you are not circumcised. After your symptoms are cured, wash your penis every day with soap and water. If you are not circumcised, be sure to pull back the foreskin to clean under it. Then dry the skin there before you put the foreskin back.",
"     </p>",
"     <p>",
"      Keeping your penis clean is important, but it is also possible to go too far. Clean the area gently, with water that is not too hot. Use mild soap, but be careful not to scrub the area too roughly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4789434\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/48/41729?source=see_link\">",
"       Patient information: Caring for an uncircumcised penis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/29/40401?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87105 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40401=[""].join("\n");
var outline_f39_29_40401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4789287\">",
"      What is balanitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4789302\">",
"      What are the symptoms of balanitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4789340\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4789372\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4789387\">",
"      How is balanitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4789419\">",
"      Can balanitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4789434\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/59/13246\">",
"      Anatomy of penis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/40/21135\">",
"       Paraphimosis",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/48/41729?source=related_link\">",
"      Patient information: Caring for an uncircumcised penis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_29_40402="Mounier Kuhn CXR";
var content_f39_29_40402=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tracheobronchomegaly Mounier-Kuhn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast tracheobronchogram shows tracheobronchomegaly with massive dilation of trachea and mainstem bronchi.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40402=[""].join("\n");
var outline_f39_29_40402=null;
var title_f39_29_40403="Pegloticase: Patient drug information";
var content_f39_29_40403=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pegloticase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=see_link\">",
"     see \"Pegloticase: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11302849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Krystexxa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11358510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. Tell your doctor about any fever, rash, feeling tired, upset stomach, throwing up, loose stools, belly pain, flu-like signs, sore throat, cough, or trouble breathing. Do not restart this drug if you have had an allergic reaction.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11358524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat gout attacks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11347432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2980719",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pegloticase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have G6PD deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11347434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11358528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bruising.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11347436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11358527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as an infusion into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F11347433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11347437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16077 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40403=[""].join("\n");
var outline_f39_29_40403=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302849\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358510\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358524\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347432\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347434\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358528\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347436\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358527\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347433\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11347437\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/38/41572?source=related_link\">",
"      Pegloticase: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_29_40404="Haemophilus influenzae type b-meningococcal serogroups CY combination vaccine: Pediatric drug information";
var content_f39_29_40404=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Haemophilus influenzae type b-meningococcal serogroups CY combination vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?40/21/41300?source=see_link\">",
"    see \"Haemophilus influenzae type b-meningococcal serogroups CY combination vaccine: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F14855816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Inactivated Bacteria",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F14856284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/21/41300?source=see_link\">",
"      see \"Haemophilus influenzae type b-meningococcal serogroups CY combination vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Primary Immunization:",
"     </b>",
"     Infants &ge;6 weeks and Children &le;18 months: I.M.: 0.5 mL per dose; administered as a 4 dose series at 2, 4, 6, and 12 through 15 months of age; first dose may be administered as early as 6 weeks of age and last dose in series as late as 18 months of age",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The ACIP recommends vaccination only for infants 6 weeks to 18 months of age who are at an increased risk for meningococcal disease. If an infant at increased risk is behind on Hib vaccine doses, Hib-MenCY-TT may be used to catch up using the current Hib schedule. If the first dose of Hib-MenCY-TT is given &ge;12 months of age, 2 doses should be given 8 weeks apart. If infants have/will receive a different Hib vaccine, a 2-dose series of a quadrivalent meningococcal vaccine is recommended (Menactra&reg; for ages 9-23 months; Menactra&reg; or Menveo&reg; for ages &gt;23 months) (CDC, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14944375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F14471244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     MenHibrix&reg;: FDA approved June 2012; availability expected April 2013. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14856293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     I.M.: Reconstitute vaccine with supplied diluent; shake well; administer immediately; in infants administer to the anterolateral aspect of the thigh; in children &ge;12 months to &le;18  months, the deltoid muscle of the arm may be used. Do not administer I.V. or subQ. Do not coadminister with other Hib-containing vaccines (CDC, 2013). U.S. law requires that the date of administration; the vaccine manufacturer; lot number of vaccine; and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F14856268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Store diluent at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F) either under refrigeration or at room temperature; do not freeze; discard if the diluent has been frozen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Reconstituted solution: Use immediately; do not freeze, discard if has been frozen.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14855817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunization against",
"     <i>",
"      Neisseria meningitidis",
"     </i>",
"     serogroups C and Y and",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type b (FDA approved in ages 6 weeks to 18 months)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends vaccination only for infants and children 6 weeks to 18 months of age who are at increased risk for meningococcal disease, including those with:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &bull; Persistent complement pathway deficiencies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &bull; Anatomic or functional asplenia, including sickle cell disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &bull; Living in communities with serogroups C and Y meningococcal disease outbreaks",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The ACIP does not recommend routine vaccination for infants not at increased risk for meningococcal disease. In addition, infants traveling to certain areas (eg, meningitis belt of sub-Saharan Africa) will require a meningococcal vaccine with serogroups A and W135; vaccination with Hib-MenCY-TT is not adequate (CDC, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14944374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       MenHibrix&reg; (Meningococcal Polysaccharide (Groups C and Y) and",
"       <i>",
"        Haemophilus",
"       </i>",
"       b Tetanus Toxoid Conjugate Vaccine) may be confused with Hiberix&reg; (",
"       <i>",
"        Haemophilus",
"       </i>",
"       b Conjugate Vaccine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F14944409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Central nervous system: Fever &ge;100.4&deg;F (38&deg;C), drowsiness, irritability",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Gastrointestinal: Appetite decreased",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Local: Injection site reactions: Pain, redness, swelling",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Rare but important or life-threatening: Allergic reactions, anaphylactic/anaphylactoid reactions, angioedema, apnea, hypotonic-hyporesponsive episode, injection site induration, rash, somnolence, seizures (with or without fever), swelling of vaccinated limb (extensive), syncope, urticaria, vasovagal response",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14856253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hypersensitivity to any component or any meningococcal-,",
"     <i>",
"      H. influenzae",
"     </i>",
"     type b-, or tetanus-containing vaccines",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14856264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute febrile illness. Use with caution in immunocompromised patients; has not been evaluated for use in immunosuppressed children; in general, severely immunocompromised patients [eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high-dose corticosteroids)] may have a reduced response to vaccination. Vaccination may not result in effective immunity in all patients; response depends upon multiple factors (eg, type of vaccine, age of patient) and is improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immune competence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with coagulation disorders, including thrombocytopenia, due to an increased risk for bleeding following I.M. administration; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14856263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine use. Guillain-Barr&eacute; syndrome occurring within 6 weeks of vaccines containing tetanus toxoid has been reported; consider potential risks and benefits prior to use. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. Menhibrix is not a substitute for routine tetanus immunization. Do not coadminister with other Hib-containing vaccines (CDC, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14975263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14975261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14944376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14944377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14856294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14856269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Provides active immunity against meningococcal disease via the formation of bactericidal antibodies directed toward the polysaccharide capsular components of",
"     <i>",
"      Neisseria meningitis",
"     </i>",
"     serogroups C and Y; stimulates production of anticapsular antibodies and to",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type b",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F14856357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     May cause increased sleeping, restlessness, fussiness, decreased appetite, or fever; use antipyretic if directed by healthcare provider. May cause some redness, pain, or swelling at injection site; consult healthcare provider if excessive or persistent. Notify healthcare provider immediately of any excessive or persistent reactions (eg, fever &gt;105&deg;F within 48 hours, inconsolable crying that occurs within 48 hours and lasts 3 hours, seizures that occur within 3 days).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14856361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     In  order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/29/40404/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Advisory Committee on Immunization Practices (ACIP) Vaccines for Children Program - Vaccines to Prevent Meningococcal Disease, Resolution No. 6/11-1. Available at:",
"      <a href=\"file://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/06-11mening-mcv.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/06-11mening-mcv.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2013, 62:52-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/29/40404/abstract-text/23344698/pubmed\" id=\"23344698\" target=\"_blank\">",
"        23344698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention and Control of Meningococcal Disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-7):1-21. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-61. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/29/40404/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/29/40404/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86367 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40404=[""].join("\n");
var outline_f39_29_40404=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855816\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856284\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944375\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471244\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856293\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856268\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14855817\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944374\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944409\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856253\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856264\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856263\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975263\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975261\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944376\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944377\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856294\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856269\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856357\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14856361\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86367\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86367|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/21/41300?source=related_link\">",
"      Haemophilus influenzae type b-meningococcal serogroups CY combination vaccine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_29_40405="T shaped uterus 1";
var content_f39_29_40405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68607%7EOBGYN%2F80368%7EOBGYN%2F62485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68607%7EOBGYN%2F80368%7EOBGYN%2F62485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diethylstilbestrol (DES)-related anomalies: T-shaped uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diethylstilbestrol (DES)-related anomalies: T-shaped uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diethylstilbestrol (DES)-related anomalies: T-shaped uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40405=[""].join("\n");
var outline_f39_29_40405=null;
var title_f39_29_40406="Hepatic granulomas";
var content_f39_29_40406=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic granulomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40406/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40406/contributors\">",
"     Steven Flamm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40406/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40406/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40406/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40406/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/29/40406/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomas can be present in the liver in a variety of conditions. Their detection in the liver may be the first clue to an ongoing systemic disease. Although the granulomas themselves rarely cause structural liver damage, it is important to identify the underlying systemic disease since it might have prognostic and therapeutic implications. Careful consideration of associated clinical symptoms and characterization of the appearance and localization of the granulomas within the liver usually leads to a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A granuloma is a circumscribed lesion that forms as a result of an inflammatory reaction in body tissues. It is characterized by a central accumulation of mononuclear cells, primarily macrophages, with a surrounding rim consisting of lymphocytes and fibroblasts. The lesions are distinct from nearby uninvolved tissue (",
"    <a class=\"graphic graphic_picture graphicRef64126 \" href=\"mobipreview.htm?18/3/18486\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Early in the development of the granuloma, lesions may appear as punched-out clusters of histiocytes or lymphocytes. The granulomas evolve with stimulation of mononuclear cells from a variety of cytokines. Activated macrophages are transformed to resemble epithelial cells (referred to as epithelioid cells), which characteristically have abundant, pale cytoplasm. Adjacent macrophages may fuse, forming multinucleated giant cells. Granulomas infiltrated by eosinophils are suggestive of a drug reaction or parasitic infection.",
"   </p>",
"   <p>",
"    The cells within the granuloma are capable of secreting a variety of proteins. As an example, epithelioid cells from patients with sarcoidosis secrete lysozyme, collagenase, and angiotensin converting enzyme (ACE). Elevated serum levels of ACE are characteristic of active sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histologic features of the granulomas and their location may be helpful for narrowing the differential diagnosis. Four histologic variants of hepatic granulomas have been recognized, the first two of which are most common in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Noncaseating - such as seen with sarcoidosis.",
"     </li>",
"     <li>",
"      Caseating &ndash; which are characterized by central necrosis. A common example is tuberculosis.",
"     </li>",
"     <li>",
"      Fibrin-ring &ndash; in which epithelioid cells surround a vacuole that often has an encircling fibrin ring. Conditions associated with fibrin-ring granulomas include, Hodgkin lymphoma, cytomegalovirus (CMV), leishmaniasis, hepatitis A, toxoplasmosis, giant cell arteritis, Boutonneuse fever, and Q fever, and use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Lipogranulomas &ndash; which contain a central lipid vacuole (usually seen in patients who ingest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"       mineral oil",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Granulomas can be located throughout the hepatic lobule. However, a tendency to be located in specific sites is recognized in some disorders. Examples include the portal or periportal location of granulomas in sarcoidosis, and the portal location in primary biliary cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of granulomatous liver disease depend upon the underlying cause and its severity. Fever is the most common clinical symptom (especially in tuberculosis, sarcoidosis, and infectious causes). Patients may also experience night sweats and weight loss. Hepatomegaly may be present. Portal hypertension is seen only in cases of sarcoid, primary biliary cirrhosis, and schistosomiasis.",
"   </p>",
"   <p>",
"    On the other hand, in many patients, minor elevations in serum aminotransferases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alkaline phosphatase may be the initial clue. However, the serum alkaline phosphatase can be normal. In other patients, the clinical features reflect the underlying systemic disease. The diagnosis is established by liver biopsy and by specific testing for the underlying diseases. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomas in the liver are associated with a myriad of disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/3\">",
"     3",
"    </a>",
"    ], the prevalence of which depends upon geographic location and the specific population. They may also be an incidental finding on otherwise normal liver biopsy specimens. Thus, an isolated granuloma (or perhaps two on a large liver biopsy specimen) does not necessarily indicate the presence of granulomatous liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly, granulomas encountered in patients with known forms of liver disease (such as hepatitis B) may represent an incidental finding that has no bearing on clinical manifestations or response to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequent causes of hepatic granulomas in the United States are sarcoidosis, tuberculosis, primary biliary cirrhosis, and drug reactions, which account for approximately 50 to 75 percent of hepatic granulomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Other diagnoses should be considered in specific settings. As an example, Leishmania tropica, which usually causes cutaneous disease only, was associated with hepatic granuloma formation in United States soldiers returning from Iraq after operation Desert Storm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is helpful to conceptualize the different causes of hepatic granulomas by subdividing them into broad general categories, including those associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic infections",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Drugs",
"     </li>",
"     <li>",
"      Autoimmune disorders",
"     </li>",
"     <li>",
"      Idiopathic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following section will summarize disorders within these categories while focusing on some of the more common causes of hepatic granulomas within each category.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among diseases thought to have an autoimmune etiology, sarcoidosis and primary biliary cirrhosis are most commonly associated with hepatic granulomas. Hepatic granulomas may also be seen in granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) and with polymyalgia rheumatica. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a systemic granulomatous disease of unknown etiology characterized by the formation of noncaseating epithelioid granulomas. Clinically recognizable gastrointestinal system involvement occurs in 0.1 to 0.9 percent of patients, although the incidence of subclinical involvement is much higher. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/14/17638?source=see_link\">",
"     \"Gastrointestinal sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Within the alimentary tract, the stomach is the most commonly involved, but sarcoidosis of the esophagus, appendix, colon, rectum, and pancreas have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/6,8-10\">",
"     6,8-10",
"    </a>",
"    ]. The liver is almost always involved, although the clinical consequences of the involvement are variable. Most patients are asymptomatic and have only biochemical abnormalities (usually an elevated alkaline phosphatase and gamma glutamyl transpeptidase). Rare patients have cirrhosis, cholestatic liver disease, and hepatic vein thrombosis. Clinically apparent liver disease is uncommon even in patients who have numerous hepatic granulomas.",
"   </p>",
"   <p>",
"    The diagnosis is suggested by liver biopsy, which will contain granulomas in the majority of specimens that are of adequate size (ie, more than 2 cm). The granulomas are often located in the portal tract. However, liver biopsy itself is not sufficient to establish the diagnosis. The serum angiotensin converting enzyme level may also be elevated, but is normal in approximately 25 percent of untreated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, there are three central steps to confirming the diagnosis since there is no pathognomonic laboratory finding (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recognition of the characteristic clinical findings",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest x-ray abnormalities.",
"     </li>",
"     <li>",
"      Securing histologic evidence of noncaseating granulomas, which is the essential component of the diagnosis.",
"     </li>",
"     <li>",
"      Ruling out infection, particularly tuberculosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of hepatic sarcoidosis depends upon the clinical manifestations of the disease. As mentioned above, the majority of patients are asymptomatic, and thus do not require specific treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/12\">",
"     12",
"    </a>",
"    ]. Whether corticosteroids could prevent hepatic disease progression or the development of complications is unproven and therefore not recommended for hepatic disease alone. In patients with severe cholestasis or portal hypertension and constitutional symptoms, a short course of corticosteroids can be considered to see if the patient has a favorable response.",
"   </p>",
"   <p>",
"    The uncommon patient who develops other hepatic complications due to sarcoidosis may also benefit from specific treatment. A number of complications have been described, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse intrahepatic biliary strictures resembling sclerosing cholangitis, which may respond to corticosteroids&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatic vein thrombosis due to narrowing of the hepatic veins from involvement with sarcoid granulomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3434?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Portal hypertension (presumably presinusoidal due to the presence of periportal granulomas) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A syndrome of cholestatic jaundice with pruritus and hypercholesterolemia resembling primary biliary cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/16\">",
"       16",
"      </a>",
"      ]. Most such patients were black males presenting with fever, hepatosplenomegaly, jaundice, and pruritus in whom liver biopsy showed ductopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"       Ursodeoxycholic acid",
"      </a>",
"      has been used in such patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Primary biliary cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary biliary cirrhosis (PBC) is characterized by an ongoing immunologic attack on the intralobular bile ducts that eventually leads to cirrhosis and liver failure. The liver profile and hepatic histology may mimic sarcoidosis. As mentioned above, some patients with sarcoidosis develop cholestatic liver disease resembling PBC. However, the disorders can usually be distinguished by the presence of anti-mitochondrial antibodies in PBC and the patient demographics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Systemic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common infections causing granulomatous liver disease in the United States include tuberculosis, acquired immunodeficiency syndrome (AIDS)-related infectious diseases (eg, Mycobacterium avium complex (MAC), cryptococcal infections), and fungal infections such as disseminated histoplasmosis and coccidioidomycosis. Elsewhere in the world, schistosomiasis, leprosy, brucellosis, and Q fever are also common (",
"    <a class=\"graphic graphic_table graphicRef81043 \" href=\"mobipreview.htm?10/9/10396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic granulomas are present in more than 90 percent of patients with miliary tuberculosis, approximately 70 percent of those with extrapulmonary tuberculosis, and about 25 percent of patients with what appears to be isolated pulmonary infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/20\">",
"     20",
"    </a>",
"    ]. Symptoms including fever, night sweats, fatigue, anorexia, and weight loss may be nonspecific. Serum aminotransferases may be minimally elevated and jaundice is rare. Granulomas are characteristically found in the portal areas and may or may not caseate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/8\">",
"     8",
"    </a>",
"    ]. Acid-fast bacilli can occasionally be seen within the granulomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     AIDS related causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIDS patients are susceptible to a variety of conditions that may be associated with hepatic granulomas. Infectious etiologies include mycobacteria (eg, M. tuberculosis and MAC), Cryptococcus neoformans, CMV, histoplasmosis, and toxoplasmosis. In addition, many of the medications used to treat these infections may themselves be associated with granulomas. Examples include sulfonamides and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Fungal diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common diseases associated with hepatic granulomas are histoplasmosis, coccidioidomycosis, cryptococcosis, candidiasis, and blastomycosis. (See appropriate topic reviews.) Histoplasmosis and coccidioidomycosis should be considered in patients living in endemic areas (southern and central regions of the United States for histoplasmosis, and the southwestern United States for coccidioidomycosis), particularly among those who are immunocompromised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Q fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Q fever is caused by exposure to Coxiella burnetii, a rickettsial agent that infects cows, goats, and sheep. Organisms may be inhaled, ingested, or acquired through tick bites. The disease is characterized by pneumonia with headaches, fever, and myalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, the hepatic granuloma characteristically has a ring of fibrinoid necrosis surrounded by lymphocytes and histiocytes (fibrin-ring granuloma). However, fibrin ring granulomas are not diagnostic of Q fever since similar lesions can be seen in patients with other disorders such as hepatitis A, Hodgkin lymphoma, and those taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/10,21,22\">",
"     10,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12502?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Q fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Brucellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brucellosis (also called undulant, Mediterranean, or Malta fever) is a zoonotic infection that is a well documented cause of fever of unknown origin. It is acquired through contact with cattle, goats, or swine, or ingestion of unpasteurized dairy products. In addition to fever, other prominent symptoms include sweats, malaise, anorexia, fatigue, weight loss, and depression. The onset of symptoms of brucellosis may be abrupt or insidious, developing over several days to weeks. Symptoms can last for months with periods in which patients feel relatively well (hence the name \"undulant\" fever).",
"   </p>",
"   <p>",
"    Patients tend to have a multitude of complaints, often without objective findings except fever. Physical findings, when present, are usually limited to minimal lymphadenopathy and occasionally hepatosplenomegaly.",
"   </p>",
"   <p>",
"    Virtually any organ system can be involved with brucellosis, and localization of the process may cause focal symptoms or findings. Four species, Brucella melitensis, B. abortus, B. suis, and B. canis, are known to cause disease in humans. Hepatic granulomas have been best described in patients infected with B. abortus and B. melitensis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of brucellosis should be considered in an individual with otherwise unexplained chronic fever and nonspecific complaints. Serum agglutinin titers of &ge;1:320 are considered diagnostic of infection. Such patients should be questioned for possible sources of exposure to Brucella, including contact with animal tissues or ingestion of unpasteurized milk or cheese. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16058?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma, and to a lesser extent non-Hodgkin lymphoma and renal cell carcinoma, have been associated with hepatic granulomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Lesions are distinct from lymphomatous areas and are not thought to reflect a concomitant infectious etiology. The presence of granulomas is not considered pertinent to the staging of Hodgkin lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs have been associated with hepatic granulomas, the most common of which are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , sulfa drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56830 \" href=\"mobipreview.htm?10/31/10747\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of hepatic granulomas may remain unclear despite careful evaluation in a subset of patients. The exact proportion is unknown but is probably in the range of 10 to 36 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/3\">",
"     3",
"    </a>",
"    ]. The term \"granulomatous hepatitis\" refers to a syndrome characterized by a prolonged febrile illness, myalgias, hepatosplenomegaly, and arthralgias of unclear etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/26\">",
"     26",
"    </a>",
"    ]. Laboratory findings are nonspecific. The sedimentation rate is often markedly elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of symptomatic idiopathic granulomatous hepatitis involves immunosuppression. A concern is that some patients initially diagnosed with granulomatous hepatitis have been subsequently diagnosed with lymphoma, tuberculosis, Q fever, or polymyalgia rheumatica during follow-up. Because immunosuppression in patients with tuberculosis may worsen the disease, it is reasonable to treat initially with an empiric course of antituberculous medications in patients in whom there is a concern about underlying tuberculosis. If there is no clinical response after four to eight weeks, empiric corticosteroids should be instituted, which usually lead to rapid improvement in symptoms and disappearance of the granulomas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticosteroids &ndash; We recommend an initial course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (20 to 40 mg per daily) for treatment of idiopathic granulomatous hepatitis in whom tuberculosis is not suspected. A biochemical response should be noted within several months. Once symptoms have improved, gradual weaning of corticosteroids should be attempted. The prognosis in patients who respond to corticosteroids is good, although relapse after discontinuation of corticosteroids is common and a repeat course of corticosteroids is often necessary.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      &ndash; Methotrexate has been used successfully in patients who did not respond to or refused corticosteroids&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/27\">",
"       27",
"      </a>",
"      ]. One such report included six patients with idiopathic granulomatous hepatitis in whom methotrexate (15",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      was associated with resolution in fever and improvement in fatigue and anorexia within three months of beginning therapy. Granulomas resolved in four patients in whom a liver biopsy was repeated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic granulomas are found in approximately 2 to 10 percent of patients who undergo a liver biopsy and may be caused by a variety of conditions (",
"    <a class=\"graphic graphic_table graphicRef81043 \" href=\"mobipreview.htm?10/9/10396\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56830 \" href=\"mobipreview.htm?10/31/10747\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76923 \" href=\"mobipreview.htm?15/11/15547\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/4,28,29\">",
"     4,28,29",
"    </a>",
"    ]. They may also be an incidental finding on otherwise normal liver biopsy specimens. Thus, an isolated granuloma (or perhaps two on a large liver biopsy specimen) does not necessarily indicate the presence of granulomatous liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40406/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many hepatologists consider the following to be useful ways of categorizing patients in whom hepatic granulomas are discovered:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those in whom the diagnosis is already known based upon clinical and laboratory features (such as patients with primary biliary cirrhosis).",
"     </li>",
"     <li>",
"      Those in whom the diagnosis can be made by liver biopsy (such as schistosomiasis).",
"     </li>",
"     <li>",
"      Those in whom the diagnosis is strongly suspected based upon clinical and laboratory features (such as sarcoidosis).",
"     </li>",
"     <li>",
"      Those in whom the diagnosis is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of hepatic granulomas may be a clue for diagnosing an underlying systemic disorder, which should be sought by obtaining a careful history and judicious laboratory testing (",
"    <a class=\"graphic graphic_table graphicRef76240 \" href=\"mobipreview.htm?1/59/1979\">",
"     table 4",
"    </a>",
"    ). Liver biopsies should be subjected to polarizing light microscopy (occasionally foreign body talc granulomas will be identified) and acid-fast and fungal staining. A thorough diagnostic workup will identify the etiology in most patients.",
"   </p>",
"   <p>",
"    The most common causes in the United Sates are sarcoidosis, mycobacterial infection (M. tuberculosis and Mycobacterium avium complex), primary biliary cirrhosis, and drug reactions. A variety of other pathogens should be considered in patients with specific risk factors who are from developing nations or who have a recent travel history (",
"    <a class=\"graphic graphic_table graphicRef81043 \" href=\"mobipreview.htm?10/9/10396\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39304?source=see_link\">",
"     \"Evaluation of fever in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment should be directed toward the underlying disorder. An empiric course of anti-tuberculous therapy should be considered if fever and other nonspecific symptoms are present, there is concern for underlying tuberculosis, and a specific diagnosis cannot be made. Corticosteroids should be used in nonresponding patients in whom the diagnostic evaluation was unrevealing.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/1\">",
"      Ishak KG. Granulomas of the liver. Adv Pathol Lab Med 1995; 8:247.",
"     </a>",
"    </li>",
"    <li>",
"     Maddrey WC. Granulomas of the liver. In: Schiff's Diseases of the Liver, Eighth Edition, Schiff ER, Sorrell MF, Maddrey WC (Eds), Lippincott-Raven, Philadelphia 1989. p.1572.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/3\">",
"      Drebber U, Kasper HU, Ratering J, et al. Hepatic granulomas: histological and molecular pathological approach to differential diagnosis--a study of 442 cases. Liver Int 2008; 28:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/4\">",
"      KLATSKIN G, YESNER R. Hepatic manifestations of sarcoidosis and other granulomatous diseases; a study based on histological examination of tissue obtained by needle biopsy of the liver. Yale J Biol Med 1950; 23:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/5\">",
"      Tahan V, Ozaras R, Lacevic N, et al. Prevalence of hepatic granulomas in chronic hepatitis B. Dig Dis Sci 2004; 49:1575.",
"     </a>",
"    </li>",
"    <li>",
"     Zakim, D, Boyer, TD. Hepatology, A Textbook of Liver Diseases, Vol 3, 3rd ed, WB Saunders, Philadelphia 1996. p.1472.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/7\">",
"      Magill AJ, Gr&ouml;gl M, Gasser RA Jr, et al. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/8\">",
"      Alvarez SZ, Carpio R. Hepatobiliary tuberculosis. Dig Dis Sci 1983; 28:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/9\">",
"      Hofmann CE, Heaton JW Jr. Q fever hepatitis: clinical manifestations and pathological findings. Gastroenterology 1982; 83:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/10\">",
"      Marazuela M, Moreno A, Yebra M, et al. Hepatic fibrin-ring granulomas: a clinicopathologic study of 23 patients. Hum Pathol 1991; 22:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/11\">",
"      Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis--its value in present clinical practice. Ann Clin Biochem 1989; 26 ( Pt 1):13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/12\">",
"      Vatti R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/13\">",
"      Alam I, Levenson SD, Ferrell LD, Bass NM. Diffuse intrahepatic biliary strictures in sarcoidosis resembling sclerosing cholangitis. Case report and review of the literature. Dig Dis Sci 1997; 42:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/14\">",
"      Russi EW, Bansky G, Pfaltz M, et al. Budd-Chiari syndrome in sarcoidosis. Am J Gastroenterol 1986; 81:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/15\">",
"      Tekeste H, Latour F, Levitt RE. Portal hypertension complicating sarcoid liver disease: case report and review of the literature. Am J Gastroenterol 1984; 79:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/16\">",
"      Maddrey WC. Sarcoidosis and primary biliary cirrhosis. Associated disorders? N Engl J Med 1983; 308:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/17\">",
"      Rudzki C, Ishak KG, Zimmerman HJ. Chronic intrahepatic cholestasis of sarcoidosis. Am J Med 1975; 59:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/18\">",
"      Bass NM, Burroughs AK, Scheuer PJ, et al. Chronic intrahepatic cholestasis due to sarcoidosis. Gut 1982; 23:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/19\">",
"      B&eacute;cheur H, Dall'osto H, Chatellier G, et al. Effect of ursodeoxycholic acid on chronic intrahepatic cholestasis due to sarcoidosis. Dig Dis Sci 1997; 42:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/20\">",
"      Klatskin G. Hepatic granulomata: problems in interpretation. Mt Sinai J Med 1977; 44:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/21\">",
"      Ruel M, Sevestre H, Henry-Biabaud E, et al. Fibrin ring granulomas in hepatitis A. Dig Dis Sci 1992; 37:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/22\">",
"      Vanderstigel M, Zafrani ES, Lejonc JL, et al. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin-ring granulomas. Gastroenterology 1986; 90:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/23\">",
"      Akritidis N, Tzivras M, Delladetsima I, et al. The liver in brucellosis. Clin Gastroenterol Hepatol 2007; 5:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/24\">",
"      Kadin ME, Donaldson SS, Dorfman RF. Isolated granulomas in Hodgkin's disease. N Engl J Med 1970; 283:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/25\">",
"      Braylan RC, Long JC, Jaffe ES, et al. Malignant lymphoma obscured by concomitant extensive epithelioid granulomas: report of three cases with similar clinicopathologic features. Cancer 1977; 39:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/26\">",
"      Simon HB, Wolff SM. Granulomatous hepatitis and prolonged fever of unknown origin: a study of 13 patients. Medicine (Baltimore) 1973; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/27\">",
"      Knox TA, Kaplan MM, Gelfand JA, Wolff SM. Methotrexate treatment of idiopathic granulomatous hepatitis. Ann Intern Med 1995; 122:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/28\">",
"      Guckian JC, Perry JE. Granulomatous hepatitis. An analysis of 63 cases and review of the literature. Ann Intern Med 1966; 65:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40406/abstract/29\">",
"      Cunnigham D, Mills PR, Quigley EM, et al. Hepatic granulomas: experience over a 10-year period in the West of Scotland. Q J Med 1982; 51:162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3582 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-DA0D917308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40406=[""].join("\n");
var outline_f39_29_40406=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Systemic infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - AIDS related causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Fungal diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Q fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Brucellosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3582|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/3/18486\" title=\"picture 1\">",
"      Granulomatous hepatitis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3582|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/9/10396\" title=\"table 1\">",
"      Infections causing liver granulomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/31/10747\" title=\"table 2\">",
"      Granulomatous liver dz meds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/11/15547\" title=\"table 3\">",
"      Granulomatous liver dz causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/59/1979\" title=\"table 4\">",
"      Lab eval liver granulomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12502?source=related_link\">",
"      Clinical manifestations and diagnosis of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/14/17638?source=related_link\">",
"      Gastrointestinal sarcoidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_29_40407="Subacute cutaneous lupus - papular";
var content_f39_29_40407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66580%7EDERM%2F55903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66580%7EDERM%2F55903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacute cutaneous lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous, scaly papules are present on the upper back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacute cutaneous lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, annular plaques with scale are present on this patient with subacute cutaneous lupus erythematosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40407=[""].join("\n");
var outline_f39_29_40407=null;
var title_f39_29_40408="Parvovirus B19 infection during pregnancy";
var content_f39_29_40408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parvovirus B19 infection during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Laura E Riley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Caraciolo J Fernandes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40408/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/29/40408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 infection is a common childhood illness. Asymptomatic or mild infection occurs most often when B19 affects immunocompetent adults. Rarely, acute infection in pregnancy may lead to fetal loss or hydrops fetalis. The issues surrounding B19 infection during pregnancy are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY/PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Parvoviruses were discovered in 1975 by electron microscopy during evaluation of tests for hepatitis B surface antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/1\">",
"     1",
"    </a>",
"    ]. Parvoviridae are small, non-enveloped DNA viruses that infect a variety of animals, usually in a species-specific fashion. Two parvoviruses have been isolated from humans, the adeno-associated parvoviruses (genus Dependovirus) and human parvovirus B19 (B19) (genus Erythrovirus). Only B19 is known to cause disease in humans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parvovirus B19 has a single-stranded DNA genome containing approximately 5,000 nucleotides. It encodes at least two major structural proteins and one nonstructural protein and serves as the template for its own replication.",
"   </p>",
"   <p>",
"    Parvovirus B19 preferentially infects rapidly dividing cells and is cytotoxic for erythroid progenitor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. B19 also may stimulate a cellular process initiating apoptosis (programmed cell death) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/4\">",
"     4",
"    </a>",
"    ]. The latter may account for the minimal inflammatory response noted in tissues infected with B19.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to B19 are found in 30 to 60 percent of adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The secondary attack rate for household contacts may be as high as 50 percent; a susceptible individual exposed in a classroom has a 20 to 30 percent risk of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32312?source=see_link\">",
"     \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women lacking antibodies to the virus are as susceptible as any other immunocompetent adult to B19 infection. However, 35 to 53 percent of pregnant women have preexisting IgG to the virus, indicating immunity from a prior infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The incidence of acute B19 infection in pregnancy is 3.3 to 3.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]; this risk varies among different occupational groups. In one study, for example, the highest infection rates occurred in schoolteachers (16 percent), followed by day care workers and homemakers (9 percent each) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 causes erythema infectiosum (EI), also known as fifth disease. It is a common childhood illness characterized by a \"slapped cheek\" appearance on the face and a \"lace-like\" erythematous rash on the trunk and extremities. Although adults can develop a rash, it is not as common as in children, and the \"slapped cheek\" appearance is rare.",
"   </p>",
"   <p>",
"    Children and adults also may experience one to four days of systemic symptoms prior to the appearance of the rash. Arthropathy affecting the joints of the hands, wrists, knees, and ankles can occur, most commonly in adults. Joint symptoms also can precede the development of a rash in adults. Arthropathy typically lasts one to two weeks. The clinical course in immunocompetent children and adults, including pregnant women, generally is self-limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with an underlying chronic anemia such as sickle cell anemia or thalassemia may experience a transient, generally self-limited, aplastic crisis caused by B19. In addition, individuals with acquired or inherited immunodeficiencies are at risk for chronic parvovirus B19 infection, which may require therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/1/31767?source=see_link\">",
"     \"Treatment and prevention of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infectivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;B19 viremia begins approximately six days after exposure and lasts for one week in immunocompetent individuals. An infected person is contagious before the onset of symptoms; B19 can be detected in blood and secretions as early as 5 to 10 days after exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Patients with normal immune systems probably are not infectious after the onset of B19-associated rash, arthralgias, or arthritis.",
"   </p>",
"   <p>",
"    Individuals with B19 IgG generally are considered immune to recurrent infection. However, in a study of five seropositive volunteers inoculated with B19, one became viremic, suggesting that reinfection is possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Maternal-fetal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;B19 infection during pregnancy may be associated with fetal loss or hydrops fetalis. However, there do not appear to be long-term developmental sequelae of infection in children who do not develop hydrops fetalis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fetal loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial reports linking B19 and poor fetal outcome suggested that the risk of stillbirth or fetal loss was greater than 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Many subsequent, larger prospective studies have more accurately established lower rates of fetal loss (",
"    <a class=\"graphic graphic_table graphicRef69006 \" href=\"mobipreview.htm?13/12/13516\">",
"     table 1",
"    </a>",
"    ). The largest prospective study of B19 infection in pregnant women included 1018 women with acute infection based upon serological studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/16\">",
"     16",
"    </a>",
"    ]. Major findings from this report were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal death occurred in 6.3 percent of pregnancies",
"      <span class=\"nowrap\">",
"       (64/1018)",
"      </span>",
"      and was limited to B19 infections diagnosed in the first one-half of pregnancy. The fetal death rate in women diagnosed with first trimester infection was 13 percent",
"      <span class=\"nowrap\">",
"       (34/256",
"      </span>",
"      first trimester infections), decreasing to 9 percent",
"      <span class=\"nowrap\">",
"       (30/322)",
"      </span>",
"      for infections diagnosed at 13 to 20 weeks of gestation, and 0",
"      <span class=\"nowrap\">",
"       (0/439)",
"      </span>",
"      after 20 weeks.",
"     </li>",
"     <li>",
"      There were six stillbirths (ie, fetal death &ge;22 weeks of gestation). Four were attributed to B19 infection prior to 20 weeks of gestation and occurred at 22 to 24 weeks; the other two stillbirths were diagnosed at 39 and 40 weeks and appeared to be unrelated to B19.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A summary of the available data suggests that the risk of fetal loss in pregnancies infected before and after 20 weeks of gestation is 11 percent and &lt;1 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a subsequent case control study, a positive parvovirus IgM test during the first trimester was more common among 2918 women with fetal loss prior to 22 weeks compared with 8429 matched controls with live births (0.8 versus 0.5 percent, respectively; OR 1.71, 95% CI 1.02-2.86) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/18\">",
"     18",
"    </a>",
"    ]. Nevertheless, the estimated contribution of parvovirus infection to the overall burden of fetal losses was low (0.1 up to 0.8 percent during epidemics).",
"   </p>",
"   <p>",
"    A separate question is what percent of third trimester stillbirths are attributable to B19? Three studies suggest that the prevalence of parvovirus B19 infection in late trimester fetal deaths is very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In a study from Sweden, fetal loss this late in pregnancy occurred in 93 of 33,759 deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/19\">",
"     19",
"    </a>",
"    ]. Polymerase chain reaction (PCR) on placental tissue revealed B19 DNA in seven of these cases. Thus, of the 0.3 percent of cases of intrauterine fetal death in the third trimester in this study, 7.5 percent were associated with evidence of B19 infection, an exceedingly small number.",
"   </p>",
"   <p>",
"    In another study from this same group, nested PCR was positive in 7 of 57 cases (15 percent) of intrauterine fetal death at &ge;22 weeks gestation compared to 0 of 53 term pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/20\">",
"     20",
"    </a>",
"    ]. Although the overall numbers are still small in a population of 14,147 deliveries, the authors suggest that this sensitive test be applied in the evaluation of intrauterine fetal loss in the late second and third trimesters. A separate study investigating the etiologies of stillbirths found a higher incidence of trisomy karyotype in parvovirus-infected fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/22\">",
"     22",
"    </a>",
"    ]. These findings suggest that infants with chromosomal abnormalities may be more susceptible to parvovirus infection, and that such chromosomal abnormalities may be responsible for some of the morbidity attributed to parvovirus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Transient effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal parvovirus infection has been associated with transient isolated fetal pleural or pericardial effusions that resolve spontaneously before term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/23\">",
"     23",
"    </a>",
"    ]. These effusions are thought to result from direct pleural or myocardial inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Fetal hydrops",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to causing fetal loss, B19 is cytotoxic to fetal red blood cell precursors and may cause anemia and hydrops fetalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Initial small series suggested hydrops complicated as many as 70 percent of third-trimester B19 infections; however, later studies indicate hydrops is a rare complication (",
"    <a class=\"graphic graphic_table graphicRef69006 \" href=\"mobipreview.htm?13/12/13516\">",
"     table 1",
"    </a>",
"    ). The risk of developing anemia and fetal hydrops appears to be greater in women infected during the first half of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/16,28\">",
"     16,28",
"    </a>",
"    ]. As an example, in the large series described above, hydrops occurred in 3.9 percent",
"    <span class=\"nowrap\">",
"     (40/1018)",
"    </span>",
"    of pregnancies, and was more common when infection was diagnosed at &le;32 weeks of gestation (4.4 versus 0.8 percent after 32 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/16\">",
"     16",
"    </a>",
"    ]. The median interval between diagnosis of maternal infection and hydrops was three weeks; 50 percent of cases occurred two to five weeks after maternal infection and 93 percent occurred within eight weeks of maternal diagnosis.",
"   </p>",
"   <p>",
"    Hydrops can lead rapidly to fetal death (within a few days to weeks) or can resolve spontaneously with an apparently normal infant at delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In a survey of obstetricians, spontaneous resolution occurred in 34 percent of 539 cases of hydrops of varying severity caused by parvovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/30\">",
"     30",
"    </a>",
"    ]. However, spontaneous resolution of severe hydrops is probably a rare event. In the report of 40 cases of hydrops, 23 were considered severe (hemoglobin less than 4.7",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or a large amount of ascites and at least one of: pleural effusions, skin edema of more than 5 mm, hydropic placenta, pericardial effusion, cardiomegaly, poor ventricular contractility, or polyhydramnios or oligohydramnios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/29\">",
"     29",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/16\">",
"     16",
"    </a>",
"    ]. Thirteen of these fetuses underwent intrauterine transfusions, with 11 survivors. Death occurred in all 10 fetuses with severe hydrops that did not receive intrauterine transfusion.",
"   </p>",
"   <p>",
"    The hydrops and fetal death are thought to result from severe B19-associated anemia. The severity of the anemia probably results from three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced survival of fetal red blood cells",
"     </li>",
"     <li>",
"      The need to meet the red cell demands of an expanding intravascular volume",
"     </li>",
"     <li>",
"      Inability of the immature immune system of some fetuses to control the infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemoglobin levels of 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or lower have been reported and presumably lead to high-output congestive heart failure. B19 also can infect myocardial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/31\">",
"     31",
"    </a>",
"    ]; thus, myocardial injury may contribute to the hydrops and fetal death in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe thrombocytopenia has been observed in 36 of 97 (37 percent) parvovirus-infected fetuses with hydrops [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Severe thrombocytopenia can lead to exsanguination at the time of intrauterine red cell transfusion; for this reason, the platelet count should be determined and platelets should be available for transfusion at the time of any fetal procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36819?source=see_link\">",
"     \"Intrauterine fetal transfusion of platelets\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link\">",
"     \"Intrauterine fetal transfusion of red blood cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children who survive fetal hydrops caused by parvovirus may have an increased risk of neurodevelopmental impairments. In one study, 28 Dutch children who had received intrauterine transfusion for fetal hydrops were evaluated at a median of five years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/35\">",
"     35",
"    </a>",
"    ]. Three had severe and two had mild cognitive developmental delays, and another child had fine motor impairment. These rates are higher than those historically seen in the Dutch population. In contrast, an earlier study of 20 children surviving fetal hydrops in Germany did not show an excess of developmental delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/36\">",
"     36",
"    </a>",
"    ]. The discrepancy in findings may be due to differences in the follow-up rate of hydrops survivors and cognitive testing methodology. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Neonatal and developmental considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus appears to be teratogenic in fetal animals, causing cerebellar hypoplasia and ataxia in cats and anencephaly, microcephaly, facial defects, and ectopic hearts in hamsters. Despite case reports suggesting a link between B19 infection during pregnancy and fetal malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], epidemiologic studies do not support this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports describe congenital abnormalities in four human newborn infants with parvovirus infection including ocular anomalies (eg, microphthalmia; dysplastic changes of the sclera, choroid, cornea and retina; and degeneration of the lens), hydrocephalus, cleft lip or palate, webbed joints, musculoskeletal anomalies, hepatocellular damage, myocarditis, congenital cardiomyopathy, and myositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/37,38,40,41\">",
"     37,38,40,41",
"    </a>",
"    ]. Congenital parvovirus infection also has been reported in two premature infants whose illness was associated with placentomegaly, edema, angioedema, hepatomegaly, anemia, thrombocytopenia, respiratory insufficiency and other non-specific features shared by life-threatening congenital infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the above associations, most intrauterine parvovirus infections do not have an adverse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/10,44,45\">",
"     10,44,45",
"    </a>",
"    ] and the bulk of the available data suggest that parvovirus B19 is not a teratogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .) Long-term studies of offspring of B19-infected pregnant women also are encouraging. Although data are limited, developmental delays are no more frequent in offspring of actively infected mothers compared to uninfected mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/36,47\">",
"     36,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pregnancy, the laboratory diagnosis of maternal parvovirus B19 infection relies primarily on IgG and IgM antibody testing, although polymerase chain reaction assays may also be helpful in certain situations. Parvovirus B19 is difficult to culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maternal parvovirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgM antibody capture radioimmunoassay and enzyme-linked immunosorbent assay (ELISA) are sensitive tests, detecting between 80 and 90 percent of patients with clinical B19 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulating IgM antibodies can be detected approximately 10 days after exposure and just prior to the onset of symptoms; they may persist for three months or longer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      B19 IgG antibodies are detected several days after IgM and usually persist for years; they are a marker of past infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, reliance on a negative IgM serologic result alone can be misleading in a patient with a significant exposure history, because in some instances maternal IgM levels may be below the detection limit. In such cases, polymerase chain reaction can be useful. In a study utilizing serum samples from 101 pregnant women with confirmed B19-induced fetal hydrops, 15 percent of the patients who were seronegative for B19 IgM antibodies had evidence of viremia by maternal B19 DNA testing. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Approach to the patient exposed to B19'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fetal parvovirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) is a sensitive method to detect small amounts of B19 DNA. Use of this technique on amniotic fluid is the method of choice to make the fetal diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Another option is to obtain fetal blood for B19 IgM; however, percutaneous fetal blood sampling, the method used to obtain fetal blood, carries a 1 percent fetal loss rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other techniques such as electron microscopy, detection of viral DNA, and probe hybridization assays for nucleic acids are available but typically are not necessary to detect acute maternal infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32312?source=see_link\">",
"     \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT EXPOSED TO B19",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women who are exposed to or have symptoms of parvovirus infection should have serologic testing for IgG and IgM antibodies.",
"   </p>",
"   <p>",
"    The discussion below gives guidance in diagnostic evaluation of the patient with possible parvovirus infection. Detailed information regarding diagnostic testing for parvovirus is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32312?source=see_link\">",
"     \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Past infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive IgG antibody and a negative IgM indicate maternal immunity; thus, the fetus is protected from infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive IgM antibody is consistent with acute parvovirus infection. The significance of this will depend on when testing is done relative to the stage of pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who are diagnosed with acute infection in the first half of pregnancy should be counseled that there is no proven risk of parvovirus-induced congenital anomalies, but there is a risk for fetal loss. The only potentially effective intervention is intrauterine fetal transfusion for treatment of severe fetal anemia; however, this procedure is not feasible before about 20 weeks of gestation due to limited visualization and the small size of the relevant anatomic structures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link\">",
"       \"Intrauterine fetal transfusion of red blood cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women who are diagnosed with acute infection beyond 20 weeks gestation should receive periodic ultrasounds (weekly beginning as early as 22 weeks) to look for signs of fetal hydrops (eg, scalp edema, ascites, polyhydramnios, cardiomegaly).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although serial ultrasounds commonly are performed, the risk of hydrops is low, and some have questioned the advantage of monitoring because the benefits of therapeutic intervention are not clear (see below). There is also controversy about how long to continue ultrasound monitoring. There have been cases of hydrops reported more than eight weeks after the initial maternal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/54\">",
"     54",
"    </a>",
"    ], suggesting that ultrasound be performed for at least eight weeks after an acute infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Susceptible host",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pregnant woman who is negative for both IgG and IgM parvovirus antibody is susceptible to infection, especially if she has contact with small children and there are parvovirus cases in the community. Management of this patient will depend on history of potential parvovirus exposure:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     No history of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, susceptible pregnant women should avoid contact with B19. However, there is no proven benefit to removal of seronegative women from high-risk employment (eg, school teacher or day care center employee) for the duration of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/55\">",
"     55",
"    </a>",
"    ]. However, careful hand washing and avoiding sharing food or drinks is likely to at least partially prevent the spread of B19. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/1/31767?source=see_link\">",
"     \"Treatment and prevention of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Recent history of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a pregnant patient has a history of recent parvovirus exposure and initial serologies are negative, we suggest additional screening for maternal B19 DNA based on the following study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum samples from 101 pregnant women with confirmed B19-induced fetal hydrops were collected at the time of invasive prenatal diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/56\">",
"       56",
"      </a>",
"      ]. Seventy-seven percent of the patients had positive IgM serologies, consistent with acute infection. However, 15 percent were seronegative, underscoring the problem of false negative serologies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing for maternal B19 DNA can be very helpful in this situation. However, if B19 DNA results are positive, the level of viremia should also be scrutinized, since low-level viremia may indicate a false positive NAAT. Repeat serologic testing at three weeks is helpful in this scenario since IgM antibody responses should be seen at this time in true infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32312?source=see_link\">",
"     \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ANEMIA AND HYDROPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate anemia generally is well tolerated by the fetus and resolves without sequelae. Severe anemia, although uncommon, can lead to hydrops fetalis and death. Because parvovirus-induced anemia is a transient process, determination of fetal hemoglobin is not necessary unless severe anemia is suggested by sonographic signs, such as fetal skin edema, ascites, or pleural or pericardial effusions. Doppler assessment of the fetal middle cerebral artery (MCA) peak systolic velocity (PSV) and ductus venosus velocity are accurate tools for the determination of fetal anemia and a noninvasive alternative to cord blood sampling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Amniocentesis to determine change in optical density of amniotic fluid at 450 nm on the spectral absorption curve (delta OD450) probably is not useful for evaluating the degree of anemia since red blood cell destruction with production of bilirubin is not the primary cause of the anemia.",
"   </p>",
"   <p>",
"    When severe anemia is suspected because of an elevated Doppler MCA PSV or signs of hydrops, the fetus requires close monitoring and assessment of fetal hematocrit by percutaneous umbilical vein sampling. Intrauterine fetal blood transfusion usually is performed if severe anemia is confirmed. As discussed above, severe thrombocytopenia can lead to exsanguination at the time of intrauterine red cell transfusion; for this reason, the platelet count should be determined and platelets should be available for transfusion at the time of any fetal procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Intrauterine blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine transfusion of RBCs is indicated to prevent fetal death from severe anemia. The procedure is generally limited to fetuses between 18 and 35 weeks of gestation because of technical limitations before 18 weeks and excessive fetal risk compared with delivery after 35 weeks. Intrauterine transfusion is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link\">",
"     \"Intrauterine fetal transfusion of red blood cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of intrauterine transfusion in parvovirus infection is suggested by a review of 14 studies and case reports of 705 fetal parvovirus B19 infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/60\">",
"     60",
"    </a>",
"    ]. Fetal transfusion for hydrops improved the survival rate (82 versus 55 percent without transfusion). Two included studies are detailed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective series of 38 hydropic fetuses, an apparently normal infant was delivered more often following intrauterine blood transfusions than in untreated pregnancies (9 of 12 versus 13 of 26, p&lt;0.05 controlling for gestational age and severity of hydrops by ultrasound) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/29\">",
"       29",
"      </a>",
"      ]. The survival rate decreased with increasing severity of hydrops on ultrasonography, and the fetuses died a median of 4.5 days after the first abnormal ultrasound examination.",
"     </li>",
"     <li>",
"      In the large survey of obstetricians, the outcome of 467 cases of hydrops was improved in cases of intrauterine transfusion with death in 27 of 164 fetuses (16 percent) who received intrauterine transfusion and in 138 of 296 fetuses (47 percent) who did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) has been used to treat acute parvovirus in immunodeficient adults and HIV-infected children. However, there is only one case report on its use as a fetal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40408/abstract/61\">",
"     61",
"    </a>",
"    ]. Given the limited available data, the use of IVIG during pregnancy currently is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32314204\">",
"    <span class=\"h2\">",
"     Delivery room and postnatal management of the hydropic infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, the management of a woman with a hydropic infant should be undertaken in a tertiary care facility staffed by individuals experienced in the care of sick neonates. As with all high-risk births, delivery of a hydropic infant mandates coordinated efforts by the obstetrician, perinatologist, and neonatal team to optimize pregnancy outcome.",
"   </p>",
"   <p>",
"    Resuscitation of such infants frequently is difficult and advance preparation is advisable. The majority of hydropic infants require respiratory assistance and mechanical ventilation. Ventilation may be compromised by pulmonary hypoplasia, pulmonary edema, airleaks, or by the accumulation of pleural or peritoneal fluid. Abdominal paracentesis and thoracocentesis of fetal ascites and pleural effusions may be needed either just prior to delivery or immediately after to facilitate resuscitation.",
"   </p>",
"   <p>",
"    Postnatal management depends upon the gestational age of the infant, other associated conditions (eg, respiratory distress syndrome), and illness severity. Infants with severe anemia and cardiovascular instability may benefit from an isovolumetric or partial exchange transfusion with packed red blood cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34393?source=see_link\">",
"     \"Nonimmune hydrops fetalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/39/33395?source=see_link\">",
"       \"Patient information: Avoiding infections in pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/5/13394?source=see_link\">",
"       \"Patient information: Erythema infectiosum (fifth disease) (The Basics )\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/52/43843?source=see_link\">",
"       \"Patient information: Avoiding infections in pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29630458\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parvovirus B19 is a small non-enveloped DNA virus that frequently infects humans, with antibodies to B19 found in 30 to 60 percent of adults. The incidence of B19 infection during pregnancy is 3.3 to 3.8 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology/pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parvovirus B19 causes erythema infectiosum, also known as fifth disease, characterized by self-limited fever and rash, and in adults, arthropathy. Viremia begins approximately six days after exposure and lasts for one week in immunocompetent individuals, who are usually infectious from the onset of viremia until the appearance of B19 associated rash or arthropathy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Infectivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most intrauterine parvovirus infections do not have an adverse outcome, and developmental delays are no more frequent in offspring of actively infected mothers compared with uninfected mothers. Rarely, infection with parvovirus B19 during pregnancy can lead to fetal loss and hydrops fetalis. The overall incidence of these complications is low and concentrated among infections that occur during the first half of pregnancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Maternal-fetal effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During pregnancy, the laboratory diagnosis of maternal parvovirus B19 infection relies primarily on IgG and IgM antibody testing to determine pre-existing immunity, acute infection, or susceptibility. Polymerase chain reaction (PCR) testing on amniotic fluid is the method of choice to make the fetal diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32312?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\", section on 'Laboratory diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women who are exposed to or have symptoms of parvovirus infection should have serologic testing for IgG and IgM antibodies. A positive parvovirus IgM is consistent with acute infection. Women diagnosed with acute infection during the first half of pregnancy should be counseled that there is no proven risk of parvovirus-induced congenital anomalies, but there is a risk for fetal loss. Women who are diagnosed with acute infection beyond 20 weeks gestation should receive weekly ultrasounds to evaluate for fetal hydrops for at least eight weeks. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Approach to the patient exposed to B19'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a pregnant woman with a recent parvovirus exposure is negative for both IgG and IgM, PCR testing of her plasma for maternal parvovirus B19 DNA may be more sensitive and should be performed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Susceptible host'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When severe anemia is suspected on ultrasound findings, the fetus requires close monitoring and assessment of fetal hematocrit by percutaneous umbilical vein sampling. Intrauterine transfusion of RBCs is indicated to prevent fetal death from severe anemia. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Intrauterine blood transfusion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link\">",
"       \"Intrauterine fetal transfusion of red blood cells\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Management of the birth of a hydropic infant should be undertaken at a tertiary care facility with experience in neonatal critical care. Drainage of fetal ascites or pleural effusions may be necessary perinatally to facilitate resuscitation. Postnatally, hydropic infants generally require mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H32314204\">",
"       'Delivery room and postnatal management of the hydropic infant'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/9/10393?source=see_link&amp;anchor=H9#H9\">",
"       \"Postnatal care of hydrops fetalis\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/1\">",
"      Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/2\">",
"      Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/3\">",
"      Young N, Mortimer P. Viruses and bone marrow failure. Blood 1984; 63:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/4\">",
"      Morey AL, Ferguson DJ, Fleming KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: evidence of cell death by apoptosis. J Pathol 1993; 169:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/5\">",
"      Koch WC, Adler SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/6\">",
"      Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/7\">",
"      American Academy of Pediatrics Committee on Infectious Diseases: Parvovirus, erythema infectiosum, and pregnancy. Pediatrics 1990; 85:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/8\">",
"      Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/9\">",
"      Rodis JF, Quinn DL, Gary GW Jr, et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 1990; 163:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/10\">",
"      Gratac&oacute;s E, Torres PJ, Vidal J, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis 1995; 171:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/11\">",
"      Cartter ML, Farley TA, Rosengren S, et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991; 163:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/12\">",
"      Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/13\">",
"      Potter CG, Potter AC, Hatton CS, et al. Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Invest 1987; 79:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/14\">",
"      Knott PD, Welply GA, Anderson MJ. Serologically proved intrauterine infection with parvovirus. Br Med J (Clin Res Ed) 1984; 289:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/15\">",
"      Brown T, Anand A, Ritchie LD, et al. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984; 2:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/16\">",
"      Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004; 24:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/17\">",
"      Markenson GR, Yancey MK. Parvovirus B19 infections in pregnancy. Semin Perinatol 1998; 22:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/18\">",
"      Lassen J, Jensen AK, Bager P, et al. Parvovirus B19 infection in the first trimester of pregnancy and risk of fetal loss: a population-based case-control study. Am J Epidemiol 2012; 176:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/19\">",
"      Skj&ouml;ldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, et al. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG 2000; 107:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/20\">",
"      Tolfvenstam T, Papadogiannakis N, Norbeck O, et al. Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet 2001; 357:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/21\">",
"      Riipinen A, V&auml;is&auml;nen E, Nuutila M, et al. Parvovirus b19 infection in fetal deaths. Clin Infect Dis 2008; 47:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/22\">",
"      Carlsen K, Beck BL, Bagger PV, et al. Pregnancy loss ascribable to parvovirus B19/erythrovirus is associated with a high prevalence of trisomy. Gynecol Obstet Invest 2010; 70:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/23\">",
"      Parilla BV, Tamura RK, Ginsberg NA. Association of parvovirus infection with isolated fetal effusions. Am J Perinatol 1997; 14:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/24\">",
"      Anand A, Gray ES, Brown T, et al. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987; 316:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/25\">",
"      Schwarz TF, Roggendorf M, Hottentr&auml;ger B, et al. Human parvovirus B19 infection in pregnancy. Lancet 1988; 2:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/26\">",
"      Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/27\">",
"      Petrikovsky BM, Baker D, Schneider E. Fetal hydrops secondary to human parvovirus infection in early pregnancy. Prenat Diagn 1996; 16:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/28\">",
"      Enders M, Klingel K, Weidner A, et al. Risk of fetal hydrops and non-hydropic late intrauterine fetal death after gestational parvovirus B19 infection. J Clin Virol 2010; 49:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/29\">",
"      Fairley CK, Smoleniec JS, Caul OE, Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995; 346:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/30\">",
"      Rodis JF, Borgida AF, Wilson M, et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol 1998; 179:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/31\">",
"      Porter HJ, Khong TY, Evans MF, et al. Parvovirus as a cause of hydrops fetalis: detection by in situ DNA hybridisation. J Clin Pathol 1988; 41:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/32\">",
"      Marton T, Martin WL, Whittle MJ. Hydrops fetalis and neonatal death from human parvovirus B19: an unusual complication. Prenat Diagn 2005; 25:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/33\">",
"      Segata M, Chaoui R, Khalek N, et al. Fetal thrombocytopenia secondary to parvovirus infection. Am J Obstet Gynecol 2007; 196:61.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/34\">",
"      de Haan TR, van den Akker ES, Porcelijn L, et al. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG 2008; 115:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/35\">",
"      De Jong EP, Lindenburg IT, van Klink JM, et al. Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome. Am J Obstet Gynecol 2012; 206:204.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/36\">",
"      Dembinski J, Haverkamp F, Maara H, et al. Neurodevelopmental outcome after intrauterine red cell transfusion for parvovirus B19-induced fetal hydrops. BJOG 2002; 109:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/37\">",
"      Weiland HT, Vermey-Keers C, Salimans MM, et al. Parvovirus B19 associated with fetal abnormality. Lancet 1987; 1:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/38\">",
"      Katz VL, McCoy MC, Kuller JA, Hansen WF. An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Am J Perinatol 1996; 13:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/39\">",
"      Kinney JS, Anderson LJ, Farrar J, et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 1988; 157:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/40\">",
"      Barton LL, Lax D, Shehab ZM, Keith JC. Congenital cardiomyopathy associated with human parvovirus B19 infection. Am Heart J 1997; 133:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/41\">",
"      Tiessen RG, van Elsacker-Niele AM, Vermeij-Keers C, et al. A fetus with a parvovirus B19 infection and congenital anomalies. Prenat Diagn 1994; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/42\">",
"      Vogel H, Kornman M, Ledet SC, et al. Congenital parvovirus infection. Pediatr Pathol Lab Med 1997; 17:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/43\">",
"      Miyagawa S, Takahashi Y, Nagai A, et al. Angio-oedema in a neonate with IgG antibodies to parvovirus B19 following intrauterine parvovirus B19 infection. Br J Dermatol 2000; 143:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/44\">",
"      Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 1990; 300:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/45\">",
"      Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998; 105:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/46\">",
"      Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol 2006; 21:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/47\">",
"      Rodis JF, Rodner C, Hansen AA, et al. Long-term outcome of children following maternal human parvovirus B19 infection. Obstet Gynecol 1998; 91:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/48\">",
"      Schwarz TF, J&auml;ger G, Gilch S. Comparison of seven commercial tests for the detection of parvovirus B19-specific IgM. Zentralbl Bakteriol 1997; 285:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/49\">",
"      Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/50\">",
"      Rotbart HA. Human parvovirus infections. Annu Rev Med 1990; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/51\">",
"      T&ouml;r&ouml;k TJ, Wang QY, Gary GW Jr, et al. Prenatal diagnosis of intrauterine infection with parvovirus B19 by the polymerase chain reaction technique. Clin Infect Dis 1992; 14:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/52\">",
"      Clewley JP. Polymerase chain reaction assay of parvovirus B19 DNA in clinical specimens. J Clin Microbiol 1989; 27:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/53\">",
"      Yamakawa Y, Oka H, Hori S, et al. Detection of human parvovirus B19 DNA by nested polymerase chain reaction. Obstet Gynecol 1995; 86:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/54\">",
"      Mielke G, Enders G. Late onset of hydrops fetalis following intrauterine parvovirus B19 infection. Fetal Diagn Ther 1997; 12:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/55\">",
"      Centers for Disease Control (CDC). Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989; 38:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/56\">",
"      Enders M, Weidner A, Rosenthal T, et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis 2008; 197:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/57\">",
"      Cosmi E, Mari G, Delle Chiaie L, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. Am J Obstet Gynecol 2002; 187:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/58\">",
"      Bizjak G, Blondin D, Hammer R, et al. Acute infection with parvovirus B19 in early pregnancy. Ultrasound Obstet Gynecol 2009; 34:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/59\">",
"      Borna S, Mirzaie F, Hanthoush-Zadeh S, et al. Middle cerebral artery peak systolic velocity and ductus venosus velocity in the investigation of nonimmune hydrops. J Clin Ultrasound 2009; 37:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/60\">",
"      von Kaisenberg CS, Jonat W. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 2001; 18:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40408/abstract/61\">",
"      Selbing A, Josefsson A, Dahle LO, Lindgren R. Parvovirus B19 infection during pregnancy treated with high-dose intravenous gammaglobulin. Lancet 1995; 345:660.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8281 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-A3347AB727-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40408=[""].join("\n");
var outline_f39_29_40408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29630458\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY/PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infectivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Maternal-fetal effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fetal loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Transient effusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Fetal hydrops",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Neonatal and developmental considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maternal parvovirus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fetal parvovirus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      APPROACH TO THE PATIENT EXPOSED TO B19",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Past infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acute infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Susceptible host",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - No history of exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Recent history of exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANAGEMENT OF ANEMIA AND HYDROPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Intrauterine blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32314204\">",
"      Delivery room and postnatal management of the hydropic infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29630458\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8281\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8281|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/12/13516\" title=\"table 1\">",
"      Pregnancy outcome B19 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32312?source=related_link\">",
"      Epidemiology and laboratory diagnosis of parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36819?source=related_link\">",
"      Intrauterine fetal transfusion of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/52/43843?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/39/33395?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/5/13394?source=related_link\">",
"      Patient information: Erythema infectiosum (fifth disease) (The Basics )",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/9/10393?source=related_link\">",
"      Postnatal care of hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/1/31767?source=related_link\">",
"      Treatment and prevention of parvovirus B19 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_29_40409="Nonurothelial bladder cancer";
var content_f39_29_40409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonurothelial bladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40409/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40409/contributors\">",
"     Julia H Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40409/contributors\">",
"     Timothy D Gilligan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40409/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40409/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40409/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/29/40409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer is the most common malignancy affecting the urinary tract. Worldwide, bladder cancer accounted for 386,000 cases and 150,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/1\">",
"     1",
"    </a>",
"    ]. In developed regions such as North America and Europe, this is predominantly urothelial carcinoma. Although urothelial cancers frequently contain nonurothelial elements, mixed tumors are considered a subset of urothelial carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonurothelial bladder cancers are classified as epithelial or nonepithelial. Approximately 90 percent of these cancers are epithelial in origin, including squamous cell carcinomas (SCCs), adenocarcinomas, and small cell (neuroendocrine) tumors. Nonepithelial cancers are rare and include sarcomas, pheochromocytomas, melanomas, and lymphomas.",
"   </p>",
"   <p>",
"    In parts of the world where infection with Schistoma haematobium is prevalent, the overall incidence of bladder cancer is much higher. In these areas, SCC accounts for approximately 75 percent of cases, TCC for 20 percent, and adenocarcinoma for 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/2\">",
"     2",
"    </a>",
"    ]. Because of differences in their natural history and treatment, schistosomal and nonschistosomal bladder cancers are considered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like urothelial carcinomas, nonurothelial bladder cancers commonly present with hematuria and bladder irritation. Nonurothelial bladder cancers are generally found to be invasive at diagnosis and characterized by more advanced stage and poorer prognosis than TCCs.",
"   </p>",
"   <p>",
"    Whether the prognosis is worse after controlling for stage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    grade is unclear. One multi-institutional study of 1131 consecutive patients (including 1042 with urothelial carcinomas and 89 with nonurothelial bladder cancers) reported no difference in five-year survival following radical cystectomy after controlling for gender, stage, and grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features and treatment of SCC, adenocarcinoma, schistosomal bladder cancers, and nonepithelial bladder cancers will be reviewed here. Small cell carcinoma of the bladder is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=see_link&amp;anchor=H5#H5\">",
"     \"Extrapulmonary small cell cancer\", section on 'Bladder ESCC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of nonurothelial bladder cancers is incompletely understood. Both the development of metaplasia and the presence of chronic infection are believed to be important factors in tumorigenesis.",
"   </p>",
"   <p>",
"    Tissue metaplasia develops in response to chronic infection and inflammation, which can lead to the development of either squamous epithelium and leukoplakia or mucinous and glandular epithelium. The factors that lead to neoplastic transformation are not known.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCC is often associated with squamous metaplasia and is seen in 16 to 28 percent of patients with leukoplakia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two patterns of metaplasia have been associated with adenocarcinoma. Cystitis cystica refers to the invagination of hyperplastic epithelial buds into the lamina propria, which may undergo further metaplasia to cystitis glandularis and is associated with vesical adenocarcinoma. A second pattern does not result in invagination into the lamina propria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic urinary tract infections (UTIs) are associated with both nonschistosomal and schistosomal bladder cancers. Infection may contribute to the development of bladder cancer through multiple mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predisposing patients to metaplasia, the initial step in carcinogenesis",
"     </li>",
"     <li>",
"      Nitrosamine production by gram-negative bacteria",
"     </li>",
"     <li>",
"      Beta-glucuronidase secretion by bacteria releasing conjugated carcinogens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Production of reactive oxygen species by inflammatory cells responding to infection, leading to DNA damage and activation of other carcinogens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative hypotheses include the development of nonurothelial bladder cancers from preexisting TCCs that undergo metaplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/7\">",
"     7",
"    </a>",
"    ] and tumor development from multipotent stem cells in the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NONSCHISTOSOMAL SCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCC accounts for 3 to 5 percent of bladder cancers in North America and Europe, and for approximately 75 percent of bladder cancers in areas where Schisotoma haematobium infection is endemic. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Schistosomal bladder cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonschistosomal SCC is diagnosed most frequently in patients in their 60s, and the incidence is roughly equal in men and women, in contrast to the male predominance seen in urothelial cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The prognosis is poor, with a five-year survival rate in the United States of 35 percent for men and 20 percent for women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/8\">",
"     8",
"    </a>",
"    ]. Most deaths occur after locoregional progression.",
"   </p>",
"   <p>",
"    Retrospective series have sought to identify risk factors associated with nonschistosomal SCC. Factors implicated include chronic or recurrent UTIs, bladder calculi, pelvic radiation therapy (RT), antecedent intravesical BCG treatment, and prolonged exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , particularly when complicated by hemorrhagic cystitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/10\">",
"     10",
"    </a>",
"    ]. Because the evidence supporting these associations comes from retrospective series, results are subject to strong selection bias. The risk of SCC has also been linked to smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic indwelling catheters also have been associated with an increased risk of SCC in some studies, although the association is controversial. Two large, population-based studies in patients with spinal cord injury did not identify an increased risk of bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, the bladder cancers that were identified in patients with neurogenic bladders had an increased incidence of muscle invasion. Based upon this observation, the investigators recommended against the use of chronic indwelling catheters in patients with neurogenic bladders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/13\">",
"     13",
"    </a>",
"    ]. Similarly, although periodic screening cystoscopies have been recommended for spinal-cord injury patients by some investigators, no studies have demonstrated a benefit from screening, perhaps on account of the extremely low incidence of cancer in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptoms of nonschistosomal SCC are hematuria and irritative symptoms, often in association with urinary tract infection (UTI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Tumors are commonly bulky and locally invasive at diagnosis, but distant metastases are present in only 8 to 10 percent of cases at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 19 cases, all patients presented with locally advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/19\">",
"     19",
"    </a>",
"    ]. Extension beyond the bladder wall was identified in 74 percent, upper urinary tract involvement in 26 percent, and prostatic urethral involvement in 35 percent. Locally recurrent disease caused death in 63 percent, while only one patient was found to have distant metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the mainstay of treatment for nonschistosomal SCC of the bladder. Retrospective series have reported five-year survival rates of 35 to 50 percent following surgery, although these studies included some patients who received preoperative RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcomes from surgery for nonschistosomal SCC were compared to results for patients with urothelial bladder in a SEER database analysis of 1422 patients diagnosed between 1988 and 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/22\">",
"     22",
"    </a>",
"    ]. The two-year all-cause mortality following cystectomy ranged from 11 percent in men with stage I disease to 72 percent in men with stage IV disease. After adjusting for age, sex, race, and initial therapy, SCC histology was associated with poorer outcomes compared to urothelial bladder cancer in those who did not undergo cystectomy for stage I or II disease and in all patients with stage III or IV disease.",
"   </p>",
"   <p>",
"    RT alone is relatively ineffective, with reported five-year survival rates ranging from 12 to 31 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/16,17,23\">",
"     16,17,23",
"    </a>",
"    ]. The strong tendency of SCC of the bladder to recur locally following radical cystectomy provides a rational for pre- or postoperative RT but there are no data indicating whether such an approach yields superior outcomes compared to surgery alone. A number of retrospective case series have suggested possible benefit for adjuvant or neoadjuvant RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/17,18,24,25\">",
"     17,18,24,25",
"    </a>",
"    ], but no controlled trials have been performed. Interpretation of these studies is difficult because of the limited number of patients, patient selection bias, and the heterogeneity of treatment groups. The rarity of nonschistosomal SCC makes it exceedingly unlikely that an adequately powered randomized trial investigating perioperative RT will ever be conducted.",
"   </p>",
"   <p>",
"    SCC appears to be resistant to the chemotherapy regimens active in metastatic disease, but only scant data on this subject are available. Although isolated case reports suggest responsiveness to the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (MVAC), a retrospective study reported no responses among four patients treated with neoadjuvant MVAC prior to cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/19\">",
"     19",
"    </a>",
"    ]. In one prospective study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and cisplatin in men with advanced non-urothelial bladder cancer (8 of 20 with squamous cell carcinoma), two of eight patients achieved complete responses; median survival was nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/26\">",
"     26",
"    </a>",
"    ]. No studies have reported an experience with chemoradiotherapy in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19897?source=see_link\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary approach to treatment in patients with nonschistosomal SCC is aggressive surgery to control locoregional disease. Given the poor prognosis in patients with locally advanced disease and the finding that most relapses are local recurrences rather than distant metastases, we suggest that adjuvant or neoadjuvant radiotherapy can be considered for patients with higher stage disease. There are no data from randomized trials and nonschistosomal SCC is too rare for such trials to be feasible.",
"   </p>",
"   <p>",
"    There are no data demonstrating a benefit from systemic chemotherapy although there are case reports of radiographic responses. For patients with unresectable or metastatic disease, we suggest that patients carefully consider whether they wish to receive or forego chemotherapy. Those interested in receiving chemotherapy should be included in formal studies or trials whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ADENOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In North America and Europe, primary adenocarcinoma is the second most common nonurothelial bladder cancer, comprising 0.5 to 2 percent of all bladder cancer cases. Primary adenocarcinoma of the bladder must be distinguished from tumors arising in other organs that either extend into or metastasize to the bladder.",
"   </p>",
"   <p>",
"    Glandular, colloid, papillary, signet-ring, and clear cell types have all been identified. The signet-ring variant appears to be associated with a poorer prognosis than other forms of adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Unlike SCCs, adenocarcinomas of the bladder frequently metastasize. In contrast to the case with TCCs, local relapse is more common than distant relapse following cystectomy for adenocarcinoma unless postoperative RT is administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27481?source=see_link&amp;anchor=H31#H31\">",
"     \"Pathology of bladder neoplasms\", section on 'Adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 10 percent of bladder adenocarcinomas arise from the urachal remnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/30\">",
"     30",
"    </a>",
"    ]. The natural history of urachal adenocarcinoma is distinct from nonurachal adenocarcinomas, a fact that has important therapeutic implications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/31\">",
"     31",
"    </a>",
"    ]. Urachal adenocarcinoma presents at an earlier median age than nonurachal adenocarcinoma (56 versus 69 years), is less likely to be high grade (35 versus 66 percent), and has a better overall five-year survival (48 versus 35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/30\">",
"     30",
"    </a>",
"    ]. Urachal adenocarcinoma is the one form of bladder cancer that is more frequent in women (45 percent of cases versus 36 percent in men).",
"   </p>",
"   <p>",
"    Factors associated with an increased risk of nonurachal adenocarcinoma include bladder exstrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/32\">",
"     32",
"    </a>",
"    ] and schistosomiasis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Schistosomal bladder cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonurachal adenocarcinoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary symptoms of nonurachal bladder adenocarcinoma are hematuria and irritative urinary symptoms. Mucusuria is less common in patients with nonurachal adenocarcinoma than in those with cancers arising in the urachal remnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Urachal adenocarcinoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    At cystoscopy, tumors are often papillary or flat infiltrating lesions with overlying edema. Muscle invasion is almost always present, and diffuse or circumferential bladder wall thickening is usually seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survival of patients with nonurachal adenocarcinoma is generally poor, with a five-year overall survival of 35 percent in a series from the Surveillance, Epidemiology and End Results (SEER) database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/30\">",
"     30",
"    </a>",
"    ]. This poor prognosis is probably due to advanced locoregional disease at diagnosis, with 60 to 65 percent of patients having T3 or T4 disease and one-third having lymph node metastases (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nonurachal adenocarcinoma associated with schistosomiasis appears to have a better prognosis, with one large series reporting a five-year survival of 55 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/37\">",
"     37",
"    </a>",
"    ]. The majority of these patients had low-grade tumors, which may account for their better survival. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Schistosomal bladder cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of nonurachal adenocarcinoma has not been defined by randomized trials. Current approaches are primarily based upon retrospective series with limited numbers of patients and major variability in stage, grade, and follow-up.",
"   </p>",
"   <p>",
"    Superficial nonurachal adenocarcinoma is rare. Case reports have suggested a response to Bacillus Calmette-Guerin (BCG). In one series of three patients with T1 lesions who were treated with transurethral resection followed by intravesical BCG, there was no evidence of recurrence 53 to 82 months after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Intravesical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Attempts to preserve the bladder with conservative treatment of nonsuperficial lesions have been associated with a poor outcome. Reported five-year survivals have been 19 to 33 percent with transurethral resection, with or without RT, and 18 percent with RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/39\">",
"     39",
"    </a>",
"    ]. Partial cystectomy has yielded poor results and is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radical cystectomy with pelvic lymph node dissection is the primary treatment option for most patients. The two largest surgical experiences with surgery come from Egypt, where schistosomiasis is endemic. Although the five-year survival rates were 46 and 55 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/29,37\">",
"     29,37",
"    </a>",
"    ], this rate may overestimate the benefit in patients with nonschistosomal disease, which tends to be higher grade. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Schistosomal bladder cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Postoperative RT has been utilized by some centers with mixed results. The non-randomized, retrospective Egyptian National Cancer Institute series of 192 patients reported that disease-free survival was 37 percent with cystectomy alone compared to 61 percent with cystectomy following by RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/29\">",
"     29",
"    </a>",
"    ]. This difference was significant on univariate and multivariate analysis. However, the benefit of adjuvant RT has not been tested in a randomized controlled trial, and enthusiasm for this approach has been dampened by reports of substantial bowel toxicity.",
"   </p>",
"   <p>",
"    Chemotherapy is reserved for unresectable disease and is of uncertain benefit. There are no randomized trials of neoadjuvant or adjuvant chemotherapy nor of chemotherapy for metastatic disease. One prospective study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in men with advanced nonurothelial bladder cancer (11 of 20 with adenocarcinoma, including six with urachal adenocarcinoma) reported a response rate of 36 percent and a median survival of 25 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/26\">",
"     26",
"    </a>",
"    ]. Another retrospective series of 21 patients, including 14 with adenocarcinoma, had a response rate of 36 percent to first line cisplatin-containing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/43\">",
"     43",
"    </a>",
"    ]. Case reports have described disappointing experiences with 5-FU, alone or in combination with other agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/19,44,45\">",
"     19,44,45",
"    </a>",
"    ]; results with newer agents, such as the taxanes and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , have not been published.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no data from randomized clinical trials, we recommend radical cystectomy with pelvic lymph node dissection as the initial management of all patients with invasive adenocarcinoma of the bladder. Lesser procedures (transurethral resection with or without intravesical BCG and partial cystectomy) are generally contraindicated.",
"   </p>",
"   <p>",
"    We consider postoperative radiation therapy to be experimental and do not recommend it outside the context of a clinical trial. For patients with unresectable or metastatic disease, we suggest that patients carefully consider whether they wish to receive or forego chemotherapy given the absence of data supporting its use. Those interested in receiving chemotherapy should be included in formal studies or trials whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Urachal adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urachus is formed early in embryonic life. In two-thirds of individuals, the urachus coalesces with the umbilical arteries to form the umbilical ligament and is obliterated by birth. Urachal adenocarcinoma arises in the urachal remnant and is characterized by its location at the dome of the bladder, usually extending into the prevesical space.",
"   </p>",
"   <p>",
"    A diagnosis of urachal adenocarcinoma is supported by the presence of a patent urachus, an absence of metaplasia (cystitis glandularis), and either no involvement or only secondary involvement of the urothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/46\">",
"     46",
"    </a>",
"    ]. Urachal adenocarcinomas are mucin-producing in 90 percent of cases. Mucusuria is not present in all patients with mucin-producing tumors but its presence is suggested of urachal adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27481?source=see_link&amp;anchor=H33#H33\">",
"     \"Pathology of bladder neoplasms\", section on 'Urachal adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for the development of urachal adenocarcinoma are poorly defined, and it is unclear whether bladder carcinogens play a role. Urachal adenocarcinoma usually presents with locally advanced disease. Hematuria is common and patients with urachal adenocarcinoma frequently present with a palpable lower abdominal mass, in contrast to those with other bladder cancers.",
"   </p>",
"   <p>",
"    A retrospective review of 151 patients with urachal adenocarcinoma identified through the Surveillance, Epidemiology and End Results (SEER) database found that patients with urachal adenocarcinoma were likely to be younger than those with nonurachal adenocarcinoma (median age 56 versus 69 years) and more likely to be female (45 percent versus 36 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/30\">",
"     30",
"    </a>",
"    ]. In multivariate analysis, patients with urachal tumors had a significantly lower risk of all cause and disease-specific mortality (HR=0.56 and HR=0.59, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All adenocarcinomas involving the dome of the bladder should be considered urachal unless proven otherwise. Surgical resection is the only curative modality, and the urachal ligament and umbilicus should be resected at cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon results from retrospective series, partial cystectomy is frequently used as an alternative to radical cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. Even with partial cystectomy, surgery should include an en bloc resection of the bladder dome, urachal ligament, and umbilicus.",
"   </p>",
"   <p>",
"    The natural history of urachal adenocarcinoma is illustrated by a retrospective analysis of 42 patients treated at M. D. Anderson [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/49\">",
"     49",
"    </a>",
"    ]. Seven patients had metastatic disease at presentation, and 35 were managed surgically. Overall, 16 patients were disease-free (38 percent) at a median follow-up of 31 months. Negative surgical margins and no lymph node involvement were favorable prognostic indicators. There was no significant difference in outcome with partial versus radical cystectomy. Well-differentiated urachal adenocarcinomas have a particularly favorable prognosis when treated surgically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of 66 cases seen at the Mayo Clinic between 1951 and 2004 evaluated the efficacy of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/47\">",
"     47",
"    </a>",
"    ]. Treatment consisted of partial cystectomy in 70 percent, complete cystectomy in 21 percent, and RT in 9 percent. The overall five-year survival rate was 49 percent. On multivariate analysis, the factors significantly associated with better survival were low tumor grade and negative surgical margins. Salvage surgery for local recurrences resulted in cure in four of eight cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/47\">",
"     47",
"    </a>",
"    ]. In patients who presented with metastatic disease and those who developed metastatic disease after initial treatment, no effective systemic treatment was identified. Twelve patients (18 percent) with positive lymph nodes or surgical margins received adjuvant multiagent chemotherapy (three patients), radiation (six patient), or a combination of the two (three patients). No improvement in cancer-specific survival was observed.",
"   </p>",
"   <p>",
"    Limited data indicate that chemotherapy has low activity against urachal adenocarcinomas. In the M. D. Anderson series, 4 of 20 patients with metastatic disease responded to chemotherapy (largely 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens), although it was unclear whether response affected survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, we recommend that patients be treated with either radical cystectomy or partial cystectomy if the tumor can be resected with adequate margins. In either case, resection should include an en bloc resection of the bladder dome, urachal ligament, and umbilicus. No role for chemotherapy or radiation has been defined. For patients with unresectable or metastatic disease, we suggest that patients carefully consider whether they wish to receive or forego chemotherapy given the absence of data supporting its use. Those interested in receiving chemotherapy should be included in formal studies or trials whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SCHISTOSOMAL BLADDER CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis (also called bilharziasis) affects roughly 200 million people worldwide. Infection with Schistosoma haematobium is most prevalent in East Africa and the Middle East, where it is responsible for the high incidence of bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In these regions, bladder cancer is the most common cancer in men and second to breast cancer in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/55\">",
"     55",
"    </a>",
"    ]. In Egypt, where public health measures have led to a dramatic decrease in the prevalence of schistosomiasis, there has been a subsequent decrease in the incidence of schistosomal bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The epidemiology of bladder cancer in Egypt is thus now much more similar to bladder cancer in Western Europe and the United States, with an older age of onset and a predominance of transitional cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The median age at diagnosis of schistosomal bladder cancer is in the forties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/58\">",
"     58",
"    </a>",
"    ]. Bladder cancer is approximately five times more common in men than women, probably due to agricultural workers' exposure to the pathogen while working in fields.",
"   </p>",
"   <p>",
"    Schistosomiasis is associated with all types of bladder cancer. In one series, SCC, TCC, adenocarcinoma, and mixed or undifferentiated tumors constituted 49, 36, 10, and 5 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/59\">",
"     59",
"    </a>",
"    ]. The pathogenesis of schistosomal bladder cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients commonly present with symptoms of cystitis. Radiographic evaluation often reveals calcification of the bladder and distal ureters. Tumors are usually low- to moderate-grade. At diagnosis, lymph node metastases are present in about 20 percent and distant metastases in 3 percent, possibly due to mural fibrosis causing delayed spread of the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard management of patients with nonmetastatic schistosomal bladder cancer is radical cystectomy with lymph node dissection.",
"   </p>",
"   <p>",
"    Results using this approach are described in an Egyptian series of 2720 consecutive cases of invasive bladder cancer treated with radical cystectomy between 1970 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/59\">",
"     59",
"    </a>",
"    ]. Schistosomal eggs were identified in 82 percent of the series. At a mean follow-up of 5.5 years, the five- and ten-year disease-free survival rates were 56 and 50 percent, respectively. In a multivariate analysis, factors associated with improved disease-free survival included a lower tumor stage, a well-differentiated tumor, and negative regional lymph nodes.",
"   </p>",
"   <p>",
"    Most treatment failures result from local recurrence. Randomized trials using combined modality approaches have suggested an improved outcome, although the optimal approach remains unclear. The reported trials of perioperative RT and chemotherapy for schistosomal bladder cancer are underpowered with regard to overall or disease-specific survival endpoints. Although most trials have failed to document a statistically significant prolongation of survival, these trials are too small to exclude a clinically significant benefit. Larger trials are needed to properly investigate the role of perioperative therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjuvant RT &mdash; Possible benefit from adjuvant RT was suggested by a trial of 236 patients (67 percent with SCC and all with T3 or T4 disease, (",
"      <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"       table 1",
"      </a>",
"      )), in which patients underwent cystectomy and were randomly assigned to conventional RT (50 Gy over five weeks), hyperfractionated RT (1.25 Gy three times a day, to a total of 37.5 Gy in 12 days), or no further therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/61\">",
"       61",
"      </a>",
"      ]. Adjuvant RT improved the five-year disease-free survival (49, 44, and 24 percent with conventional RT, hyperfractionated RT, and no further therapy, respectively) and local control (87, 93, and 50 percent, respectively). An improved outcome was not observed in patients with lymph node metastases.",
"     </li>",
"     <li>",
"      Neoadjuvant RT &mdash; Neoadjuvant RT has not been adequately evaluated. In one small trial, 92 patients (77 percent SCC, 54 percent with T3 or T4 disease, (",
"      <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"       table 1",
"      </a>",
"      )) were randomly assigned to cystectomy alone or neoadjuvant RT followed by cystectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/60\">",
"       60",
"      </a>",
"      ]. The improvement in survival with neoadjuvant RT was small and not statistically significant (40 versus 32 percent with cystectomy alone). In another trial in 48 patients with T3 disease, including 31 SCC and 5 adenocarcinoma patients, patients who received either hyperfractionated or conventionally fractionated neoadjuvant RT had a significantly improved two-year disease-free survival rate compared to patients treated with radical cystectomy alone (53 versus 19 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chemotherapy &mdash; Small studies of perioperative chemotherapy have shown mixed results. In a pilot trial, 71 patients with T2 or T3 disease (",
"      <a class=\"graphic graphic_table graphicRef53395 \" href=\"mobipreview.htm?25/52/26445\">",
"       table 1",
"      </a>",
"      ) were randomly assigned to radical cystectomy alone or to two cycles of neoadjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      , radical cystectomy, and four additional cycles of chemotherapy. Two-year disease-free survival was significantly higher with chemotherapy (74 versus 38 percent with radical cystectomy alone) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/63\">",
"       63",
"      </a>",
"      ]. In a preliminary report of another trial, 114 patients (60 percent with SCC) were randomly assigned to immediate cystectomy or to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      prior to cystectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/64\">",
"       64",
"      </a>",
"      ]. Although 56 percent of patients responded to neoadjuvant chemotherapy, no difference in survival was seen in this underpowered study.",
"      <br/>",
"      <br/>",
"      Multiple chemotherapeutic agents have activity in patients with advanced schistosomal bladder cancer. In phase II trials conducted in Egypt, epirubicin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      all had significant activity (response rates of 60, 44, 40, and 36 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/65\">",
"       65",
"      </a>",
"      ]. Combination regimens have also been evaluated, including gemcitabine plus cisplatin, which achieved a 55 percent response rate in 37 patients with moderate toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/66\">",
"       66",
"      </a>",
"      ]. These response rates are similar to those seen in urothelial bladder cancers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19897?source=see_link\">",
"       \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemoradiation &mdash; Chemoradiation has been investigated in patients with high-risk locally advanced bladder cancer in the adjuvant setting. In an underpowered trial, 146 patients with pathological stage IIIB or IVA or lymph node involvement who had undergone radical cystectomy were randomly assigned to RT with or without four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/67\">",
"       67",
"      </a>",
"      ]. In a preliminary report, disease-free survival at 45 months was prolonged with chemotherapy (70 versus 28 percent), though the difference was not statistically significant. Distant metastasis-free survival was also insignificantly prolonged. Chemoradiation was well tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, we recommend radical cystectomy with lymph node dissection for patients with nonmetastatic schistosomal bladder cancer, although there are no formal clinical trials documenting the superiority of this approach compared to lesser procedures. Patients should be offered enrollment in randomized controlled trials of adjuvant or neoadjuvant RT or chemotherapy whenever possible.",
"   </p>",
"   <p>",
"    For patients with unresectable or metastatic disease who wish to receive chemotherapy outside the context of a clinical trial, it is reasonable to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . However, the absence of randomized controlled trials makes it impossible to define a standard of care. We suggest that patients carefully consider whether they wish to receive or forego chemotherapy given the paucity of data supporting its use. Those interested in receiving chemotherapy should be included in formal studies or trials whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NONEPITHELIAL BLADDER CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonepithelial bladder cancer includes sarcomas, carcinosarcomas, and sarcomatoid cancers, paragangliomas, primary bladder melanomas, and lymphomas. Each accounts for less than 1 percent of all nonurothelial bladder cancers. In general, treatment is guided by the approaches used for these cancers arising at other sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder sarcoma is a malignant mesenchymal tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/68\">",
"     68",
"    </a>",
"    ]. One review of the literature identified 192 cases of bladder sarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/69\">",
"     69",
"    </a>",
"    ]. The diagnosis is most frequently made between the ages of 50 and 60 with a slight male predominance. One-half of bladder sarcomas are leiomyosarcomas and approximately 20 percent are rhabdomyosarcomas. Risk factors include a history of local irradiation, prior",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    treatment, and schistosomiasis.",
"   </p>",
"   <p>",
"    Localized disease is treated with radical cystectomy. The goal of obtaining wide negative margins (recommended 4 to 5 cm) generally precludes partial cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/69\">",
"     69",
"    </a>",
"    ]. Preoperative chemotherapy and radiation to downstage locally advanced disease, as employed in children, is being explored.",
"   </p>",
"   <p>",
"    Management of metastatic disease frequently consists of multimodality approaches including resection, radiation, and chemotherapy with single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis depends upon the patient's age and the extent, rather than the type, of tumor. Five-year overall survival ranged from 60 to 80 percent in small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Carcinosarcoma and sarcomatoid carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinosarcoma is a rare biphasic mixture of carcinoma and sarcoma. Sarcomatoid carcinomas of the bladder are primarily spindle cell tumors with epithelial differentiation, most commonly urothelial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These tumors are exceedingly rare and highly aggressive. A review of one center's experience with 15 carcinosarcomas and 26 sarcomatoid carcinomas found that the two exhibited similar clinical pictures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/72\">",
"     72",
"    </a>",
"    ]. Both were more common in elderly, male patients, and were diagnosed at an advanced stage.",
"   </p>",
"   <p>",
"    Cystectomy, often followed by RT, is the mainstay of treatment. However, these cancers are associated with a poor prognosis, with a median survival of 17 months for carcinosarcoma and 10 months for sarcomatoid tumors despite aggressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/72\">",
"     72",
"    </a>",
"    ]. A complete remission with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    was described in a case report of a patient with metastatic sarcomatoid carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/73\">",
"     73",
"    </a>",
"    ]. A second case report describes a pathologic complete response at partial cystectomy in a patient with carcinosarcoma treated with neoadjuvant chemoradiotherapy using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and gemcitabine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Paragangliomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paragangliomas account for less than 0.05 percent of nonurothelial bladder cancers and 10 percent of extraadrenal pheochromocytomas; approximately 15 percent are malignant. Bladder paragangliomas demonstrate a slight female predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paragangliomas are thought to arise from embryonic nests of chromaffin cells in the sympathetic plexus of the detrusor muscle. Release of catecholamines can be triggered by voiding, bladder distention, defecation, or sexual intercourse. Typical symptoms include diaphoresis, paroxysmal hypertension, palpitations, headaches and syncope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a bladder paraganglioma is suspected, cystoscopy should be accompanied by adrenergic blockade. Biopsy should be avoided, since these tumors are vascular and often covered by intact urothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of pheochromocytoma in adults\", section on 'Medical preparation for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment consists of partial cystectomy with pelvic lymph node dissection. Transurethral resection is considered inadequate, as most paragangliomas involve the entire thickness of the bladder wall. Radical cystectomy is recommended with large tumors or if lymphatic involvement is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most melanomas identified in the bladder are metastatic from another site. A review of the literature identified only 11 cases of primary bladder melanoma, most frequently arising in the bladder or female urethra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/76\">",
"     76",
"    </a>",
"    ]. The postulated cell of origin is neural crest cells. The prognosis is guarded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Unusual sites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lymphoma of the bladder is rare, with fewer than 100 cases reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. It is more common in women (3:1 ratio women to men) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/79\">",
"     79",
"    </a>",
"    ]. Most are MALT (marginal zone) lymphomas. MALT tumors are thought to result from chronic inflammation; in one series two-thirds of patients had chronic cystitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/77\">",
"     77",
"    </a>",
"    ]. The disease is usually localized at diagnosis.",
"   </p>",
"   <p>",
"    As with other lymphomas, treatment consists of chemotherapy with or without radiation. The prognosis is excellent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Lymphoepithelioma-like carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoepithelioma-like carcinoma of the urinary bladder is a rare epithelial tumor characterized by a lymphoid infiltrate suggestive of lymphoma. Fewer than 50 cases have been reported in the literature. It is usually muscle-invasive at the time of diagnosis but appears to have a better prognosis than other primary bladder cancers. The small number of patients identified precludes definitive treatment recommendations, but long-term survival has been reported after transurethral resection, partial cystectomy, or radical cystectomy, with or without adjuvant chemotherapy or RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40409/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct extension of cancer into the bladder can occur from the colon, rectum, prostate, or uterus. The most common cancers to metastasize to the bladder are melanoma and lymphoma. Other common primary sites include the stomach, breast, kidney, lung and pancreas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In North America and Europe, 10 percent of all bladder cancers are nonurothelial, primarily either squamous cell carcinomas (SCCs) or adenocarcinomas. Adenocarcinomas are classified based upon whether they arise from metaplastic urothelium or from a urachal remnant. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Nonschistosomal SCC'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Adenocarcinoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Infection with Schistosoma haematobium is associated with SCCs, urothelial carcinoma, and adenocarcinomas of the bladder. In areas where such infections are endemic, nonurothelial bladder cancers comprise about 80 percent of bladder cancer cases, mostly SCC. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Schistosomal bladder cancer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    SCCs and adenocarcinomas of the bladder are aggressive tumors. Most deaths from SCC are due to locoregional progression while adenocarcinomas are prone to relapse both locally and distantly. Management of nonmetastatic, nonurothelial bladder cancer is based upon histology and identifiable risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with nonschistosomal SCC, we recommend radical cystectomy with pelvic lymph node dissection to control locoregional disease (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonschistosomal SCC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with invasive, nonschistosomal, nonurachal adenocarcinoma, we recommend radical cystectomy with pelvic lymph node dissection to control locoregional disease (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In the rare cases with superficial disease, we suggest radical cystectomy with pelvic lymph node dissection, although transurethral resection and intravesical BCG may be an alternative (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nonurachal adenocarcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with urachal adenocarcinoma, we recommend aggressive surgery including resection of the bladder, urachal ligament, and umbilicus to control locoregional disease (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Partial cystectomy is an alternative to radical cystectomy in appropriately selected patients but should include an en bloc resection of the bladder dome, urachal ligament, and umbilicus. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Urachal adenocarcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with schistosomal bladder cancer, we recommend radical cystectomy with pelvic lymph node dissection to control locoregional disease (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Schistosomal bladder cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with metastatic nonurothelial, non-small cell bladder cancers, we recommend that patient management should be based upon the histology of the primary tumor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Given the absence of data showing a survival or quality-of-life benefit from chemotherapy for these diseases, patients should be offered palliative care as an alternative to chemotherapy. Those electing to receive chemotherapy should be encouraged to consider enrolling on a clinical trial if an appropriate trial is available. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nonepithelial bladder cancer, we use the therapies that are most appropriate for these tumor types when they occur in other locations, in the absence of any better evidence. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nonepithelial bladder cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/2\">",
"      Ghoneim MA, el-Mekresh MM, el-Baz MA, et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997; 158:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/3\">",
"      Nishiyama H, Habuchi T, Watanabe J, et al. Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol 2004; 45:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/4\">",
"      Ozbey I, Aksoy Y, Polat O, et al. Squamous metaplasia of the bladder: findings in 14 patients and review of the literature. Int Urol Nephrol 1999; 31:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/5\">",
"      Khan MS, Thornhill JA, Gaffney E, et al. Keratinising squamous metaplasia of the bladder: natural history and rationalization of management based on review of 54 years experience. Eur Urol 2002; 42:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/6\">",
"      El-Merzabani MM, El-Aaser AA, Zakhary NI. A study on the aetiological factors of bilharzial bladder cancer in Egypt--1. Nitrosamines and their precursors in urine. Eur J Cancer 1979; 15:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/7\">",
"      Kunze E. Histogenesis of nonurothelial carcinomas in the human and rat urinary bladder. Exp Toxicol Pathol 1998; 50:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/8\">",
"      Lynch CF, Cohen MB. Urinary system. Cancer 1995; 75:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/9\">",
"      Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 1988; 48:3853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/10\">",
"      Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol 2003; 44:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/11\">",
"      Fortuny J, Kogevinas M, Chang-Claude J, et al. Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study. Int J Cancer 1999; 80:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/12\">",
"      Subramonian K, Cartwright RA, Harnden P, Harrison SC. Bladder cancer in patients with spinal cord injuries. BJU Int 2004; 93:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/13\">",
"      Pannek J. Transitional cell carcinoma in patients with spinal cord injury: a high risk malignancy? Urology 2002; 59:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/14\">",
"      Hamid R, Bycroft J, Arya M, Shah PJ. Screening cystoscopy and biopsy in patients with neuropathic bladder and chronic suprapubic indwelling catheters: is it valid? J Urol 2003; 170:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/15\">",
"      Yang CC, Clowers DE. Screening cystoscopy in chronically catheterized spinal cord injury patients. Spinal Cord 1999; 37:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/16\">",
"      Johnson DE, Schoenwald MB, Ayala AG, Miller LS. Squamous cell carcinoma of the bladder. J Urol 1976; 115:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/17\">",
"      Rundle JS, Hart AJ, McGeorge A, et al. Squamous cell carcinoma of bladder. A review of 114 patients. Br J Urol 1982; 54:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/18\">",
"      Swanson DA, Liles A, Zagars GK. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol 1990; 143:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/19\">",
"      Serretta V, Pomara G, Piazza F, Gange E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol 2000; 37:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/20\">",
"      Rogers CG, Palapattu GS, Shariat SF, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006; 175:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/21\">",
"      Kassouf W, Spiess PE, Siefker-Radtke A, et al. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 2007; 110:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/22\">",
"      Scosyrev E, Yao J, Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology 2009; 73:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/23\">",
"      Jones MA, Bloom HJ, Williams G, et al. The management of squamous cell carcinoma of the bladder. Br J Urol 1980; 52:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/24\">",
"      Richie JP, Waisman J, Skinner DG, Dretler SP. Squamous carcinoma of the bladder: treatment by radical cystectomy. J Urol 1976; 115:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/25\">",
"      Tannenbaum SI, Carson CC 3rd, Tatum A, Paulson DF. Squamous carcinoma of urinary bladder. Urology 1983; 22:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/26\">",
"      Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 2007; 69:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/27\">",
"      Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991; 67:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/28\">",
"      Fiter L, Gimeno F, Martin L, G&oacute;mez Tejeda L. Signet-ring cell adenocarcinoma of bladder. Urology 1993; 41:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/29\">",
"      Zaghloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol 2006; 24:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/30\">",
"      Wright JL, Porter MP, Li CI, et al. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 2006; 107:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/31\">",
"      Wilson TG, Pritchett TR, Lieskovsky G, et al. Primary adenocarcinoma of bladder. Urology 1991; 38:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/32\">",
"      CULP DA. THE HISTOLOGY OF THE EXSTROPHIED BLADDER. J Urol 1964; 91:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/33\">",
"      Johnson DE, Hodge GB, Abdul-Karim FW, Ayala AG. Urachal carcinoma. Urology 1985; 26:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/34\">",
"      Kakizoe T, Matsumoto K, Andoh M, et al. Adenocarcinoma of urachus. Report of 7 cases and review of literature. Urology 1983; 21:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/35\">",
"      Sheldon CA, Clayman RV, Gonzalez R, et al. Malignant urachal lesions. J Urol 1984; 131:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/36\">",
"      Hughes MJ, Fisher C, Sohaib SA. Imaging features of primary nonurachal adenocarcinoma of the bladder. AJR Am J Roentgenol 2004; 183:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/37\">",
"      el-Mekresh MM, el-Baz MA, Abol-Enein H, Ghoneim MA. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol 1998; 82:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/38\">",
"      Holm&auml;ng S, Aldenborg F. Stage T1 adenocarcinoma of the urinary bladder--complete response after transurethral resection and intravesical bacillus Calmette-Guerin. Scand J Urol Nephrol 2000; 34:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/39\">",
"      Anderstr&ouml;m C, Johansson SL, von Schultz L. Primary adenocarcinoma of the urinary bladder. A clinicopathologic and prognostic study. Cancer 1983; 52:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/40\">",
"      Xiaoxu L, Jianhong L, Jinfeng W, Klotz LH. Bladder adenocarcinoma: 31 reported cases. Can J Urol 2001; 8:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/41\">",
"      Thomas DG, Ward AM, Williams JL. A study of 52 cases of adenocarcinoma of the bladder. Br J Urol 1971; 43:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/42\">",
"      Abenoza P, Manivel C, Fraley EE. Primary adenocarcinoma of urinary bladder. Clinicopathologic study of 16 cases. Urology 1987; 29:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/43\">",
"      Hong JY, Choi MK, Uhm JE, et al. Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. Med Oncol 2009; 26:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/44\">",
"      Hatch TR, Fuchs EF. Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder. Urology 1989; 33:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/45\">",
"      Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology 1985; 26:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/46\">",
"      Manunta A, Vincendeau S, Kiriakou G, et al. Non-transitional cell bladder carcinomas. BJU Int 2005; 95:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/47\">",
"      Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer 2006; 107:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/48\">",
"      Herr HW, Bochner BH, Sharp D, et al. Urachal carcinoma: contemporary surgical outcomes. J Urol 2007; 178:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/49\">",
"      Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol 2003; 169:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/50\">",
"      Henly DR, Farrow GM, Zincke H. Urachal cancer: role of conservative surgery. Urology 1993; 42:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/51\">",
"      Pinthus JH, Haddad R, Trachtenberg J, et al. Population based survival data on urachal tumors. J Urol 2006; 175:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/52\">",
"      Gopalan A, Sharp DS, Fine SW, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol 2009; 33:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/53\">",
"      Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 1999; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/54\">",
"      el-Mawla NG, el-Bolkainy MN, Khaled HM. Bladder cancer in Africa: update. Semin Oncol 2001; 28:174.",
"     </a>",
"    </li>",
"    <li>",
"     Hassan N, Mounir M, El-Basmi A, et al. Statistical Report for NCI. National Cancer Institute; Cairo, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/56\">",
"      Salem S, Mitchell RE, El-Alim El-Dorey A, et al. Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt. BJU Int 2011; 107:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/57\">",
"      Gouda I, Mokhtar N, Bilal D, et al. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst 2007; 19:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/58\">",
"      Shokeir AA. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int 2004; 93:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/59\">",
"      Ghoneim MA, Abdel-Latif M, el-Mekresh M, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008; 180:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/60\">",
"      Ghoneim MA, Ashamallah AK, Awaad HK, Whitmore WF Jr. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol 1985; 134:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/61\">",
"      Zaghloul MS, Awwad HK, Akoush HH, et al. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys 1992; 23:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/62\">",
"      Awwad H, El-Baki HA, El-Bolkainy N, et al. Pre-operative irradiation of T3-carcinoma in bilharzial bladder: a comparison between hyperfractionation and conventional fractionation. Int J Radiat Oncol Biol Phys 1979; 5:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/63\">",
"      Gad el Mawla N, Mansour MA, Eissa S, et al. A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder. Ann Oncol 1991; 2:137.",
"     </a>",
"    </li>",
"    <li>",
"     Khaled H, Zaghloul M, Ghoneim M, et al. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive bladder cancer: Effect on bladder preservation and survival. Proc Am Soc Clin Oncol 2003; 22:411 (abstr 1652).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/65\">",
"      Gad-el-Mawla N, Hamza MR, Zikri ZK, et al. Chemotherapy in invasive carcinoma of the bladder. A review of phase II trials in Egypt. Acta Oncol 1989; 28:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/66\">",
"      Khaled HM, Hamza MR, Mansour O, et al. A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma. Eur J Cancer 2000; 36 Suppl 2:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/67\">",
"      Zaghoul MS, Khaled HM, Lotayef M et al. A controlled prospective randomized trial of adjuvant chemoradiotherapy following radical cystectomy in advanced high risk bladder cancer (abstract). J Clin Oncol 2007; 25:255s.",
"     </a>",
"    </li>",
"    <li>",
"     Nakagawa T, Frank I, Takahashi S, et al. sarcomas and carcinomsarcomas in adults. In: Comprehensive Textbook of Genitourinary Oncology, Vogelzang NJ, Scardino PT, Shipley WU, et al (Eds), Lippincott Williams &amp; Wilkins, New York 2005. p.862.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/69\">",
"      Parekh DJ, Jung C, O'Conner J, et al. Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology 2002; 60:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/70\">",
"      Russo P, Brady MS, Conlon K, et al. Adult urological sarcoma. J Urol 1992; 147:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/71\">",
"      Spiess PE, Kassouf W, Steinberg JR, et al. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol 2007; 25:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/72\">",
"      Lopez-Beltran A, Pacelli A, Rothenberg HJ, et al. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol 1998; 159:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/73\">",
"      Froehner M, Gaertner HJ, Manseck A, Wirth MP. Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man. Urology 2001; 58:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/74\">",
"      Hoshi S, Sasaki M, Muto A, et al. Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy. Int J Urol 2007; 14:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/75\">",
"      Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/76\">",
"      Tainio HM, Kylm&auml;l&auml; TM, Haapasalo HK. Primary malignant melanoma of the urinary bladder associated with widespread metastases. Scand J Urol Nephrol 1999; 33:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/77\">",
"      Kempton CL, Kurtin PJ, Inwards DJ, et al. Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. Am J Surg Pathol 1997; 21:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/78\">",
"      Bates AW, Norton AJ, Baithun SI. Malignant lymphoma of the urinary bladder: a clinicopathological study of 11 cases. J Clin Pathol 2000; 53:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/79\">",
"      Al-Maghrabi J, Kamel-Reid S, Jewett M, et al. Primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type arising in the urinary bladder: report of 4 cases with molecular genetic analysis. Arch Pathol Lab Med 2001; 125:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/80\">",
"      Porcaro AB, Gilioli E, Migliorini F, et al. Primary lymphoepithelioma-like carcinoma of the urinary bladder: report of one case with review and update of the literature after a pooled analysis of 43 patients. Int Urol Nephrol 2003; 35:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40409/abstract/81\">",
"      Mayer EK, Beckley I, Winkler MH. Lymphoepithelioma-like carcinoma of the urinary bladder--diagnostic and clinical implications. Nat Clin Pract Urol 2007; 4:167.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2964 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40409=[""].join("\n");
var outline_f39_29_40409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NONSCHISTOSOMAL SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonurachal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Urachal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SCHISTOSOMAL BLADDER CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NONEPITHELIAL BLADDER CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Carcinosarcoma and sarcomatoid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Paragangliomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Lymphoepithelioma-like carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2964|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/52/26445\" title=\"table 1\">",
"      TNM staging bladder CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/31/3578?source=related_link\">",
"      Extrapulmonary small cell cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27481?source=related_link\">",
"      Pathology of bladder neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19897?source=related_link\">",
"      Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_29_40410="Complications and screening in children and adolescents with type 1 diabetes mellitus";
var content_f39_29_40410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications and screening in children and adolescents with type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40410/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40410/contributors\">",
"     Lynne L Levitsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40410/contributors\">",
"     Madhusmita Misra, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40410/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/29/40410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/29/40410/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/29/40410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes mellitus (T1DM), one of the most common chronic diseases in childhood, is caused by insulin deficiency resulting from the destruction of insulin-producing pancreatic beta cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children and adolescents with T1DM, the most common complications include hypoglycemia, hyperglycemia, diabetic ketoacidosis (DKA), and psychiatric disorders. The pathogenesis of long-term vascular sequelae including retinopathy, nephropathy, neuropathy and cardiovascular disease begins in childhood, although clinical manifestations of these complications are uncommon before adulthood.",
"   </p>",
"   <p>",
"    The complications of T1DM that occur in childhood will be presented here. The management, presentation, and diagnosis of T1DM in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPOGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is the most common complication of T1DM in childhood. Hypoglycemia is usually defined as a blood glucose level &lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It can occur in any child in whom the dose of administered insulin exceeds insulin requirement. Responses to hypoglycemia include release of counterregulatory hormones such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    , epinephrine, cortisol, and growth hormone. However, over time, the glucagon response usually is impaired and the epinephrine surge may be attenuated, increasing the risk of persistent hypoglycemia. This is especially likely to occur in tightly controlled patients with frequent biochemical hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemic symptoms may be adrenergic due to sympathetic neural activation and epinephrine release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/3\">",
"     3",
"    </a>",
"    ], and neuroglycopenic, resulting from direct effects of hypoglycemia on the central nervous system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenergic symptoms &mdash; Tremor, pallor, rapid heart rate, palpitations, and diaphoresis.",
"     </li>",
"     <li>",
"      Neuroglycopenic symptoms &mdash; Fatigue, lethargy, headaches, behavior changes, drowsiness, unconsciousness, seizures, or coma. The severity of the neuroglycopenic symptoms increases with the severity of hypoglycemia and resultant central nervous system energy deprivation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypoglycemia unawareness is a condition characterized by a lack of warning symptoms of hypoglycemia, due to blunting of the autonomic epinephrine response. This is more commonly seen in children with long duration of diabetes, and increases the risk of severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent hypoglycemia. Any episode of hypoglycemia can lower the glucose threshold at which adrenergic discharge and symptoms occur, increasing the risk for subsequent severe hypoglycemia. Prevention of hypoglycemia for a few weeks can restore hypoglycemia awareness. Impairment of the epinephrine response occurs in 30 percent or more of children and adolescents whose diabetes is well controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, nocturnal hypoglycemia is common with reported incidences of 14 to 47 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Symptoms can be subtle and include nightmares, restless sleep, and upon awakening, headache, confusion, or behavior changes. Decreased release of counter-regulatory hormones during the night may contribute to nocturnal hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of hypoglycemia is classified by symptoms and the response needed for successful treatment. Although these symptom patterns are common, children and their parents show poor ability to detect either high or low blood glucose levels based on symptoms alone. Therefore, regular and confirmatory blood glucose monitoring is important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Blood glucose monitoring'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild &mdash; Mild hypoglycemia is associated with adrenergic and mild neuroglycopenic symptoms (ie, headaches and behavior changes). Older children can recognize symptoms and, without the assistance of a second person, can adequately treat themselves with oral intake of a rapidly absorbed carbohydrate. However, infants and very young children are unable to communicate symptoms of hypoglycemia to caregivers, and may not have the same adrenergic signs as older children. Thus, caregivers need to be trained to recognize and treat nonspecific symptoms associated with hypoglycemia in this age group. These symptoms include poor feeding, lethargy, jitteriness, and hypotonia.",
"     </li>",
"     <li>",
"      Moderate &mdash; Patients with moderate hypoglycemia are neurologically impaired to a level that requires help from a second person to administer oral therapy. In the absence of a person to aid therapy, moderate episodes could become severe (see below); therefore, most research studies conservatively classify moderate episodes together with severe episodes.",
"     </li>",
"     <li>",
"      Severe &mdash; This degree of hypoglycemia is recognized by the presence of severe neurologic symptoms (seizures or coma) or requirement for intervention with subcutaneous or intramuscular",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intravenous dextrose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of hypoglycemia is associated with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age of the patient",
"     </li>",
"     <li>",
"      Degree of glycemic control",
"     </li>",
"     <li>",
"      Insulin regimen",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Timing, frequency, and carbohydrate content of meals",
"     </li>",
"     <li>",
"      Acute illness",
"     </li>",
"     <li>",
"      Psychological and socioeconomic factors including patient education and self care behavior",
"     </li>",
"     <li>",
"      Occurrence of a prior hypoglycemic episode",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemic episodes are more common and severe in younger children because food intake, activity, and adherence to treatment schedules are less predictable in younger compared to older children. Aiming for tight glycemic control can further increase the risk of hypoglycemia in this age group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Age-based care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One observational study reported that severe episodes of symptomatic hypoglycemia were most common in infants (55 percent), followed by two to five year old (45 percent) and five to nine year old children (13 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/8\">",
"       8",
"      </a>",
"      ]. The glycated hemoglobin levels (A1C) measured closest to a hypoglycemic episode were 8.7, 8.5, and 7.6 percent for infants, two to five year old children, and five to nine year old children, respectively.",
"     </li>",
"     <li>",
"      In a second observational study, the incidence of severe hypoglycemia decreased with age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/9\">",
"       9",
"      </a>",
"      ]. In girls &lt;7 years of age, 7 to 12 years of age, and &ge;13 years of age, the frequency of hypoglycemia was 24, 19, and 14 episodes per 100 patient years, respectively. Recurrent hypoglycemia occurred frequently in a minority of patients, with 20 percent of patients accounting for 80 percent of episodes.",
"     </li>",
"     <li>",
"      Recurrent hypoglycemia is also more common in younger children. In one study, 60 percent of children with recurrent episodes were less than 13 years old [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, stricter glycemic control is associated with an increased risk of hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. This was best illustrated in a retrospective review of 709 children, which demonstrated that lowering A1C from 10.2 to 8.8 percent was associated with an increase in the frequency of hypoglycemic episodes (4.8 to 15.6 episodes per 100 patient years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/11\">",
"     11",
"    </a>",
"    ]. The rise in frequency was greatest in children younger than six years of age (14.0 to 42.1 episodes per 100 patient years). However, in families competent in diabetes management, A1C &lt;8 percent can be achieved without increasing the risk for hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/6\">",
"     6",
"    </a>",
"    ]. Additionally, in a group of children who achieved a glycated hemoglobin level of 7 percent or less during a one-year trial of treatment with sensor-augmented pump therapy, no severe hypoglycemic events were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk of hypoglycemia in young children has led to higher targeted A1C goals in this age group, because prepubertal children appear to be protected from the microvascular complications of diabetes. Thus the need for tight diabetes control in this age group must be balanced against the associated risk of hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Age-specific goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Insulin regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin dosing regimens are an important predictor of the risk of hypoglycemia. In general, intensive insulin therapy has the advantage of improved glycemic control and probably also reduces the risk for hypoglycemia when appropriately administered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link&amp;anchor=H11299132#H11299132\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Value of an intensive regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7434998\">",
"    <span class=\"h4\">",
"     Conventional regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional insulin regimens used a fixed daily injection schedule using intermediate-, rapid-, and short-acting insulins. The incidence of hypoglycemia in children treated with a conventional regimen ranges between 20 and 60 episodes per 100 patient years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/9,10,13\">",
"     9,10,13",
"    </a>",
"    ]. Certain characteristics of the insulin regimen are associated with hypoglycemia risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients using a fixed conventional insulin regimen are at risk for hypoglycemic events because the regimen includes an intermediate-acting insulin such as NPH insulin, which peaks several hours after administration. Hypoglycemia can occur if adequate glucose is not available at the time of peak insulin effect. As an example, if NPH is given at dinner or bedtime, nocturnal hypoglycemia may occur between 12 AM to 4 AM, when NPH effect peaks (",
"      <a class=\"graphic graphic_table graphicRef73676 \" href=\"mobipreview.htm?1/62/2028\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59453 \" href=\"mobipreview.htm?9/2/9262\">",
"       figure 1",
"      </a>",
"      ). The risk is increased at night because sleep impairs the counter-regulatory hormone responses to hypoglycemia. Similarly, a missed morning snack or delayed lunch may result in hypoglycemia as a consequence of the morning NPH insulin reaching its peak without commensurate food intake.",
"     </li>",
"     <li>",
"      Snacks between meals and bedtime snacks containing complex carbohydrates (with fat to delay absorption) reduce the frequency and severity of hypoglycemic episodes in children receiving conventional insulin regimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7435005\">",
"    <span class=\"h4\">",
"     Intensive regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, intensive therapy that delivers a basal insulin dose with intermittent boluses to cover food intake is associated with a lower risk of hypoglycemia than the conventional insulin regimens described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/14-23\">",
"     14-23",
"    </a>",
"    ]. The risk for hypoglycemia has been examined for specific types of intensive insulin therapies: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensive insulin therapy can be delivered by multiple daily injections. Most regimens use",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/50/17190?source=see_link\">",
"       insulin glargine",
"      </a>",
"      , a long-acting insulin analog, to deliver insulin at a consistent basal rate without a peak effect (",
"      <a class=\"graphic graphic_table graphicRef73676 \" href=\"mobipreview.htm?1/62/2028\">",
"       table 1",
"      </a>",
"      ). Boluses of a rapid-acting insulin such as lispro or aspart are given before meals and snacks. Observational studies have shown that this approach reduces the incidence of severe hypoglycemic episodes in all age groups including children &lt;6 years of age as compared to conventional fixed insulin regimens. These data are discussed in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link&amp;anchor=H20#H20\">",
"       \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Multiple daily injections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Insulin pump therapy is an alternate form of intensive insulin therapy, in which the insulin pump provides a continuous subcutaneous infusion of insulin delivered at a basal rate with boluses administered with meals and snacks. Observational studies suggest that use of an insulin pump reduced the rate of hypoglycemic events as compared to the regimen of multiple daily injections previously used by the same subjects. However, randomized trials do not consistently show an advantage of insulin pump over multiple daily injections. These data are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link&amp;anchor=H21#H21\">",
"       \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Insulin pump'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Frequent administration of boluses of very-rapid and rapid-acting insulin may precipitate low blood sugar. This is a consequence of a \"stacking effect\" when a bolus of insulin is administered before the effect of a previous bolus has cleared. &nbsp;",
"     </li>",
"     <li>",
"      Devices that continuously monitor blood glucose have been used to enhance insulin dosing for patients using an insulin pump. Preliminary trials suggest that this approach may reduce the risk of hypoglycemia compared with standard insulin pump therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link&amp;anchor=H16#H16\">",
"       \"Management of type 1 diabetes mellitus in children and adolescents\", section on 'Continuous glucose monitoring'",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is a well-established cause of hypoglycemia because of the following physiologic responses to vigorous activity:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased insulin absorption from the injection site because of increased blood flow",
"     </li>",
"     <li>",
"      More rapid utilization of glucose",
"     </li>",
"     <li>",
"      Increased sensitivity to insulin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of exercise can be delayed several hours and vary among individuals.",
"   </p>",
"   <p>",
"    Recommendations to avoid hypoglycemia during exercise include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitoring blood glucose before, during, and after vigorous activity. If this is a new activity, monitoring should be done up to 12 hours after physical activity because of possible delayed effects.",
"     </li>",
"     <li>",
"      Consuming a snack before",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      during the time of increased activity.",
"     </li>",
"     <li>",
"      Reducing the last insulin dose before activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High blood glucose levels can sometimes be a consequence of exercise in children who participate in competitive sports because of release of counterregulatory hormones from stress associated with the activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute illness &mdash; During acute illnesses associated with nausea, vomiting, and anorexia, hypoglycemia may occur because of poor oral intake if the doses of insulins with meal-associated peaks are not appropriately adjusted. Hyperglycemia can also occur during acute illnesses because of peripheral insulin resistance. Frequent blood glucose monitoring is mandatory for insulin dose adjustment based upon the blood glucose measurements. Insulin must never be omitted because hyperglycemia and diabetic ketoacidosis can develop without basal insulin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1142?source=see_link&amp;anchor=H2#H2\">",
"       \"Special situations in children and adolescents with type 1 diabetes mellitus\", section on 'Sick-day management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meals &mdash; Variations in the timing and carbohydrate content of food intake result in erratic glycemic effects and an increased risk of hypoglycemia. Children who are on a fixed conventional insulin regimen are particularly vulnerable if the schedule and carbohydrate content of meals are not consistent because insulin doses will not match glycemic needs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link\">",
"       \"Nutritional considerations in type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychological and socioeconomic factors &mdash; Increased risk of hypoglycemia is associated with lower socio-economic status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/9\">",
"       9",
"      </a>",
"      ] and psychiatric disorders. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Psychiatric disorders'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia may be symptomatic, or can be detected by a low blood glucose concentration in the absence of symptoms. If a patient is symptomatic, confirmatory measurement of blood glucose should be obtained if possible. However, if confirmation is not possible, treatment should not be delayed. When in doubt, treat as if hypoglycemia is present.",
"   </p>",
"   <p>",
"    Patients with mild and moderate hypoglycemia should be treated orally with a concentrated and rapidly absorbed simple carbohydrate food source, such as sweetened fruit juice, glucose tablets, or cake frosting. One double-blind crossover study suggested that glucose and sucrose were more effective than fructose in treating hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/24\">",
"     24",
"    </a>",
"    ]. Simple carbohydrates rapidly raise blood glucose concentration and need to be followed by consumption of a snack that contains a mixed food source in order to sustain blood glucose level. Examples include a peanut butter sandwich or a bagel with cream cheese. Blood glucose should be checked again in 15 to 20 minutes to confirm that glucose values have normalized and to determine whether further intervention is necessary. The patient may need more carbohydrates until normal blood sugars are sustained.",
"   </p>",
"   <p>",
"    Patients with severe hypoglycemia (ie, unresponsiveness, seizures) require intervention with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravenous dextrose.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     Glucagon",
"    </a>",
"    administered subcutaneously or intramuscularly, at the following doses, is usually sufficient to increase blood glucose within a few minutes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &le;20 kg: 0.02 to 0.03",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 0.5 mg",
"     </li>",
"     <li>",
"      &gt;20 kg: 1 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral intake of concentrated carbohydrates is necessary following",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    administration. Because both severe hypoglycemia and glucagon may cause nausea within 45 minutes to an hour, immediate feeding upon awakening from the confused state is mandatory.",
"   </p>",
"   <p>",
"    Every child should have a",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    kit at home,",
"    <span class=\"nowrap\">",
"     school/daycare,",
"    </span>",
"    and in the car during long journeys. Prescriptions should be refilled before the date of expiration.",
"   </p>",
"   <p>",
"    Intravenous dextrose can be given as a solution of 25 percent dextrose at a dose of 0.1",
"    <span class=\"nowrap\">",
"     gram/kg",
"    </span>",
"    if there is intravenous access and competent medical personnel are available to administer the dose.",
"   </p>",
"   <p>",
"    Every patient with diabetes should wear an identification band to ensure appropriate intervention by emergency personnel should such a situation arise. The MedicAlert system is one of the best systems in current use (",
"    <a class=\"external\" href=\"file://www.medicalert.org/\">",
"     www.medicalert.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neurologic sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early onset of diabetes appears to be associated with an increased risk for mild neuropsychological dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. One hypothesis is that these effects are caused by severe or repeated episodes of hypoglycemia, which may have deleterious effects on brain development and learning, particularly in young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe hypoglycemia clearly has short-term effects on cognitive function. Single acute episodes of hypoglycemia can transiently reduce mental efficiency, including attention and memory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], alter findings on the electroencephalogram, and increase regional cerebral blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/33\">",
"     33",
"    </a>",
"    ]. Case reports exist of acute and transient cortical blindness associated with severe hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Stroke-like hemiparesis can occur and persist for up to 24 hours after a severe episode. Hypoglycemia can affect critical activities, such as driving or performance in standardized school examinations, and reduce efficiency on mathematical tasks, even in patients with mild hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Impaired performance of mathematical tasks can also occur during periods of hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although prolonged hypoglycemia in other disorders is recognized to lead to severe neurologic dysfunction, an association between hypoglycemia and long-term cognitive deficits in diabetes has not been established. Early onset diabetes (&lt;6 years of age) was associated with a 16 percent prevalence of mesial temporal sclerosis in the hippocampus, as compared with a reported prevalence of less than 1 percent in healthy children. Insults to the hippocampus can affect memory or other cognitive functions. However, in this series, the finding was not more prevalent in children with seizures or documented severe hypoglycemia, and its implication remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies provide evidence against an association between hypoglycemia and cognitive impairment. In a large group of adults and adolescents enrolled in the Diabetes Control and Complications Trial (DCCT), neither tight glucose control (intensive therapy) nor recurrent severe hypoglycemia were associated with cognitive deficits after an average of 6.5 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/39\">",
"     39",
"    </a>",
"    ]. Long-term follow up of the DCCT cohort after 18 years of therapy still revealed no association between cognitive function and frequency of episodes of hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, although early onset of diabetes may be associated with an increased risk for neuropsychological dysfunction and structural changes in the hippocampus, it is not clear that these effects are mediated by chronic or acute severe episodes of hypoglycemia. Indeed, some studies suggest that chronic hyperglycemia may be responsible for cognitive dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]; children with a history of DKA have been reported to have lower rates of accurate memory on structured tasks than those without a history of DKA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fear of hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fear of hypoglycemia on the part of the child or caregiver can result in poor glycemic control. Some children and parents who are concerned about hypoglycemia may keep blood glucose values above recommended targets in an effort to avoid hypoglycemic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Counseling about this issue and careful attention to insulin dose calculations should be an important part of diabetes management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HYPERGLYCEMIA AND DKA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with diabetes, hyperglycemia occurs when insulin levels are inadequate to regulate normal postprandial glucose disposal and prevent inappropriate gluconeogenesis and glycogenolysis. If hyperglycemia is the result of basal insulin deficiency, and is not adequately treated with additional insulin therapy, lipid breakdown occurs with production and accumulation of ketoacids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44295?source=see_link\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic ketoacidosis (DKA) is a common and potentially fatal complication of type 1 diabetes mellitus (T1DM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/49\">",
"     49",
"    </a>",
"    ]. It can be present at the initial presentation of T1DM or can occur in a patient with known diabetes. Relative insulin deficiency is the only cause of DKA. Omission of insulin dosing is the most common cause. DKA also can result from increased insulin needs because of physiologic stress from intercurrent illnesses, trauma, or surgery. Children treated with insulin pump therapy are particularly prone to develop DKA if insulin delivery fails to occur because of pump failure or a kink in the catheter or tubing. Because this regimen does not include any long-acting insulin, DKA can develop quickly. Frequent blood sugar testing helps avoid this complication.",
"   </p>",
"   <p>",
"    The presentation, clinical features, diagnosis, and treatment of DKA are discussed separately. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Mortality'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have hyperglycemia and positive urine ketones or increased blood ketone concentrations are treated with additional insulin. Most cases of DKA can be avoided or aborted with adequate insulin administration (with or without additional carbohydrates), fluid intake, and meticulous monitoring of blood glucose and ketone concentrations. Patients and their families need to learn to carefully monitor blood glucose and ketone levels during times of stress, when insulin needs are increased, and administer additional insulin for elevated blood glucose and ketone concentrations. They must also check for urine or blood ketones when blood glucose is &ge;250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or during acute episodes of increased stress. Teaching should include information regarding the parameters of when it is necessary to call the diabetes care team for assistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with T1DM grow normally. However, poor glycemic control can result in poor linear growth, poor weight gain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed skeletal and pubertal development. Conversely, treatment with excessive insulin can lead to excessive weight gain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link&amp;anchor=H14#H14\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\", section on 'Weight gain with intensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Height and weight should be monitored carefully at least twice a year and plotted on growth curves, so that deviations can be detected early and therapy appropriately adjusted.",
"   </p>",
"   <p>",
"    Mauriac syndrome occurs in children with poorly controlled T1DM, and is characterized by growth attenuation, delayed puberty, hepatomegaly with abnormal glycogen storage and steatosis, and Cushingoid features. It is rare in the modern era of insulin therapy, but is occasionally reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. The mechanisms of Mauriac syndrome are not well understood but may involve hypercortisolemia induced by episodes of hyperglycemia and ketosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/54\">",
"     54",
"    </a>",
"    ]. Catch-up growth generally occurs if diabetic control is restored. However, individuals who are quickly restored to euglycemia may have worsening of retinopathy, and should be followed closely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with T1DM are at increased risk for developing other autoimmune diseases, most commonly autoimmune thyroiditis and celiac disease. The ADA recommends that children with T1DM should be screened for these diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5,55\">",
"     5,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=see_link\">",
"     \"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PSYCHIATRIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative psychological impact of the diagnosis of diabetes on children and adolescents has been well established and is primarily manifested as depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/56-60\">",
"     56-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is more prevalent in children and adolescents with diabetes than those without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/56\">",
"     56",
"    </a>",
"    ]. The highest rate of depression occurs in the first year after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/57\">",
"     57",
"    </a>",
"    ]. Adolescent girls are at greater risk than adolescent boys for recurrent episodes of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the literature, published in 2002, reported a twofold greater prevalence of depression in diabetic children when compared to youths without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/56\">",
"     56",
"    </a>",
"    ]. In adolescents, there was a threefold increased risk. Furthermore, insulin-dependent diabetes was a risk factor for attempted suicide in a study using a Danish registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two subsequent observational studies evaluated diabetic adolescent patients for depression. Both studies utilized the Center for Epidemiological Studies Depression scale (CSE-D), a 20 item, self-reported measure of current depression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a survey of 231 adolescents with T1DM, 33 percent of patients met the criteria for depression by exceeding targeted scores for depression on CSE-D [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/59\">",
"       59",
"      </a>",
"      ]. After adjusting for gender, age, socioeconomic status, and A1C concentrations, adolescent patients who reported depressive symptoms had a 2.5-fold increased likelihood for hospitalization for diabetic complications.",
"     </li>",
"     <li>",
"      In another study of 2672 diabetic adolescents, primarily with T1DM (n=2266), the overall prevalence of depression was 22.6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/60\">",
"       60",
"      </a>",
"      ]. Symptoms of mild depression were found in 14 percent of the group and moderate to severe depression in 8.6 percent. Depression was associated with higher A1C levels and increased frequency of emergency department visits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comprehensive management of diabetes that addresses the psychological impact of diabetes in children and adolescents can improve glycemic control and reduce the frequency of hospitalizations even in the high-risk adolescent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two controlled studies, structured psychoeducational support significantly improved glycemic control and reduced hospital admission rate in adolescents who had previously been poorly controlled [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a systematic review of 543 children and adolescents with T1DM from 10 studies, patients who received psychological therapy had a 0.48 percent (95% CI, 0.05 to 0.91 percent) reduction in their glycated hemoglobin (A1C) compared to control patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/64\">",
"       64",
"      </a>",
"      ]. Psychological intervention included counseling, cognitive behavior therapy, family systems therapy, and psychodynamic therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because depression occurs commonly in adolescents with diabetes and psychological intervention can improve care, we agree with the American Diabetes Association (ADA) recommendation to screen children &ge;10 years of age for depression yearly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5\">",
"     5",
"    </a>",
"    ]. A positive screen should be confirmed by a skilled mental health worker and intervention initiated if appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Eating disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescent girls with diabetes are more likely to develop an eating disorder compared to girls without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In one observational report, adolescent girls (age range 12 to 19 years) with T1DM were 2.4 times more likely to develop a clinical eating disorder and 1.9 times more likely to have a subclinical eating disorder than those without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/65\">",
"     65",
"    </a>",
"    ]. One manifestation of an eating disorder peculiar to diabetes is the purposeful omission of insulin for weight loss.",
"   </p>",
"   <p>",
"    Patients with eating disorders have poorer metabolic control and require more frequent hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. They also have an increased mortality rate compared with patients with only diabetes or only an eating disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     VASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults and adolescents, conclusive randomized trials have established that poor glycemic control is causally associated with long-term vascular sequelae of T1DM. Complications include nephropathy, retinopathy, neuropathy and cardiovascular disease, which primarily present in adulthood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of these vascular complications begins at disease onset. Although children and adolescents rarely have clinical evidence of these conditions, subclinical findings of vascular disease can be detected in a significant number of children and adolescents with diabetes. For example, increased vascular stiffness is seen in children with T1DM (particularly males) compared with healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/70\">",
"     70",
"    </a>",
"    ]. The risk of vascular disease depends on the duration of diabetes, degree of glycemic control, genetic susceptibility, pubertal status, gender, and other lifestyle factors (eg, smoking, diet, and exercise). Exercise is associated with decreased early markers of atherosclerosis in children with T1DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which poor glycemic control predisposes to vascular disease is incompletely understood. A brief summary is provided here and a detailed overview of the proposed pathogenesis of vascular disease in T1DM is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential pathogenetic processes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accumulation of advanced glycosylation end products that contribute to microvascular disease.",
"     </li>",
"     <li>",
"      Accumulation of cellular",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      , which interferes with cellular metabolism.",
"     </li>",
"     <li>",
"      End-organ response with activation of cytokines, profibrotic elements, vascular growth factors, inflammation, and activation of protein kinase C. Other specific end organ responses include mesangial matrix expansion and glomerular hypertension in the kidney, impairment of retinal blood flow and microthrombus formation in the eye, and oxidative stress and ischemia in the nervous system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific discussions on the pathogenesis of each of the vascular complications are also found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of diabetic nephropathy\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=see_link\">",
"     \"Pathogenesis of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41928?source=see_link\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest sign of diabetic nephropathy is microalbuminuria defined as persistent albumin excretion between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     microgram/min).",
"    </span>",
"    Microalbuminuria, if not treated successfully, may progress to overt proteinuria, defined as persistent albumin excretion &gt;300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (&gt;200",
"    <span class=\"nowrap\">",
"     microgram/min).",
"    </span>",
"   </p>",
"   <p>",
"    Screening",
"    for microalbuminuria permits detection and treatment at a time when appropriate therapy can reverse, retard, or prevent further progression of renal disease. As nephropathy progresses to overt proteinuria, irreversible damage occurs and there is an increased risk of end-stage renal failure. The rates of diabetic nephropathy have decreased during the past decades in several populations, coinciding with improved glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. The prognosis of diabetic nephropathy has dramatically improved with better glycemic control, more aggressive antihypertensive therapy, and the use of angiotensin converting enzyme (ACE) inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Longer duration of diabetes and poor glycemic control are associated with increased risk of developing nephropathy, as illustrated in the following studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/75-79\">",
"     75-79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large population-based study, the cumulative prevalence of microalbuminuria was 26 percent after 10 years of diabetes and 51 percent after 19 years of diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/80\">",
"       80",
"      </a>",
"      ]. Macroalbuminuria eventually developed in 14 percent, at a mean age of 18.5 years. Glycemic control, as measured by mean A1C concentrations, was a strong predictor of the risk for microalbuminuria. However, the risk of developing microalbuminuria by age 20 was approximately 15 percent even in patients with mean A1C levels &lt;8.5 percent.",
"     </li>",
"     <li>",
"      In a large observational study of 447 German adolescents, persistent microalbuminuria was seen in 5 and 10 percent of patients with duration of diabetes &gt;11 and 13 years, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/79\">",
"       79",
"      </a>",
"      ]. Microalbuminuria occurred in three children &lt;11 years of age and in 12 patients with duration of disease &lt;5 years.",
"     </li>",
"     <li>",
"      In a retrospective review of 100 patients, the mean age at onset of diabetes was 6.5 &plusmn; 3.5 years and the mean duration of diabetes was 12 &plusmn; 3.5 years. Patients with mean A1C &lt;9 percent were less likely to develop microalbuminuria as compared with those with mean A1C &gt;9 (9.7 versus 43.7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of age at the onset of diabetes on the rate of progression of diabetic nephropathy is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study from Wales reported that children diagnosed before 15 years of age had more rapid progression to the onset of proteinuria and a poorer renal outcome as compared with adults diagnosed between 21 and 25 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, analysis of 4,414 patients with duration of disease &gt;15 years, derived from two national Swedish registries, demonstrated that patients who presented before puberty had a lower risk of developing ESRD than those presenting after puberty [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/74\">",
"       74",
"      </a>",
"      ]. ESRD did not develop in any patient with onset of diabetes before five years of age. This finding was confirmed in a later Swedish study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another population-based study (also cited above) supports the conclusion that younger age at presentation with diabetes is associated with more gradual progression to nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/80\">",
"       80",
"      </a>",
"      ]. Children diagnosed before the age of five had a lower prevalence of microalbuminuria than those diagnosed after age 11 (17.4 versus 28.9 percent after 10 years of diabetes, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible predictors for microalbuminuria include higher levels of albumin excretion (but not in the micro-albuminuric range) during the first two years following onset of diabetes and a higher-than-expected rate of increase in albumin excretion in the first five years of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/83\">",
"     83",
"    </a>",
"    ]. Smoking considerably increases the risk of progression of microalbuminuria to overt nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/84\">",
"     84",
"    </a>",
"    ]. In addition, hypertension increases the risk and severity of nephropathy. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Hypertension'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is necessary to detect and treat microalbuminuria. With appropriate treatment, microalbuminuria can be reversed and further progression of renal disease halted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the recommendation of the American Diabetes Association (ADA) that annual screening for microalbuminuria should be initiated when the child is 10 years old and has had diabetes for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5,55\">",
"     5,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Annual screening is most conveniently done on a random urine sample in which the albumin to creatinine ratio is measured. More frequent testing should be performed if the albumin to creatinine ratio is increasing. Twelve-hour overnight and 24-hour sampling should be obtained for confirmation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link&amp;anchor=H2#H2\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\", section on 'Detection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If persistent microalbuminuria is confirmed, non-diabetes-related causes of renal diseases including orthostatic proteinuria should first be excluded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26262?source=see_link\">",
"     \"Evaluation of proteinuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of microalbuminuria is summarized below. A more complete discussion is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link&amp;anchor=H16#H16\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review glycemic control and implement measures for improvement.",
"     </li>",
"     <li>",
"      If hypertension is present, treat aggressively to normalize blood pressure. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Hypertension'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Treat with an angiotensin converting enzyme (ACE) inhibitor. ACE inhibitors are effective in reversing microalbuminuria and overt nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/55\">",
"       55",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/18/32040?source=see_link\">",
"       Enalapril",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/38/15976?source=see_link\">",
"       lisinopril",
"      </a>",
"      have been used effectively and safely in children. Data are lacking regarding the use of angiotensin II receptor antagonists in children, and we do not recommend their use until they are shown to be as effective and safe as ACE inhibitors.",
"     </li>",
"     <li>",
"      If there is elevation of serum lipids, treat to improve lipid profile. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Cardiovascular disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients and families should be counseled regarding the increased risk of nephropathy with smoking. Cessation interventions should be offered, if appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents with diabetes generally have higher systolic and diastolic blood pressure than healthy adolescents. Two studies that utilized 24 hour ambulatory blood pressure monitoring reported increased systolic and diastolic pressures in children with diabetes compared to their non-diabetic siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Risk factors for hypertension include ethnicity (minority groups), obesity, and poor glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/87\">",
"     87",
"    </a>",
"    ]. Elevations in blood pressure are associated with subsequent development of microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/86\">",
"     86",
"    </a>",
"    ], and patients with microalbuminuria had higher blood pressures than those without microalbuminuria.",
"   </p>",
"   <p>",
"    Hypertension is defined as either systolic or diastolic blood pressure above the 95th percentile for age, gender, and height (or",
"    <span class=\"nowrap\">",
"     &gt;130/80",
"    </span>",
"    mmHg, if 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile exceeds this value) on at least three occasions. Prehypertension (which the ADA terms \"high-normal\" blood pressure) is defined as systolic or diastolic blood pressure between the 90th and 95th percentiles. These standards can be determined from a table (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"mobipreview.htm?7/45/7894\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"mobipreview.htm?7/46/7910\">",
"     table 3",
"    </a>",
"    ) or using the calculators for boys (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). If hypertension is detected, other causes of hypertension should be evaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2729?source=see_link\">",
"     \"Evaluation of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonpharmacologic intervention, such as diet and exercise, should be initiated for all children with blood pressures in the prehypertensive range. Pharmacologic treatment using an ACE inhibitor should be started for children with blood pressure in the hypertensive range (above the 95th percentile) or for those with blood pressure in the prehypertensive range despite nonpharmacologic intervention for three to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/55\">",
"     55",
"    </a>",
"    ]. These thresholds for initiating pharmacologic treatment are lower than those used for children without diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'Whom to treat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/38/15976?source=see_link\">",
"     Lisinopril",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/18/32040?source=see_link\">",
"     enalapril",
"    </a>",
"    are ACE inhibitors that have been shown to be effective and safe in children, and have been shown to protect against the development of progressive nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/88\">",
"     88",
"    </a>",
"    ]. Therapy should be targeted to decrease blood pressure values below the 90th percentile for age, gender, and height (",
"    <a class=\"graphic graphic_table graphicRef63856 \" href=\"mobipreview.htm?7/45/7894\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52646 \" href=\"mobipreview.htm?7/46/7910\">",
"     table 3",
"    </a>",
"    ). Other hypertensive agents can be used if the patient cannot tolerate ACE inhibitors or if targeted blood pressure goals are not reached. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, controlled trials have established increasing risk for diabetic retinopathy with longer duration of diabetes and poorer glycemic control. Observational data from children confirm these same relationships [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/76,77,89-93\">",
"     76,77,89-93",
"    </a>",
"    ]. This was illustrated best in a large study of 441 children (median age of 15.5 years and median duration of diabetes 6.3 years) followed over a five-year period between 1991 and 1995 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/91\">",
"     91",
"    </a>",
"    ]. Results are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixteen percent of patients had mild nonproliferative retinopathy on ophthalmologic examination. More advanced disease was present in four other patients.",
"     </li>",
"     <li>",
"      The median duration of diabetes at the time of detection of retinal changes was 16.6 years. Patients with poorer glycemic control developed retinopathy more rapidly than those with good glycemic control: the median disease duration prior to detection of retinopathy was 15.5 years for patients with A1C values &ge; 7.5 percent, as compared with 18.3 years for those with A1C values &lt;7.5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other risk factors associated with retinopathy include hypertension, hyperlipidemia, smoking, and genetic susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/92-95\">",
"     92-95",
"    </a>",
"    ]. Hypertension with microalbuminuria is associated with accelerated progression of retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/94,96\">",
"     94,96",
"    </a>",
"    ]. Persistent microalbuminuria is a risk factor for impaired color vision, which can precede retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/97\">",
"     97",
"    </a>",
"    ]. Even before frank retinopathy develops, alterations in retinal microvascular geometry can be found, and are associated with longer duration of diabetes and poor control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a brief summary of the retinal changes seen in patients with T1DM. A more complete description is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link\">",
"     \"Classification and clinical features of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Background retinopathy describes the earliest retinal changes including dilated retinal venules, microaneurysms, and capillary leakage (",
"      <a class=\"graphic graphic_picture graphicRef68898 \" href=\"mobipreview.htm?13/11/13503\">",
"       picture 1",
"      </a>",
"      ). Loss of visual acuity can occur if these changes are near the macula.",
"     </li>",
"     <li>",
"      Preproliferative retinopathy is the second stage of retinopathy with retinal microinfarcts visible as small flame-shaped blot hemorrhages proximal to the occlusion (",
"      <a class=\"graphic graphic_picture graphicRef75988 \" href=\"mobipreview.htm?13/20/13647\">",
"       picture 2",
"      </a>",
"      ) and \"cotton wool\" or \"soft exudates\" distal to the occlusion (",
"      <a class=\"graphic graphic_picture graphicRef67621 \" href=\"mobipreview.htm?13/42/13999\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Proliferative retinopathy is the most severe form. It includes retinal ischemia, proliferation of new retinal blood vessels (",
"      <a class=\"graphic graphic_picture graphicRef82311 \" href=\"mobipreview.htm?38/30/39407\">",
"       picture 4",
"      </a>",
"      ), further hemorrhage, scarring resulting from contraction of fibrovascular proliferation, and retinal detachment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children and adolescents with any degree of retinopathy usually have either background or preproliferative retinopathy. In one study of children with average age of diabetes onset at 11 years, the first retinal changes occurred an average of 9 years after diabetes onset, and clinically significant retinopathy about 14 years after diabetes onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is mandated in order to detect early reversible retinal changes. Screening also identifies patients with more advanced disease that may be amenable to laser therapy, which, if applied in a timely manner, may prevent further progression of disease and vision loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the recommendation of the ADA that all children who have had diabetes for three to five years or more should have an annual ophthalmologic evaluation starting at 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5,55\">",
"     5,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a brief summary of the treatment of retinopathy in patients with T1DM. A more complete discussion is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strict glycemic control can prevent, retard, or delay the onset of retinopathy. Background retinopathy can be reversed with better glycemic control, although initial worsening may occur.",
"     </li>",
"     <li>",
"      In patients with more advanced disease, laser therapy, if applied in a timely manner, may prevent progression of disease and visual loss.",
"     </li>",
"     <li>",
"      If hypertension is present, ACE inhibitors should be started because they retard progression of retinopathy similar to their effect on diabetic nephropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although symptomatic diabetic neuropathy is uncommon in children and adolescents with T1DM, sub-clinical impairment of neurologic function has been reported in up to 68 percent of pediatric patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/77,99-107\">",
"     77,99-107",
"    </a>",
"    ]. In children, both autonomic and peripheral neurologic systems can be affected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16934?source=see_link\">",
"     \"Epidemiology and classification of diabetic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired autonomic functions include abnormal heart rate variability and postural blood pressure control, pupillary adaptation to darkness, and vibratory threshold [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/77,99-102\">",
"       77,99-102",
"      </a>",
"      ]. Puberty is a critical time for the development of diabetic cardiac autonomic dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/99,103\">",
"       99,103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impaired peripheral nerve functions include nerve conduction and sensory perception [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/103-107\">",
"       103-107",
"      </a>",
"      ]. The earliest evidence of peripheral neuropathy is distal sensory loss (distal symmetric sensorimotor polyneuropathy) affecting the \"gloves and stockings\" distribution, best tested with a 10g monofilament. Nerve conduction studies, however, demonstrate a higher prevalence of subclinical motor rather than sensory neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to other microvascular complications, the risk of diabetic neuropathy increases with poor glycemic control and longer duration of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/90,99,100,106,108\">",
"     90,99,100,106,108",
"    </a>",
"    ]. Improved glycemic control improves nerve function in diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12986?source=see_link\">",
"     \"Treatment of diabetic neuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41928?source=see_link\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend testing for vibration (using a tuning fork) and pressure sensation (using a 10 g monofilament) at least annually in children older than 10 years old. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18551?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is a major cause of morbidity and mortality in adults with T1DM. As an example, a study conducted in the United Kingdom during the 1990s documented a four-fold increase in risk for major cardiovascular disease in adult men with diabetes, and an eight-fold increase in adult women, as compared with healthy individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/109\">",
"     109",
"    </a>",
"    ]. Although clinically apparent disease is rare during childhood, abnormalities in cardiac function and serum lipid profiles suggest that the disease process begins early in the course of diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with T1DM have reduced left ventricular size and decreased stroke volume even in the absence of hypertension or nephropathy, thought to represent a metabolically induced cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/110\">",
"     110",
"    </a>",
"    ]. Decreased myocardial contractility has been reported in children with longstanding and poorly controlled diabetes. In addition, homocysteine levels after a methionine load are higher in children with microvascular complications than in healthy children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dyslipidemia, atherosclerotic changes, and vascular stiffness are more common in children with diabetes than in healthy children and are associated with poor glycemic control, as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study compared lipid profiles of 682 children with T1DM with those of healthy children in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/112\">",
"       112",
"      </a>",
"      ]. Total cholesterol &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      was more common in children with diabetes compared with the general population (15.4 versus 11.2 percent), and abnormal total cholesterol or HDL were seen more frequently in children with diabetes (18.6 versus 16.3 percent). Hemoglobin A1C levels were significantly related to total cholesterol and non-HDL levels.",
"     </li>",
"     <li>",
"      In an observational study of 141 English children (age range 7.7 to 19 years), lipid profiles were obtained three years after diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/115\">",
"       115",
"      </a>",
"      ]. Elevated levels of cholesterol or triglycerides were seen in 15 and 18 percent of patients, respectively. Six percent of patients had elevation of both cholesterol and triglycerides. In a multiple regression analysis, total cholesterol and triglyceride levels correlated with increased A1C and the mean parental (both parents) total cholesterol levels.",
"     </li>",
"     <li>",
"      Children and adolescents with T1DM are more likely to develop early atherosclerotic changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/71,116-118\">",
"       71,116-118",
"      </a>",
"      ]. One study used carotid artery intima-media thickness (IMT) as measured by high-resolution ultrasound as an index of atherosclerotic changes in 50 children (mean age 11 &plusmn; 2 years) with T1DM, and compared the results with those of 35 matched control healthy children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/117\">",
"       117",
"      </a>",
"      ]. The IMT was significantly increased in children with diabetes (0.47 &plusmn; 0.04 versus 0.42 &plusmn; 0.04 mm, p&lt;.0001). In a multivariate analysis, diabetes, increased low-density lipoprotein cholesterol (LDL), and higher systolic blood pressure were associated with increased carotid artery IMT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Screening for dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening should be provided to patients with T1DM as it can detect hyperlipidemia, which can be improved by better glycemic control and dietary changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the following ADA guidelines for screening for hyperlipidemia in children with T1DM (",
"    <a class=\"graphic graphic_table graphicRef75008 \" href=\"mobipreview.htm?34/21/35164\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5,55,119\">",
"     5,55,119",
"    </a>",
"    ]. After glucose control has been established, a lipid profile (ideally performed in the fasting state) should be obtained in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepubertal children (2 to 10 years), if there is a family history of hypercholesterolemia (defined as total cholesterol &gt;240",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      [6.2",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      a cardiovascular event before 55 years of age, or if the family history is unknown. Screening is also recommended if the child is overweight or obese [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/120\">",
"       120",
"      </a>",
"      ]. Borderline or abnormal values should be repeated for confirmation. If the profile is within the accepted risk levels (LDL &lt;100",
"      <span class=\"nowrap\">",
"       mg/dl),",
"      </span>",
"      it should be repeated every five years.",
"     </li>",
"     <li>",
"      Adolescents (puberty or &gt;10 years of age), at the time of diagnosis. Borderline or abnormal values should be repeated for confirmation. If the profile is within the accepted risk levels (LDL &lt;100",
"      <span class=\"nowrap\">",
"       mg/dl),",
"      </span>",
"      it should be repeated every five years. However, if glycemic control is very poor or if lipids are abnormal, more frequent screening (such as annually) may be clinically prudent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Treatment of hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate therapy of dyslipidemia begins with diet, exercise, and improvement in glycemic control.",
"   </p>",
"   <p>",
"    As for other children, the initial step in therapy is to limit dietary fat according to the American Heart Association's \"step 2\" diet (dietary cholesterol less than 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and saturated fat less than 7 percent of total calories). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    .) In addition, blood glucose and weight control should be optimized. Fasting lipid profiles should be performed after 3 months and 6 months of intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Goal lipid levels for children with diabetes are similar to established guidelines for all children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/121\">",
"     121",
"    </a>",
"    ], but are somewhat more stringent in recognition of their increased cardiovascular risk. The ADA recommends the following lipid goals for children with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/119\">",
"     119",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LDL &lt;100",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"     </li>",
"     <li>",
"      HDL &gt;35",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"     </li>",
"     <li>",
"      Triglycerides &lt;150",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children with lipid levels that fall outside of these parameters, the screen should be repeated in the fasted state for confirmation.",
"   </p>",
"   <p>",
"    Subsequent intervention is based primarily on LDL levels, as outlined below. Factors that prompt use of medication for children in this category include other cardiovascular risk factors (other lipid parameters, smoking status, blood pressure, and family history), as well as assessment of whether nonpharmacologic options have been optimized.",
"   </p>",
"   <p>",
"    If dietary and other lifestyle changes fail to reduce LDL to target levels, pharmacologic treatment with lipid-lowering agents is recommended for children with diabetes over 10 years of age with the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5,119\">",
"     5,119",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LDL &ge;160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.14",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      LDL between 130 and 159 (3.36 to 4.13",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      if one or more other cardiovascular risk factors are present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of pharmacologic therapy is an LDL &lt;100",
"    <span class=\"nowrap\">",
"     mg/dl.",
"    </span>",
"    HMG-CoA reductase inhibitors (statins) are generally recommended as first-line therapy. The",
"    <a class=\"external\" href=\"file://circ.ahajournals.org/cgi/reprint/115/14/1948\">",
"     American Heart Association has published recommendations",
"    </a>",
"    to guide decisions regarding treatment of high-risk lipid abnormalities in children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/120\">",
"     120",
"    </a>",
"    ]. However, it is important to recognize that consensus statements about the use of lipid-lowering agents in children are largely extrapolated from experience in adults, and are not based upon long-term outcome data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/122\">",
"     122",
"    </a>",
"    ]. The use of statins in early pregnancy may be associated with risks to the fetus, and it is recommended that statins be discontinued prior to conception if possible. This is an important consideration when treating adolescent girls who may become pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/123\">",
"     123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H19#H19\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Risks in pregnancy and breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications in pediatric patients with T1DM include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroparesis &mdash; Postprandial antral hypomotility and delayed gastric emptying occur in many children with T1DM and are associated with nausea, vomiting, chronic abdominal pain and constipation following meals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/124,125\">",
"       124,125",
"      </a>",
"      ]. This can result in poor glycemic control and early satiety. Thus, delayed gastric emptying should be investigated in children with poor glycemic control and decreased caloric intake.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/47/759?source=see_link\">",
"       Metoclopramide",
"      </a>",
"      helps improve gastroparesis.",
"     </li>",
"     <li>",
"      Necrobiosis lipoidica &mdash; This inflammatory skin condition associated with diabetes mellitus can be seen in 1 to 2 percent of children with diabetes and is more common in those with poorer glycemic control. Asymptomatic skin lesions usually occur on the shin as oval or irregularly shaped, indurated plaques with central atrophy and yellow pigmentation (",
"      <a class=\"graphic graphic_picture graphicRef74010 \" href=\"mobipreview.htm?10/36/10816\">",
"       picture 5",
"      </a>",
"      ). Patients with this condition have an increased risk for diabetic retinopathy and nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Joint mobility &mdash; Limited joint mobility, primarily affecting the hands and feet, occurred in the past in 9 to 50 percent of patients &gt;10 years of age with T1DM and duration of diabetes that is &gt;5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/99,127\">",
"     99,127",
"    </a>",
"    ]. Higher A1C increases the risk of restricted joint mobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/128\">",
"     128",
"    </a>",
"    ]. In severe cases, the skin has a thick and waxy appearance. Restricted joint mobility is detected when the patient cannot flatten the fingers on a flat surface or cannot completely appose their hands when asked to press both hands together in a praying position. Limited joint mobility is associated with other complications associated with poor glycemic control (ie, retinopathy and nephropathy). Because of improvements in diabetes control in Western countries, this complication is rather rare today [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menstrual irregularities &mdash; In postmenarchal females, 19 percent will have menstrual irregularities, which increase in frequency with poor control and are most prevalent when A1C exceeds 10 percent. Menstrual cycles become more regular with better glycemic control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paronychia &mdash; Adolescents with T1DM have a high prevalence of paronychia as compared with non-diabetic adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/131\">",
"       131",
"      </a>",
"      ]. The risk of paronychia increases with duration of diabetes and is associated with impaired vibration sensation. It is associated with other complications associated with poor glycemic control (ie, retinopathy and nephropathy).",
"     </li>",
"     <li>",
"      Calcium, vitamin D, and bone changes &mdash; Patients with diabetes who have persistent microalbuminuria have lower levels of 25 hydroxy vitamin D, 1,25 dihydroxy vitamin D, and osteocalcin as compared with children with diabetes who are normo-albuminuric [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/132\">",
"       132",
"      </a>",
"      ]. Increased calcium losses in urine have been demonstrated, which improve with use of ACE inhibitors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/133\">",
"       133",
"      </a>",
"      ]. A lower rate of bone mineral accrual and decreased bone mineral content has been demonstrated in children and adolescents with T1DM compared to healthy children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/134,135\">",
"       134,135",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the death rate from diabetes decreased by 61 percent between 1968 to 1969 and 2008 to 2009 (from 2.69 to 1.05 per 1 million youths) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/136\">",
"     136",
"    </a>",
"    ]. The percentage decrease was larger among children younger than 10 years than among 10- to 19-year-old youths. In the older age group, there was actually a slight increase in diabetes-related deaths from 1984 to 2009, following an initial decrease in diabetes-related deaths between 1968 and 1985. This study did not distinguish between type 1 and type 2 diabetes, but the mortality rates in the 10- to 19-year-old age group are likely influenced, in part, by patients with type 2 diabetes (T2DM). This is because there was a rising incidence of T2DM in adolescents during the same time period, reaching 33 percent of all cases by 2003 in the 10- to 19-year-old age range (and higher than this in minority populations), while the proportion in younger children remains low, at 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/137\">",
"     137",
"    </a>",
"    ]. A previous report from the Centers for Disease Control and Prevention (CDC) highlighted disparities in diabetes mortality by race among youths in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/138\">",
"     138",
"    </a>",
"    ]. Because T2DM in youth is more prevalent in ethnic minorities, the increasing proportion of T2DM in the older age group may have affected diabetes-specific mortality.",
"   </p>",
"   <p>",
"    In children, adolescents, and young adults with insulin dependent diabetes, the primary cause of death is diabetic ketoacidosis (DKA). This was illustrated in a retrospective review of all deaths in the city of Chicago of individuals who, at or below 24 years of age at the time of their death, had a diagnosis of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/49\">",
"     49",
"    </a>",
"    ]. Results are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 30 deaths, 22 patients were known to have diabetes before death; in the other 8 patients, death occurred at the time of diagnosis.",
"     </li>",
"     <li>",
"      Cause of death in the 22 patients with known diabetes included 12 from DKA, 5 from chronic renal failure, 1 from hypoglycemia, and 4 from other causes not related to their diabetes.",
"     </li>",
"     <li>",
"      Deaths appeared to be disproportionately increased in non-Hispanic blacks (23 deaths) and Hispanics (5 deaths) when compared to the ethnic distribution in the city of Chicago. This may reflect differences in access to comprehensive diabetes care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another series described 83 deaths attributed to diabetes among children and adolescents in England [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/29/40410/abstract/139\">",
"     139",
"    </a>",
"    ]. Over 80 percent of the deaths were related to",
"    <span class=\"nowrap\">",
"     hyperglycemia/DKA,",
"    </span>",
"    and most of the deaths that occurred in hospital were attributed to cerebral edema. Of note, 41 percent of the patients died at home or were moribund on arrival at the hospital, suggesting a need for closer supervision of this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=see_link\">",
"       \"Patient information: My child has diabetes: How will we manage? (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=see_link\">",
"       \"Patient information: Giving your child insulin (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common complication of type 1 diabetes mellitus (T1DM) is hypoglycemia, defined as blood glucose &lt;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Hypoglycemia can lead to acute and permanent neurologic complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for hypoglycemia include younger age, strict glycemic control, conventional (split-mixed) insulin therapy with a fixed daily insulin schedule, increased vigorous activity, depression, and acute illnesses. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoglycemia is classified by severity of symptoms and the response needed for successful treatment of the patient. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild hypoglycemia is associated with tremor, palpitations, diaphoresis, headaches and behavior changes. Impairment is mild and at a level that older children can treat themselves with oral intake of a rapidly-absorbed carbohydrate such as sweetened fruit juice, glucose tablets, or cake frosting, followed by consumption of a snack with mixed food source, such as a peanut butter sandwich or bagel with cream cheese.",
"     </li>",
"     <li>",
"      Moderate hypoglycemia occurs when neurological impairment is severe enough in an older child that a second person has to administer the above oral therapy.",
"     </li>",
"     <li>",
"      Severe hypoglycemia presents with severe neurologic symptoms (seizures or coma) requiring subcutaneous administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"       glucagon",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      administration of intravenous dextrose. Glucagon is usually sufficient: dosing for children &le;20 kg is 0.02 to 0.03",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 0.5 mg, and for children &gt;20 kg is 1 mg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperglycemia and diabetic ketoacidosis (DKA) &mdash; Hyperglycemia occurs when insulin levels are inadequate to meet their metabolic needs. If hyperglycemia is not treated, ketoacids are produced resulting in DKA. Patients and their families need to learn to monitor blood glucose carefully, especially during times of stress, when insulin needs are increased, and administer additional insulin for elevated blood glucose. They must also check for urine or blood ketones when blood glucose &ge;250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or during times of acute stress.",
"     </li>",
"     <li>",
"      DKA is the most common cause of death in children and adolescents with T1DM. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hyperglycemia and DKA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Mortality'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41480?source=see_link\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Growth",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth failure &mdash; Although most children with T1DM maintain normal growth and development, growth failure and delayed puberty can be seen in patients with poor glycemic control. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obesity &mdash; Treatment with excess insulin can result in excessive weight gain. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Growth'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Psychological",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression &mdash; Depression and eating disorders are common complications in adolescents with diabetes and are associated with poor glycemic control and an increased frequency of hospitalization. Psychological intervention of at-risk adolescents improves compliance and glycemic control.",
"      <br/>",
"      <br/>",
"      In children &ge;10 years of age, we recommend annual screening for depression (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For at-risk adolescents, psychological intervention improves compliance and glycemic control. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Screening for vascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathogenesis of diabetic vascular complications (nephropathy, retinopathy, neuropathy, and cardiovascular disease) begins at diabetes onset. In both adults and children, the risk of these sequelae increases with poor glycemic control and duration of diabetes. Although children and adolescents do not have clinical evidence of these conditions, subclinical findings of vascular disease can be detected in a significant number of children and adolescents with diabetes. Early detection allows for intervention, such as improved glycemic control, that may reverse vascular disease or delay further progression.",
"   </p>",
"   <p>",
"    For all children and adolescents with T1DM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend annual screening for microalbuminuria (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Screening should be initiated when the child is 10 years old and has had diabetes for five years. Microalbuminuria is the earliest stage of diabetic nephropathy and is reversible with appropriate therapy. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend annual screening for diabetic retinopathy by ophthalmologic evaluation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Screening should be initiated at the age of 10 years for all children who have had diabetes for three to five years. The early stages of diabetic retinopathy can be reversed with appropriate therapy. More advanced disease may require laser therapy to prevent further progression of disease and visual loss. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Retinopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend screening for hyperlipidemia in all diabetic adolescents (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also recommend screening in prepubertal children (2 to 10 years of age) with a positive family history of hypercholesterolemia or early coronary artery disease, or if the family history is unknown (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If the profile is within the accepted risk levels (LDL &lt;100",
"      <span class=\"nowrap\">",
"       mg/dl),",
"      </span>",
"      it should be repeated every five years. If glycemic control is very poor, more frequent screening may be necessary. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Screening for dyslipidemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Screening for autoimmune diseases",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with T1DM are at increased risk for autoimmune thyroid disease and celiac disease. All patients should be screened periodically for immune-mediated thyroid dysfunction. Screening for both diseases is recommended by the ADA. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=see_link\">",
"       \"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/1\">",
"      Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/2\">",
"      Clarke W, Jones T, Rewers A, et al. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 2008; 9:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/3\">",
"      DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab 2004; 287:E32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/4\">",
"      Diabetes Research in Children Network (DirecNet) Study Group, Tsalikian E, Tamborlane W, et al. Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care 2009; 32:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/5\">",
"      Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/6\">",
"      Kaufman FR, Austin J, Neinstein A, et al. Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes. J Pediatr 2002; 141:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/7\">",
"      Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/8\">",
"      Lteif AN, Schwenk WF 2nd. Type 1 diabetes mellitus in early childhood: glycemic control and associated risk of hypoglycemic reactions. Mayo Clin Proc 1999; 74:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/9\">",
"      Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. JAMA 2002; 287:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/10\">",
"      Levine BS, Anderson BJ, Butler DA, et al. Predictors of glycemic control and short-term adverse outcomes in youth with type 1 diabetes. J Pediatr 2001; 139:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/11\">",
"      Davis EA, Keating B, Byrne GC, et al. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch Dis Child 1998; 78:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/12\">",
"      Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/13\">",
"      Jones TW, Davis EA. Hypoglycemia in children with type 1 diabetes: current issues and controversies. Pediatr Diabetes 2003; 4:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/14\">",
"      Dixon B, Peter Chase H, Burdick J, et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005; 6:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/15\">",
"      Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005; 115:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/16\">",
"      Colino E, L&oacute;pez-Capap&eacute; M, Golmayo L, et al. Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2005; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/17\">",
"      Berhe T, Postellon D, Wilson B, Stone R. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study. Pediatrics 2006; 117:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/18\">",
"      Nimri R, Weintrob N, Benzaquen H, et al. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006; 117:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/19\">",
"      Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003; 143:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/20\">",
"      Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/21\">",
"      Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004; 114:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/22\">",
"      Litton J, Rice A, Friedman N, et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002; 141:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/23\">",
"      Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/24\">",
"      Husband AC, Crawford S, McCoy LA, Pacaud D. The effectiveness of glucose, sucrose, and fructose in treating hypoglycemia in children with type 1 diabetes. Pediatr Diabetes 2010; 11:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/25\">",
"      Northam EA, Anderson PJ, Werther GA, et al. Neuropsychological complications of IDDM in children 2 years after disease onset. Diabetes Care 1998; 21:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/26\">",
"      Rovet J, Alvarez M. Attentional functioning in children and adolescents with IDDM. Diabetes Care 1997; 20:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/27\">",
"      Bj&oslash;rgaas M, Gimse R, Vik T, Sand T. Cognitive function in type 1 diabetic children with and without episodes of severe hypoglycaemia. Acta Paediatr 1997; 86:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/28\">",
"      Hershey T, Perantie DC, Warren SL, et al. Frequency and timing of severe hypoglycemia affects spatial memory in children with type 1 diabetes. Diabetes Care 2005; 28:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/29\">",
"      Wootton-Gorges SL, Glaser NS. Imaging of the brain in children with type I diabetes mellitus. Pediatr Radiol 2007; 37:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/30\">",
"      Gaudieri PA, Chen R, Greer TF, Holmes CS. Cognitive function in children with type 1 diabetes: a meta-analysis. Diabetes Care 2008; 31:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/31\">",
"      McAulay V, Deary IJ, Ferguson SC, Frier BM. Acute hypoglycemia in humans causes attentional dysfunction while nonverbal intelligence is preserved. Diabetes Care 2001; 24:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/32\">",
"      Sommerfield AJ, Deary IJ, McAulay V, Frier BM. Short-term, delayed, and working memory are impaired during hypoglycemia in individuals with type 1 diabetes. Diabetes Care 2003; 26:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/33\">",
"      Ryan CM, Becker DJ. Hypoglycemia in children with type 1 diabetes mellitus. Risk factors, cognitive function, and management. Endocrinol Metab Clin North Am 1999; 28:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/34\">",
"      Mukamel M, Weitz R, Nissenkorn I, et al. Acute cortical blindness associated with hypoglycemia. J Pediatr 1981; 98:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/35\">",
"      Garty BZ, Dinari G, Nitzan M. Transient acute cortical blindness associated with hypoglycemia. Pediatr Neurol 1987; 3:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/36\">",
"      Cox DJ, Gonder-Frederick LA, Kovatchev BP, et al. Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care 2000; 23:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/37\">",
"      Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, et al. Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 2009; 32:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/38\">",
"      Ho MS, Weller NJ, Ives FJ, et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr 2008; 153:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/39\">",
"      Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996; 124:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/40\">",
"      Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/41\">",
"      Perantie DC, Lim A, Wu J, et al. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes 2008; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/42\">",
"      Perantie DC, Wu J, Koller JM, et al. Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care 2007; 30:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/43\">",
"      Ghetti S, Lee JK, Sims CE, et al. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J Pediatr 2010; 156:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/44\">",
"      Shehata G, Eltayeb A. Cognitive function and event-related potentials in children with type 1 diabetes mellitus. J Child Neurol 2010; 25:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/45\">",
"      Marrero DG, Guare JC, Vandagriff JL, Fineberg NS. Fear of hypoglycemia in the parents of children and adolescents with diabetes: maladaptive or healthy response? Diabetes Educ 1997; 23:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/46\">",
"      Green LB, Wysocki T, Reineck BM. Fear of hypoglycemia in children and adolescents with diabetes. J Pediatr Psychol 1990; 15:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/47\">",
"      Clarke WL, Gonder-Frederick A, Snyder AL, Cox DJ. Maternal fear of hypoglycemia in their children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 1998; 11 Suppl 1:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/48\">",
"      Barnard K, Thomas S, Royle P, et al. Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr 2010; 10:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/49\">",
"      Lipton R, Good G, Mikhailov T, et al. Ethnic differences in mortality from insulin-dependent diabetes mellitus among people less than 25 years of age. Pediatrics 1999; 103:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/50\">",
"      Franzese A, Iorio R, Buono P, et al. Mauriac syndrome still exists. Diabetes Res Clin Pract 2001; 54:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/51\">",
"      Elder CJ, Natarajan A. Mauriac syndrome--a modern reality. J Pediatr Endocrinol Metab 2010; 23:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/52\">",
"      Kim MS, Quintos JB. Mauriac syndrome: growth failure and type 1 diabetes mellitus. Pediatr Endocrinol Rev 2008; 5 Suppl 4:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/53\">",
"      Bua J, Marchetti F, Faleschini E, et al. Hepatic glycogenosis in an adolescent with diabetes. J Pediatr 2010; 157:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/54\">",
"      Dorchy H, Van Vliet G. Cause of dwarfism in Mauriac syndrome. J Pediatr 1981; 98:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/55\">",
"      American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/56\">",
"      Grey M, Whittemore R, Tamborlane W. Depression in type 1 diabetes in children: natural history and correlates. J Psychosom Res 2002; 53:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/57\">",
"      Kovacs M, Goldston D, Obrosky DS, Bonar LK. Psychiatric disorders in youths with IDDM: rates and risk factors. Diabetes Care 1997; 20:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/58\">",
"      Kovacs M, Obrosky DS, Goldston D, Drash A. Major depressive disorder in youths with IDDM. A controlled prospective study of course and outcome. Diabetes Care 1997; 20:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/59\">",
"      Stewart SM, Rao U, Emslie GJ, et al. Depressive symptoms predict hospitalization for adolescents with type 1 diabetes mellitus. Pediatrics 2005; 115:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/60\">",
"      Lawrence JM, Standiford DA, Loots B, et al. Prevalence and correlates of depressed mood among youth with diabetes: the SEARCH for Diabetes in Youth study. Pediatrics 2006; 117:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/61\">",
"      Christiansen E, Stenager E. Risk for attempted suicide in children and youths after contact with somatic hospitals: a Danish register based nested case-control study. J Epidemiol Community Health 2012; 66:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/62\">",
"      Svoren BM, Butler D, Levine BS, et al. Reducing acute adverse outcomes in youths with type 1 diabetes: a randomized, controlled trial. Pediatrics 2003; 112:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/63\">",
"      Ellis DA, Frey MA, Naar-King S, et al. Use of multisystemic therapy to improve regimen adherence among adolescents with type 1 diabetes in chronic poor metabolic control: a randomized controlled trial. Diabetes Care 2005; 28:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/64\">",
"      Winkley K, Ismail K, Landau S, Eisler I. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 2006; 333:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/65\">",
"      Affenito SG, Adams CH. Are eating disorders more prevalent in females with type 1 diabetes mellitus when the impact of insulin omission is considered? Nutr Rev 2001; 59:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/66\">",
"      Meltzer LJ, Johnson SB, Prine JM, et al. Disordered eating, body mass, and glycemic control in adolescents with type 1 diabetes. Diabetes Care 2001; 24:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/67\">",
"      Jones JM, Lawson ML, Daneman D, et al. Eating disorders in adolescent females with and without type 1 diabetes: cross sectional study. BMJ 2000; 320:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/68\">",
"      Cohn BA, Cirillo PM, Wingard DL, et al. Gender differences in hospitalizations for IDDM among adolescents in California, 1991. Implications for prevention. Diabetes Care 1997; 20:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/69\">",
"      Nielsen S, Emborg C, M&oslash;lbak AG. Mortality in concurrent type 1 diabetes and anorexia nervosa. Diabetes Care 2002; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/70\">",
"      Urbina EM, Wadwa RP, Davis C, et al. Prevalence of increased arterial stiffness in children with type 1 diabetes mellitus differs by measurement site and sex: the SEARCH for Diabetes in Youth Study. J Pediatr 2010; 156:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/71\">",
"      Trigona B, Aggoun Y, Maggio A, et al. Preclinical noninvasive markers of atherosclerosis in children and adolescents with type 1 diabetes are influenced by physical activity. J Pediatr 2010; 157:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/72\">",
"      Nordwall M, Bojestig M, Arnqvist HJ, et al. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Link&ouml;ping Diabetes Complications Study. Diabetologia 2004; 47:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/73\">",
"      Pambianco G, Costacou T, Ellis D, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/74\">",
"      Svensson M, Nystr&ouml;m L, Sch&ouml;n S, Dahlquist G. Age at onset of childhood-onset type 1 diabetes and the development of end-stage renal disease: a nationwide population-based study. Diabetes Care 2006; 29:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/75\">",
"      Schultz CJ, Konopelska-Bahu T, Dalton RN, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 1999; 22:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/76\">",
"      Svensson M, Eriksson JW, Dahlquist G. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. Diabetes Care 2004; 27:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/77\">",
"      Bognetti E, Calori G, Meschi F, et al. Prevalence and correlations of early microvascular complications in young type I diabetic patients: role of puberty. J Pediatr Endocrinol Metab 1997; 10:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/78\">",
"      Roe TF, Costin G, Kaufman FR, Carlson ME. Blood glucose control and albuminuria in type 1 diabetes mellitus. J Pediatr 1991; 119:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/79\">",
"      Holl RW, Grabert M, Thon A, Heinze E. Urinary excretion of albumin in adolescents with type 1 diabetes: persistent versus intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control. Diabetes Care 1999; 22:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/80\">",
"      Amin R, Widmer B, Prevost AT, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008; 336:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/81\">",
"      Harvey JN, Allagoa B. The long-term renal and retinal outcome of childhood-onset Type 1 diabetes. Diabet Med 2004; 21:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/82\">",
"      M&ouml;llsten A, Svensson M, Waernbaum I, et al. Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: a nationwide population-based cohort study. Diabetes 2010; 59:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/83\">",
"      Schultz CJ, Neil HA, Dalton RN, et al. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care 2000; 23:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/84\">",
"      Holl RW, Grabert M, Heinze E, Debatin KM. Objective assessment of smoking habits by urinary cotinine measurement in adolescents and young adults with type 1 diabetes. Reliability of reported cigarette consumption and relationship to urinary albumin excretion. Diabetes Care 1998; 21:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/85\">",
"      Theochari MA, Vyssoulis GP, Toutouzas PK, Bartsocas CS. Arterial blood pressure changes in children and adolescents with insulin-dependent diabetes mellitus. J Pediatr 1996; 129:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/86\">",
"      Guntsche Z, Sarav&iacute; FD, Reynals EA, et al. Parental hypertension and 24 h-blood pressure in children prior to diabetic nephropathy. Pediatr Nephrol 2002; 17:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/87\">",
"      Rodriguez BL, Dabelea D, Liese AD, et al. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr 2010; 157:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/88\">",
"      Hilgers KF, D&ouml;tsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 2004; 19:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/89\">",
"      Danne T, Kordonouri O, H&ouml;vener G, Weber B. Diabetic angiopathy in children. Diabet Med 1997; 14:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/90\">",
"      Olsen BS, Johannesen J, Sj&oslash;lie AK, et al. Metabolic control and prevalence of microvascular complications in young Danish patients with Type 1 diabetes mellitus. Danish Study Group of Diabetes in Childhood. Diabet Med 1999; 16:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/91\">",
"      Holl RW, Lang GE, Grabert M, et al. Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control. J Pediatr 1998; 132:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/92\">",
"      Danne T, Kordonouri O, Enders I, et al. Factors modifying the effect of hyperglycemia on the development of retinopathy in adolescents with diabetes. Results of the Berlin Retinopathy Study. Horm Res 1998; 50 Suppl 1:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/93\">",
"      Danne T, Kordonouri O, Enders I, H&ouml;vener G. Monitoring for retinopathy in children and adolescents with type 1 diabetes. Acta Paediatr Suppl 1998; 425:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/94\">",
"      Verrotti A, Catino M, Di Ricco L, et al. Prevention of microvascular complications in diabetic children and adolescents. Acta Paediatr Suppl 1999; 88:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/95\">",
"      Kordonouri O, Danne T, Hopfenm&uuml;ller W, et al. Lipid profiles and blood pressure: are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus? Acta Paediatr 1996; 85:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/96\">",
"      Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ 2008; 337:a918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/97\">",
"      Verrotti A, Lobefalo L, Chiarelli F, et al. Colour vision and persistent microalbuminuria in children with type-1 (insulin-dependent) diabetes mellitus: a longitudinal study. Diabetes Res Clin Pract 1995; 30:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/98\">",
"      Sasongko MB, Wang JJ, Donaghue KC, et al. Alterations in retinal microvascular geometry in young type 1 diabetes. Diabetes Care 2010; 33:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/99\">",
"      Karavanaki K, Baum JD. Prevalence of microvascular and neurologic abnormalities in a population of diabetic children. J Pediatr Endocrinol Metab 1999; 12:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/100\">",
"      Karavanaki K, Baum JD. Coexistence of impaired indices of autonomic neuropathy and diabetic nephropathy in a cohort of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2003; 16:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/101\">",
"      Verrotti A, Chiarelli F, Blasetti A, Morgese G. Autonomic neuropathy in diabetic children. J Paediatr Child Health 1995; 31:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/102\">",
"      Massin MM, Derkenne B, Tallsund M, et al. Cardiac autonomic dysfunction in diabetic children. Diabetes Care 1999; 22:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/103\">",
"      Barkai L, Kempler P, V&aacute;mosi I, et al. Peripheral sensory nerve dysfunction in children and adolescents with type 1 diabetes mellitus. Diabet Med 1998; 15:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/104\">",
"      Hyllienmark L, Brismar T, Ludvigsson J. Subclinical nerve dysfunction in children and adolescents with IDDM. Diabetologia 1995; 38:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/105\">",
"      Bao XH, Wong V, Wang Q, Low LC. Prevalence of peripheral neuropathy with insulin-dependent diabetes mellitus. Pediatr Neurol 1999; 20:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/106\">",
"      Solders G, Thalme B, Aguirre-Aquino M, et al. Nerve conduction and autonomic nerve function in diabetic children. A 10-year follow-up study. Acta Paediatr 1997; 86:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/107\">",
"      Abad F, D&iacute;az-G&oacute;mez NM, Rodr&iacute;guez I, et al. Subclinical pain and thermal sensory dysfunction in children and adolescents with Type 1 diabetes mellitus. Diabet Med 2002; 19:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/108\">",
"      Olsen BS, Sj&oslash;lie A, Hougaard P, et al. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. J Diabetes Complications 2000; 14:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/109\">",
"      Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006; 29:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/110\">",
"      G&oslash;tzsche O, Darwish A, G&oslash;tzsche L, et al. Incipient cardiomyopathy in young insulin-dependent diabetic patients: a seven-year prospective Doppler echocardiographic study. Diabet Med 1996; 13:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/111\">",
"      Chiarelli F, Pomilio M, Mohn A, et al. Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr 2000; 137:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/112\">",
"      Maahs DM, Maniatis AK, Nadeau K, et al. Total cholesterol and high-density lipoprotein levels in pediatric subjects with type 1 diabetes mellitus. J Pediatr 2005; 147:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/113\">",
"      Maahs DM, Wadwa RP, McFann K, et al. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes. J Pediatr 2007; 150:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/114\">",
"      Maahs DM, Dabelea D, D'Agostino RB Jr, et al. Glucose control predicts 2-year change in lipid profile in youth with type 1 diabetes. J Pediatr 2013; 162:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/115\">",
"      Abraha A, Schultz C, Konopelska-Bahu T, et al. Glycaemic control and familial factors determine hyperlipidaemia in early childhood diabetes. Oxford Regional Prospective Study of Childhood Diabetes. Diabet Med 1999; 16:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/116\">",
"      Parikh A, Sochett EB, McCrindle BW, et al. Carotid artery distensibility and cardiac function in adolescents with type 1 diabetes. J Pediatr 2000; 137:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/117\">",
"      J&auml;rvisalo MJ, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002; 51:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/118\">",
"      Harrington J, Pe&ntilde;a AS, Gent R, et al. Aortic intima media thickness is an early marker of atherosclerosis in children with type 1 diabetes mellitus. J Pediatr 2010; 156:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/119\">",
"      American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003; 26:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/120\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/121\">",
"      Kavey RE, Daniels SR, Lauer RM, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. J Pediatr 2003; 142:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/122\">",
"      Maahs DM, Wadwa RP, Bishop F, et al. Dyslipidemia in youth with diabetes: to treat or not to treat? J Pediatr 2008; 153:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/123\">",
"      Petersen EE, Mitchell AA, Carey JC, et al. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A 2008; 146A:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/124\">",
"      Vaisman N, Weintrob N, Blumental A, et al. Gastric emptying in patients with type I diabetes mellitus. Ann N Y Acad Sci 1999; 873:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/125\">",
"      Cucchiara S, Franzese A, Salvia G, et al. Gastric emptying delay and gastric electrical derangement in IDDM. Diabetes Care 1998; 21:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/126\">",
"      Verrotti A, Chiarelli F, Amerio P, Morgese G. Necrobiosis lipoidica diabeticorum in children and adolescents: a clue for underlying renal and retinal disease. Pediatr Dermatol 1995; 12:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/127\">",
"      Vukovi�� J, Dumi�� M, Radica A, et al. Risk factors for expression and progression of limited joint mobility in insulin-dependent childhood diabetes. Acta Diabetol 1996; 33:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/128\">",
"      Silverstein JH, Gordon G, Pollock BH, Rosenbloom AL. Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. J Pediatr 1998; 132:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/129\">",
"      Infante JR, Rosenbloom AL, Silverstein JH, et al. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr 2001; 138:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/130\">",
"      Schroeder B, Hertweck SP, Sanfilippo JS, Foster MB. Correlation between glycemic control and menstruation in diabetic adolescents. J Reprod Med 2000; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/131\">",
"      Kapellen TM, Galler A, Kiess W. Higher frequency of paronychia (nail bed infections) in pediatric and adolescent patients with type 1 diabetes mellitus than in non-diabetic peers. J Pediatr Endocrinol Metab 2003; 16:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/132\">",
"      Verrotti A, Basciani F, Carle F, et al. Calcium metabolism in adolescents and young adults with type 1 diabetes mellitus without and with persistent microalbuminuria. J Endocrinol Invest 1999; 22:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/133\">",
"      Y&uuml;ksel H, Darcan S, Kabasakal C, et al. Effect of enalapril on proteinuria, phosphaturia, and calciuria in insulin-dependent diabetes. Pediatr Nephrol 1998; 12:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/134\">",
"      Salvatoni A, Mancassola G, Biasoli R, et al. Bone mineral density in diabetic children and adolescents: a follow-up study. Bone 2004; 34:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/135\">",
"      Chobot AP, Haffke A, Polanska J, et al. Bone status in adolescents with type 1 diabetes. Diabetologia 2010; 53:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/136\">",
"      Centers for Disease Control and Prevention. Diabetes death rates among youths aged &le; 19 years--United States, 1968-2009. MMWR Morb Mortal Wkly Rep 2012; 61:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/137\">",
"      Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/138\">",
"      Centers for Disease Control and Prevention (CDC). Racial disparities in diabetes mortality among persons aged 1-19 years--United States, 1979-2004. MMWR Morb Mortal Wkly Rep 2007; 56:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/29/40410/abstract/139\">",
"      Edge JA, Ford-Adams ME, Dunger DB. Causes of death in children with insulin dependent diabetes 1990-96. Arch Dis Child 1999; 81:318.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5818 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40410=[""].join("\n");
var outline_f39_29_40410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Insulin regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7434998\">",
"      Conventional regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7435005\">",
"      Intensive regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neurologic sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fear of hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HYPERGLYCEMIA AND DKA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AUTOIMMUNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PSYCHIATRIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Eating disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nephropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Retinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Screening for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Treatment of hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      MISCELLANEOUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Psychological",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Screening for vascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Screening for autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5818|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/2/9262\" title=\"figure 1\">",
"      Time course of insulin action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5818|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/11/13503\" title=\"picture 1\">",
"      Retinal microaneurysms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/20/13647\" title=\"picture 2\">",
"      Retinal blot hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/42/13999\" title=\"picture 3\">",
"      Cotton wool spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/30/39407\" title=\"picture 4\">",
"      Retinal neovascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/36/10816\" title=\"picture 5\">",
"      Necrobiosis lipoidica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5818|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/62/2028\" title=\"table 1\">",
"      Insulin pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7894\" title=\"table 2\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/46/7910\" title=\"table 3\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/21/35164\" title=\"table 4\">",
"      ADA lipid guideline",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=related_link\">",
"      Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16934?source=related_link\">",
"      Epidemiology and classification of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44295?source=related_link\">",
"      Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/42/2729?source=related_link\">",
"      Evaluation of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41928?source=related_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=related_link\">",
"      Pathogenesis of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=related_link\">",
"      Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1142?source=related_link\">",
"      Special situations in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12986?source=related_link\">",
"      Treatment of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_29_40411="Rx bacterial vaginosis";
var content_f39_29_40411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for bacterial vaginosis (nonpregnant women)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metronidazole 500 mg oral twice daily for seven days",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metronidazole gel 0.75 percent 5 g* (one full applicator) intravaginally once daily for five days",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin 2 percent cream 5 g",
"        <sup>",
"         &bull;",
"        </sup>",
"        (one full applicator) intravaginally at bedtime for seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin 300 mg orally twice daily for seven days",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin ovule (vaginal suppository) 100 mg intravaginally once daily for three days",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tinidazole 2 g orally for two days",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tinidazole 1 g orally once daily for five days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Although data are limited, metronidazole 750 mg extended release tablets once daily for seven days OR a single vaginal dose of clindamycin 2 percent bioadhesive cream (US trade name: Clindesse) 5 g",
"    <sup>",
"     &bull;",
"    </sup>",
"    , one full applicator, also appear to be effective.",
"    <div class=\"footnotes\">",
"     * 5 grams of metronidazole 0.75 percent vaginal gel contains 37.5 mg of metronidazole.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     5 grams of clindamycin 2 percent vaginal cream contains 100 mg of clindamycin.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR Recomm Rep 2010 (RR-12); 59.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40411=[""].join("\n");
var outline_f39_29_40411=null;
var title_f39_29_40412="Foster care resources";
var content_f39_29_40412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources for clinicians and parents caring for children in foster care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Resource",
"       </td>",
"       <td class=\"subtitle1\">",
"        Web address/description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        American Academy of Pediatrics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Healthy Foster Care America",
"       </td>",
"       <td>",
"        <a href=\"file://www.aap.org/fostercare\" target=\"_blank\">",
"         www.aap.org/fostercare",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        - Children's Health Topics: Foster Care",
"       </td>",
"       <td>",
"        <a href=\"file://www.aap.org/healthtopics/fostercare.cfm\" target=\"_blank\">",
"         www.aap.org/healthtopics/fostercare.cfm",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        American Academy of Child and Adolescent Psychiatry",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://www.aacap.org/\" target=\"_blank\">",
"          www.aacap.org",
"         </a>",
"        </p>",
"        Helpful information for children with mental health needs",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        The Annie E. Casey Family Foundation",
"       </td>",
"       <td>",
"        <a href=\"file://www.aecf.org/OurWork/ChildWelfarePermanence.aspx\" target=\"_blank\">",
"         www.aecf.org/OurWork/ChildWelfarePermanence.aspx",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        California Evidence-Based Clearinghouse for Child Welfare",
"       </td>",
"       <td>",
"        <a href=\"file://www.cebc4cw.org/\" target=\"_blank\">",
"         www.cebc4cw.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Chapin Hall",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://www.chapinhall.org/research/areas/child-welfare-and-foster-care-systems\" target=\"_blank\">",
"          www.chapinhall.org/research/areas/child-welfare-and-foster-care-systems",
"         </a>",
"        </p>",
"        Has information on child welfare and maltreatment prevention",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Child Welfare League of America",
"       </td>",
"       <td>",
"        <a href=\"file://www.cwla.org\" target=\"_blank\">",
"         www.cwla.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Harvard University Center for the Developing Child",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://developingchild.harvard.edu/\" target=\"_blank\">",
"          developingchild.harvard.edu",
"         </a>",
"        </p>",
"        Provides information about the effects of toxic stress",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        National Center for Medical Home Implementation",
"       </td>",
"       <td>",
"        <a href=\"file://www.medicalhomeinfo.org\" target=\"_blank\">",
"         www.medicalhomeinfo.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        National Child Traumatic Stress Network",
"       </td>",
"       <td>",
"        <a href=\"file://www.nctsn.org\" target=\"_blank\">",
"         www.nctsn.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zero to Three",
"       </td>",
"       <td>",
"        <p>",
"         <a href=\"file://www.zerotothree.org/about-us/areas-of-expertise/free-parent-brochures-and-guides/age-based-handouts.html\" target=\"_blank\">",
"          www.zerotothree.org/about-us/areas-of-expertise/free-parent-brochures-and-guides/age-based-handouts.html",
"         </a>",
"        </p>",
"        Has information specifically for young children and a section aimed at parent education",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40412=[""].join("\n");
var outline_f39_29_40412=null;
var title_f39_29_40413="Zoonoses from Cats A";
var content_f39_29_40413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57235%7EID%2F70031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57235%7EID%2F70031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses cats",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Feline symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Infectious saliva",
"       </td>",
"       <td>",
"        Bartonella henselae",
"       </td>",
"       <td>",
"        Cat scratch disease, lymphadenopathy",
"       </td>",
"       <td>",
"        Asymptomatic even with bacteremia",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pasteurella",
"       </td>",
"       <td>",
"        Skin and soft-tissue infections, septic arthritis, osteomyelitis",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rabies",
"       </td>",
"       <td>",
"        Acute progressive encephalitis",
"       </td>",
"       <td>",
"        Stages: prodromal, furious, and paralytic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capnocytophaga",
"       </td>",
"       <td>",
"        Skin and soft-tissue infections, sepsis, meningitis",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cowpox",
"       </td>",
"       <td>",
"        Painful, hemorrhagic pustules or black eschars",
"       </td>",
"       <td>",
"        Ulcerated, crusted focal skin lesions; systemic illness possible",
"       </td>",
"       <td>",
"        Europe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        Fecal",
"       </td>",
"       <td>",
"        Salmonella Campylobacter Cryptosporidium Giardia",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Asymptomatic or gastroenteritis",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxocara cati",
"       </td>",
"       <td>",
"        Visceral larva migrans and ocular larva migrans",
"       </td>",
"       <td>",
"        Asymptomatic",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ancylostoma caninum",
"       </td>",
"       <td>",
"        Cutaneous larva migrans",
"       </td>",
"       <td>",
"        Hookworm",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcus granulosus",
"       </td>",
"       <td>",
"        Hydatid cysts, echinococcosis",
"       </td>",
"       <td>",
"        Hydatid cysts, echinococcosis",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasma gondii",
"       </td>",
"       <td>",
"        Lymphadenopathy, cerebral, congenital infection",
"       </td>",
"       <td>",
"        Asymptomatic, may be associated with co-infection with feline leukemia virus or feline immuno- deficiency virus",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dipylidium caninum",
"       </td>",
"       <td>",
"        Asymptomatic to abdominal pain, diarrhea, pruritus ani, and urticaria",
"       </td>",
"       <td>",
"        Tapeworm",
"       </td>",
"       <td>",
"        Most common in ranching areas of the Mediterranean, South America, and Australia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses cats, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Feline symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Aerosol",
"       </td>",
"       <td>",
"        Bordetella bronchiseptica",
"       </td>",
"       <td>",
"        Asymptomatic to upper respiratory tract infections to pneumonia",
"       </td>",
"       <td>",
"        Kennel cough",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxiella burnetii",
"       </td>",
"       <td>",
"        Q fever, including a self-limited flu-like illness, +/- pneumonia, +/- hepatitis, +/- endocarditis",
"       </td>",
"       <td>",
"        Asymptomatic; infection may cause abortion or rapid death of newborn kittens",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Tick or flea bites",
"       </td>",
"       <td>",
"        B. burgdorferi",
"       </td>",
"       <td>",
"        Lyme disease",
"       </td>",
"       <td>",
"        Lyme disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichia chaffeensis and Anaplasma phagocytophilum",
"       </td>",
"       <td>",
"        Ehrlichiosis Anaplasmosis",
"       </td>",
"       <td>",
"        Asymptomatic or similar to human disease",
"       </td>",
"       <td>",
"        North America Few cases Europe, Africa, Mexico",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Babesia microti (United States); Babesia divergens (Europe)",
"       </td>",
"       <td>",
"        Babesiosis",
"       </td>",
"       <td>",
"        Asymptomatic or similar to human disease",
"       </td>",
"       <td>",
"        Focal areas of United States and Europe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia pestis",
"       </td>",
"       <td>",
"        Plague",
"       </td>",
"       <td>",
"        Fever, loss of appetite, can have severe illness",
"       </td>",
"       <td>",
"        Majority in south central United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Francisella tularensis",
"       </td>",
"       <td>",
"        Tularemia",
"       </td>",
"       <td>",
"        Fever, loss of appetite, can have severe illness",
"       </td>",
"       <td>",
"        Worldwide In the United States (Arkansas, Missouri Oklahoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Direct contact",
"       </td>",
"       <td>",
"        Sporothrix schenckii",
"       </td>",
"       <td>",
"        Sporotrichosis",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microsporum canis",
"       </td>",
"       <td>",
"        Dermatophyte; ringworm",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine",
"       </td>",
"       <td>",
"        Leptospira interrogans",
"       </td>",
"       <td>",
"        Leptosiprosis, subclinical to severe, potentially fatal illness",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40413=[""].join("\n");
var outline_f39_29_40413=null;
var title_f39_29_40414="Diagram of circumcised penis";
var content_f39_29_40414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram of circumcised penis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40414=[""].join("\n");
var outline_f39_29_40414=null;
var title_f39_29_40415="Posterior drawer test";
var content_f39_29_40415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior drawer test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The posterior drawer test is used to assess the integrity of the posterior cruciate ligament. With the knee flexed to 90&ordm; and the foot stabilized, the proximal tibia is grasped firmly with both hands and the tibia is forcibly pushed posteriorly, noting any laxity compared with the other side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_29_40415=[""].join("\n");
var outline_f39_29_40415=null;
